User:Prof. Squirrel/Notes
| {{/Template}} |
| {{/cross-ref}} |
| {{/WIPTemplate}} |
Figure
| copy | * {{Cite web | last=Choudhary | first=Gargi | title=Determination of Acepromazine and its Major Metabolite in Equine Serum by LC-MS/MS using the Finnigan LCQ Deca XP Plus Ion Trap Mass Spectrometer | url=http://tools.thermofisher.com/content/sfs/brochures/App-Note-318-Determination-of-Acepromazine-and-its-Major-Metabolite-in-Equine-Serum.pdf | publisher=Thermo Electron Corporation}}
|
Ettinger, Stephen J.; Feldman, Edward C. (2009-12-24). Textbook of Veterinary Internal Medicine - eBook. Elsevier Health Sciences. ISBN 9781437702828.
| copy | {{cite book | last1=Ettinger | first1=Stephen J. | last2=Feldman | first2=Edward C. | title=Textbook of Veterinary Internal Medicine - eBook | date=2009-12-24 | publisher=Elsevier Health Sciences | isbn=9781437702828 | url=https://books.google.com/books?id=4Qzau1jagOYC&pg=PA1394-IA32&dq=acepromazine%20cats&pg=PA1394-IA32}} |
- Boxers & vasovagal syncompe w/ace probably bc combo of bradycardia (due to decreasing sympathetic stimulation) and vasodilation, which causes hypotension
- Can be avoided by using Ace with atropine
- Hypothermia increased in smaller animals such as cats [from another book] bc larger surface area → more blood in vessels at surface, so more heat lost
Khuly, Patty (2009-10-22). "Acepromazine: Why I'm not a big fan when it comes to sedation via 'ace'". PetMD. Retrieved 2017-06-12.
| copy | {{Cite web | last=Khuly | first=Patty | title=Acepromazine: Why I'm not a big fan when it comes to sedation via 'ace' | work=PetMD | accessdate=2017-06-12 | date=2009-10-22 | url=http://www.petmd.com/blogs/fullyvetted/2009/october/acepromazine-why-im-not-big-fan-when-it-comes-sedation-ace-6937}} |
- Most common uses in dogs/cats:
- Oral sedative before stressful events (travel, storms, grooming, vet visits)
- Disagreement on this: since it can make animal more sensitive to noise/other sensory input, shouldn't really be used with aggressive dogs – can sometimes increase aggression (due to dysphoria by phenothiazine)
- Inj tranq for aggressive/fractious animal at vet office
- W/opiate as a pre-med
- Lower dose of other drug needed
- Reduce protential for arrhythmias and vomiting
- Except boxers – they can get life-threatening arrhythmias
- Some minor relaxing
- Post-op w/pain releiver to enhance/lower dose of pain reliever neeeded
- Oral sedative before stressful events (travel, storms, grooming, vet visits)
Kolahian, Saeed (2014). "Efficacy of Different Antiemetics with Different Mechanism of Action on Xylazine Induced Emesis in Cats" (PDF). Iranian Journal of Veterinary Surgery. 9 (1): 10.
| copy | {{cite journal|last=Kolahian|first=Saeed|title=Efficacy of Different Antiemetics with Different Mechanism of Action on Xylazine Induced Emesis in Cats| journal=Iranian Journal of Veterinary Surgery | year=2014 | volume=9 | number=1 | url=http://www.ivsajournals.com/article_5789_6e9336886fafc7a62f1c710ade9bc1ef.pdf | page=10}} |
- Acts as antiemetic. At least in cats, it acts:
- On chemoreceptor trigger zone in area postrema
- On NTS in medulla obongata
Maddison, Jill E.; Page, Stephen W.; Church, David, eds. (2008). Small Animal Clinical Pharmacology (2 ed.). Edinburgh; New York: Saunders/Elsevier. ISBN 9780702028588.
| copy | {{cite book | editor-first=Jill E. |editor-last=Maddison |editor2-first=Stephen W. | editor2-last=Page |editor3-first=David | editor3-last=Church | title=Small Animal Clinical Pharmacology | location=Edinburgh; New York | date=2008 | edition=2 | publisher=Saunders/Elsevier | isbn=9780702028588 | url=https://books.google.com/books?id=RpsROVqemk8C&lpg=PA115}} |
p.115
- Sedative effect more in dogs, but licensed for both dog and cat use
- Antiemetic effects
- Mainly ant. at D2; also has ant. action at H1, alpha1, and mAch
Pharmokinetics
- Better absorption from IM than SQ sites
- Starts 30 min after IM injection (faster if IV)
- 4-6 hours sedation
- Oral dose: not as effective, so need higher dose
- Lipophilic and widely distributed
- High degree of protein binding
- Metabolized by hepatic microsomal enzymes
- Oxidized to sulfoxides and glucuronide conjucation
- Impaired liver → longer effect
- Metabolites excreted in urine
Adverse effects
- CNS
- BC dopamine, high doses can lead to extrapyramidal signs (restlessness, rigidity, tremor, catalepsy)
- Fever, bc modify thermoregulation mechas at hypothalamus
- Cardiovascular
- Peripheral vasodilation → drop in BP (mainly by anti-alpha1)
- Clinical doses don't really affect HR
p.116
- Respiratory
- Not much
- GI
- Anti chol: Spasmolytic action on gut → reduce GI motility in dogs; reduced salivation
- Other
- Quite mild antihistamine effect compared to other phenothiazines
- Reduction in hematocrit: liver and spleen sequester/hog RBCs
- Can temporarily reduce clotting activity
Contraindications
- Hypovolemia/shock
- Hx of seizures
- Reduced doses:
- Hepatic or cardiac problems
- Young, old, or weak
- Bracycephalic breeds (esp. boxer)
- Giant breeds
Known drug interactions
- CNS depressant effect makes other drugs' CNS depressant effects stronger as well, so having an opioid, even in nonpainful pt, increases sedation (need to use less)
p.130, 131
- Effects:
- hypersensitivity to noise, startle more easily
Marroum, Patrick John (1990). Pharmacokinetic studies of acepromazine in the cat and the horse, studies in lipophilicity, red blood cell partitioning and protein binding (PhD). University of Florida.
| copy | {{Cite thesis | last=Marroum | first=Patrick John | title=Pharmacokinetic studies of acepromazine in the cat and the horse, studies in lipophilicity, red blood cell partitioning and protein binding | date=1990 | url=http://archive.org/details/pharmacokinetics00marr | publisher=University of Florida | type=PhD }} |
p.5
- Phenothiazines in general:
- Sedation
- Decreased anxiety
- Decreased spontaneous motor activity
- Interruption of intellectual stuff/complex behavior
- Antihistaminic and hypotensive
- By blocking post-synaptic dopamine receptors
- Result: increase in production of dopamine metabolites, which interferes with dopamine action as NT in
p.7
- Pre-anesthetic in dog, cat, and horse
- Potentiates barbituates
p.13
- [Picture of metabolism of ace]
p.116
- Erratic absorption in cat, with very high variability from one cat to the next
Riviere, Jim E.; Papich, Mark G. (2009-03-17). Veterinary Pharmacology and Therapeutics. John Wiley & Sons. p. 516. ISBN 9780813820613.
| copy | {{cite book | last1=Riviere | first1=Jim E. | last2=Papich | first2=Mark G. | title=Veterinary Pharmacology and Therapeutics | date=2009-03-17 | publisher=John Wiley & Sons | isbn=9780813820613 | url=https://books.google.com/books?id=ievLulSqwBAC&pg=PA516 | page=516}} |
- Ace can cause spont. motor activity (both dogs & cats, but especially in cats)
- DA receptor blockade in striatum and inactivating DA receptors in substantia nigra
Valverde, A; Cantwell, S; Hernández, J; Brotherson, C (April 2003). "Effects of acepromazine on the incidence of vomiting associated with opioid administration in dogs". Veterinary Anaesthesia and Analgesia. 30 (2): 99. doi:10.1046/j.1467-2995.2003.01331.x. ISSN 1467-2987.
| copy | {{cite journal | last1=Valverde | first1=A | last2=Cantwell | first2=S | last3=Hernández | first3=J | last4=Brotherson | first4=C | title=Effects of acepromazine on the incidence of vomiting associated with opioid administration in dogs | journal=Veterinary Anaesthesia and Analgesia | date=April 2003 | doi=10.1046/j.1467-2995.2003.01331.x | issn=14672987 | volume=30 | issue=2 | pages=99 | url=http://www.vaajournal.org/article/S1467-2987(16)30962-X/fulltext}} |
- Antiemetic by acting on chemoreceptor trigger zone (dogs)
- In conjunction with opioids, can reduce vomiting
Wingfield, Wayne; Raffe, Marc (2002-09-29). The Veterinary ICU Book. Teton NewMedia. p. 81. ISBN 9781893441132.
| copy | {{cite book | last1=Wingfield | first1=Wayne | last2=Raffe | first2=Marc | title=The Veterinary ICU Book | date=2002-09-29 | publisher=Teton NewMedia | isbn=9781893441132 | url=https://books.google.com/books?id=-DN35GUKOBgC&pg=PA81|page=81}} |
- Ace can be used in cats, but less predictable than in dogs, and less sedation
"Adequan Canine Injectable (Prescription)". Doctors Foster and Smith. Retrieved 2017-07-10.
| copy | {{cite web | title=Adequan Canine Injectable (Prescription) | work=Doctors Foster and Smith | accessdate=2017-07-10 | url=http://www.drsfostersmith.com/product/prod_display.cfm?pcatid=10309}} |
- Polysulfated glycosaminoglycan (PSGAG) inhibits enzymes that degrade cartilage
- Decrease inflammation that comes once cartilage is broken down
- Stimulates production of synovial (joint) fluid & collagen
- No inj. generics
- Multiple injections over several weeks, will take several treatments to actually see it working
- Improves signs, but doesn't actually reverse changes in bone that happen with arthritis
- Don't use if hypersensitive to PSGAG or have bleeding disorder
"Patient Information Sheet" (PDF). Doctor Foster and Smith Pharmacy. 2007-09-14. Retrieved 2017-07-10.
| copy | {{cite web | title=Patient Information Sheet | work=Doctor Foster and Smith Pharmacy | accessdate=2017-07-10 | date=2007-09-14 | url=http://www.drsfostersmith.com/Rx_Info_Sheets/rx_psgag.pdf}} |
- Injectable polysulfated glycosaminoglycan (PSGAG)
- No injectable generics available
- Signs of degenerative or traumatic arthritis in dogs & horses
- Also has been used in cats and rabbits
- IM (intramusc) and sometimes intra-articular (directly into the joint)
- Side effects of intra-articular: joint pain, swelling, lameness, rare infection of joint
- Side effects (K9): decreased blood clotting → bleeding from nose, blood in stool (or dark stool)
- Overdose is rare; signs: joint pain, swelling, lameness
Bryant, Jennifer O. (2012-12-10). The USDF Guide to Dressage: The Official Guide of the United States Dressage Foundation. Storey Publishing. ISBN 9781612122748.
| copy | {{cite book | last=Bryant | first=Jennifer O. | title=The USDF Guide to Dressage: The Official Guide of the United States Dressage Foundation | date=2012-12-10 | url=https://books.google.com/books?id=yHp40CJHd_gC&pg=PA285 | publisher=Storey Publishing | isbn=9781612122748}} |
- One of most widely prescribed joint supplements for horses
- IM done more than IA
Fox, Steven M. (2009-12-15). Chronic Pain in Small Animal Medicine. CRC Press. pp. 197–200. ISBN 9781840765670.
| copy | {{cite book | last=Fox | first=Steven M. | title=Chronic Pain in Small Animal Medicine | date=2009-12-15 | url=https://books.google.com/books?id=KvY5LR5yHQwC&pg=PA197 | publisher=CRC Press | isbn=9781840765670 | pages=197-200}} |
- "Chondroprotectant"
- Inhibit serine proteinases (play role in IL-1 mediated degradation of cartilage proteoglycans and collagen)
- Reportedly inhibits some catabolic enzymes (elastase, stromelysin, metalloproteinases, cathepsin G and B1, hyaluronidases), which degrade collagen, proteoglycans, and hyaluronic acid
- Inhibit PGE synthesis, stimulates GAG synthesis
- Inhibits aggrecanases, MMPs, NO, PGE2
- Potentiating effect on synth of hyaluronic acid by synovial membrane cells
- Increase concentration of hyaluronan
- Within 2 hours, enters joint and starts its shit
- Best to give in early stages of osteoarthritis - once hylaine cartilage is gone, it's gone
Goldberg, Mary Ellen (2014-10-23). Pain Management for Veterinary Technicians and Nurses. John Wiley & Sons. p. 140. ISBN 9781118811160.
| copy | {{cite book | last=Goldberg | first=Mary Ellen | title=Pain Management for Veterinary Technicians and Nurses | date=2014-10-23 | url=https://books.google.com/books?id=ECMVBQAAQBAJ&pg=PA140 | publisher=John Wiley & Sons | isbn=9781118811160 | page=140}} |
- Probably works also by altering C-reactive protein
- Improve lameness, range of motion, and pain
- 4.4 mg/Kg IM every 3-5 days for 8 injections in dogs
- Horses: 500mg ove every 4 days for 7 injections
- Can be continued once or twice every month if needed
- Off-label SQ route
- Off-label in cats at 2-5 mg/kg at 1-2 times a week for 8 injections
Khuly, Patty (2010-03-05). "Why I Love Adequan for Cats and Dogs". PetMD. Retrieved 2017-07-10.
| copy | {{cite web | last=Khuly | first=Patty | title=Why I Love Adequan for Cats and Dogs | work=PetMD | accessdate=2017-07-10 | date=2010-03-05 | url=http://www.petmd.com/blogs/fullyvetted/2010/march/adequan_cats_dogs-7028}} |
- Only approved for dogs and hoses
- Also used unofficially in cats
- Interstitial cystitis
- Derived from cow tracheas (WHAT)
- Inhibits enzyme that breaks down cartilage, increase thickness of joint fluid
- Also reduces bladder swelling and helps repair tracheas
Papich, Mark G. (2007). "Polysulfated Glycosaminoglycan". Saunders Handbook of Veterinary Drugs (2nd ed.). St. Louis, Mo: Saunders/Elsevier. pp. 537–538. ISBN 9781416028888.
| copy | {{cite book | last=Papich | first=Mark G. | title=Saunders Handbook of Veterinary Drugs | chapter=Polysulfated Glycosaminoglycan | location=St. Louis, Mo | date=2007 | edition=2nd | publisher=Saunders/Elsevier | isbn=9781416028888 | pages=537–538}} |
- Dogs/horses to treat/prevent deg. joint disease
- IA (aseptic) effective, IM may be too low for some
- Effective for acute arthritis, might not be as great for chronic arthropathy
Plumb, Donald C. (2011). "Polysulfated glycosaminoglycan (PSGAG)". Plumb's Veterinary Drug Handbook (7th ed.). Stockholm, Wisconsin; Ames, Iowa: Wiley. pp. 837–839. ISBN 9780470959640.
| copy | {{cite book | last=Plumb | first=Donald C. | title=Plumb's Veterinary Drug Handbook | chapter=Polysulfated glycosaminoglycan (PSGAG) | location=Stockholm, Wisconsin; Ames, Iowa | date=2011 | edition=7th | publisher=Wiley | isbn=9780470959640 | pages=837–839}} |
- Adequan, Chondropotect
- "Proteolytic enz, inhibitor; chondroprotectant"
- Some studies: PSGAG much less effective in joints w/acute trauma but no degenerative enz
- Pharm
- Acts as precursor to proteoglycan synth
- Deposited in all layers of joint cartilage, preferentially taken up by osteoarthritic cartilage
- IM: peak level in JOINTS @ 48 hours, lasts up to 96 hours
- No contraindication for IM use
- Hypersensitivity - contraindicates IA use
- But don't in place of other if infection is there
- Dose-related inhib of of coag/hemostasis in dogs
- FDA: category B for pregnancy
- Unknown if enters milk
- Overdose difficult
- 2% of horses getting up to 1250mg IA (normal IA dose is 250) got temporary clinical signs assoc. w/joint inflammation
- Some concern using it w/other NSAIDs or w/anticoags, since is heparin analgue
- Horses: IM, IA
- Dogs: non-infectious degenerative or traumatic arthritis or osteoarthritis: IM
- Cats: chondroprotective: IM
- Rabbits: arthritis: SQ or IM
- No human-labeled products
Schulz, Kurt; Beale, Brian; Holsworth, Ian (2005). The Pet Lover's Guide to Canine Arthritis & Joint Problems. Elsevier Health Sciences. ISBN 9781416026143.
| copy | {{cite book | last1=Schulz | first1=Kurt | last2=Beale | first2=Brian | last3=Holsworth | first3=Ian | title=The Pet Lover's Guide to Canine Arthritis & Joint Problems | date=2005 | url=https://books.google.com/books?id=6nS8k6asA6UC&pg=PA192 | publisher=Elsevier Health Sciences | isbn=9781416026143}} |
- PSGAGs are much larger than chondroitin sulfate (which is also used as a nutritional supplement), so more like the actual molecules in cartilage – once in the joint, it's more likely to stay there
- How it works is in theory
- Studies show conflicting results, so probably not Adequan alone causing significant healing
- Does seem to work in some dogs
- Works same way as supplements like glucosamine and chrondroitin
US National Library of Medicine (2016-08-24). "ADEQUAN CANINE". DailyMed. Retrieved 2017-07-10.
| copy | {{cite web | last=US National Library of Medicine | title=ADEQUAN CANINE | work=DailyMed | accessdate=2017-07-10 | date=2016-08-24 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b0fbf2e7-5a2a-4fa2-957c-3d4693a891fe}} |
- Rx veterinarian
- GAG in PSGAG is mostly chondroitin sulfate w/3-4 sulfate esters per disaccharide unit
- Molec. weight of PSGAG for Adequan is 3,000-15,000 daltons
- Mechanism
- Inhibit serine proteases (play a role in Il-L mediated degradation of proteoglycans and collagen)
- Inhibit synth of Prostoglandin E2 (which increases loss of proteoglycan)
- Stimulate synth of protein, collagen, proteoglycans, hyaluronic acid
- IM injection (rabbit): max concentration after 20-40 minutes
- Drug distributed to all tissues, inc. cartilage, lungs, eyes, spinal cord, heart, and brain
- Binds ot serium proteins in blood at 30-40%
- Diffuses from synovial fluid to cartilage (relatively low molecular weight), where it's deposited into cartilage matrix
- Metabolism
- In rabbits: liver, spleen, bone marrow, may also be in kidneys
- If not protein bound, excreted mainly by kidneys (some in feces)
- Toxicity
- At high concentration (50mg/kg): increased prothrombin time, decreased platelet count, increased ALT and cholesterol, increased weights of liver and kidney (latter 2 also at 15 mg/kg)
- Microscopic lesions at liver, kidneys, lymph nodes (at 15 mg/kg and 50 mg/kg)
- IM inflammation, hemorrhage, and degeneration dose-related; at 5mg/kg, 15, and 50
- Normal dose is 2mg/lb (4.4mg/kg)
- At high concentration (50mg/kg): increased prothrombin time, decreased platelet count, increased ALT and cholesterol, increased weights of liver and kidney (latter 2 also at 15 mg/kg)
- Contraindications
- Hypersensitivity to PSGAG
- Bleeding disorders (PSGAG is synthetic heparinoid)
- Supplied in 5mL multiple dose vials, by Elanco
- UNII: 268AW7000T
- NDC: 58198-0975
- Inactive ingredients
Wanamaker, Boyce P.; Massey, Kathy (2014-03-25). Applied Pharmacology for Veterinary Technicians - E-Book. Elsevier Health Sciences. p. 392. ISBN 9780323291705.
| copy | {{cite book | last1=Wanamaker | first1=Boyce P. | last2=Massey | first2=Kathy | title=Applied Pharmacology for Veterinary Technicians - E-Book | date=2014-03-25 | url=https://books.google.com/books?id=7s3sAwAAQBAJ&pg=PA392 | publisher=Elsevier Health Sciences | isbn=9780323291705 | page=392}} |
- PSGAG: repeat chain of hexosamine and hexuronic acid
- Extracted from bovine trachea for commercial use
- Preferentially taken up by osteoathritic cartilage
- Inhibit enzymes that damage cartilage matrix
- Also increase synovial fluid viscosity
- Reduce inflammation by inhibiting release of prostaglandin (released at joint injury)
- Use: noninfectious degenerative/traumatic joint dysfunction/lameness in horses' carpal joints
- And degenerative joint disorders in dogs
- And lameness in swine
- Can use amikacin w/intraartcular injection to prevent inf
White, Gary W; Stites, Trent; Jones, E. Wynn; Jordan, Scott (2003-07-01). "Efficacy of Intramuscular Chondroitin Sulfate and Compounded Acetyl-d-Glucosamine in a Positive Controlled Study of Equine Carpitis". Journal of Equine Veterinary Science. 23 (7): 295–300. doi:10.1016/S0737-0806(03)01006-2. ISSN 0737-0806. Retrieved 2017-07-10.
| copy | {{cite journal | last1=White | first1=Gary W | last2=Stites | first2=Trent | last3=Jones | first3=E. Wynn | last4=Jordan | first4=Scott | title=Efficacy of Intramuscular Chondroitin Sulfate and Compounded Acetyl-d-Glucosamine in a Positive Controlled Study of Equine Carpitis | journal=Journal of Equine Veterinary Science | accessdate=2017-07-10 | date=2003-07-01 | url=http://www.sciencedirect.com/science/article/pii/S0737080603010062 | doi=10.1016/S0737-0806(03)01006-2 | issn=0737-0806 | volume=23 | issue=7 | pages=295-300}} |
- No "generics" of Adequan actually approved as generics by FDA
- Contain chondroitin monosulfate and compounded acetyl-d-glucosamine, which are recommended off-label as Adequan substitutes
- Neither work as well as Adequan
White, Gary W. (1988-11-01). "Adequan: A review for the practicing veterinarian". Journal of Equine Veterinary Science. 8 (6): 463–468. doi:10.1016/S0737-0806(88)80096-0. ISSN 0737-0806. Retrieved 2017-07-10.
| copy | {{cite journal | last=White | first=Gary W. | title=Adequan: A review for the practicing veterinarian | journal=Journal of Equine Veterinary Science | accessdate=2017-07-10 | date=1988-11-01 | url=http://www.sciencedirect.com/science/article/pii/S0737080688800960 | doi=10.1016/S0737-0806(88)80096-0 | issn=0737-0806 | volume=8 | issue=6 | pages=463-468}} |
- Cartilage matrix in joints = proteoglycan complexes, collagen, water
- Proteoglycan complexes: protein core + glycosaminoglycan side chains (keratin, chondroitin sulfate)
- Attached to a strand of hyaluronate
- Hyaluronate works as "boundary lubricant" of soft tissue and as barrier btw blood vessels of sonival membrane and synovial cavity
- GAG: "polyanionic", adjacent side chains are pushed away → "bottle brush" of side chains
- Water is trapped in these complexes → can compress
- Exchange of stuff from chondrocytes and synovial fluid due to pumping action, which results from normal movement (when moving your joints)
- Under "mechanical load": products of metabolism of chondrocyte are pushed out into fluid
- Pressure relieved → fluid goes back into chondrocytes, bringing substrates and shit
- Intersperesed with collagen fibers
- Attached to a strand of hyaluronate
- Degenerative joint disease: start losing proteoglycan, which exposes collagen fibers and chrondrocytes to mechanical stress
- Damaged matrix has increased water content, damaging normal nutrient exhange btw chondrocytes and synovial fluid
- Which makes it harder for chondrocytes to repair what damage they can
- And matrix continues to be lost, and cartilage loses more capacity to withstand stress
- Collagen network collapses irreversably, and lose function of joint
- Softening/thickening oc cartilage → cartilage bexomes thinner → cartilage fragments and thickness lost → "marginal osteophyte formation" → "sclerosis of the subchondral bone, bone lysis, and lost of joint space"
- Quality/quantity of hyaluronate decreased
- Lowers viscosity of synovial fluid
- Increases friction; WBCs and enzymes enter synovial fluid and reach cartilage
- Inflammation
- Prostaglandin E2: longer vasodilation, increased blood vessel permeability, reduce threshold of pain receptors, negative effect on PG metabolism
- Enzymes released in response to injury destroy parts of cartilage matrix
- inc. lysosomal elastase, cathepsin B1, cahepsin G, hyaluronidase, serine protease, neurtral metalloproteinase
- PSGAG molec weight: 10,000–12,000 daltons
- Chemically close to glycosaminoglycans in cartilage, and related to heparin
- Affinity for deposition into cartilage, esp. damaged cartilage
- Excreted by kidneys, only partially breaks down active drug
- LD50 over 1000 mg/kg (IV, dogs)
- Mechanism
- PSGAG caused more chondrocytes to be synthesized
- Decrease in chondrocyte-death caused by steroids
- Inhibits the enzymes that are released in response to injury of joints that are listed above
- Inhibits dissociation of PG and hyaluronate caused by lysosomal enzymes
- Inhibits ability of cathepsin B1 as collagenase
- Inhibits neutral proteases as proteoglycanase
- Inhibits collagenase from being activated from inactive state
- Inhibits loss of PGs from cartilage
- Decrease inflammation → synovial fluid restored to normal
- Increase viscosity and decrease protein concentration in fluid
- Decreased infl → decreased pain (pain in degenerative joint disease very dependent on inflammation of of soft tissue)
- Inhibits synth of prostaglandin E2
- Inhibits complement reaction (part of infl response)
- Inhibits clotting system (blood coag → fibrinolysis, cell lysis, contributing to local inflammation)
- Chondroprotection
- Adequan approved for horses in US in 1984
White, Gary W. (2003-11-01). "Using glycosaminoglycans for treating equine joint diseases". dvm360. Retrieved 2017-07-10.
| copy | {{cite web | last=White | first=Gary W. | title=Using glycosaminoglycans for treating equine joint diseases | work=dvm360 | accessdate=2017-07-10 | date=2003-11-01 | url=http://veterinarynews.dvm360.com/using-glycosaminoglycans-treating-equine-joint-diseases}} |
- "Disease modifying osteoarthritis drug" bc inhibits enzymes that degrade and positive effect on synth of hyaluronic acid and GAGs
- [structure]
"Albendazole (Albenza) Use During Pregnancy". Drugs.com. Retrieved 4 August 2017.
| copy | <ref>{{cite web | title=Albendazole (Albenza) Use During Pregnancy | work=Drugs.com | accessdate=4 August 2017 | url=https://www.drugs.com/pregnancy/albendazole.html}}</ref> |
- Australia: category D
- Contraindicated during pregnancy and 1 month prior to conception
- US: category C
- Only use during pregnancy if there are no alternatives and benefits outweigh risks
- Teratogencicity (embryotoxicity and skeletal malfmormations) in pregnatn rats and rabbit
- Alb and metabolites excreted into breast milk
- But little was absorbed systemically, WHO says it's ok with breastfeeding
"Albendazole Monograph for Professionals". Drugs.com. Retrieved 24 July 2017.
| copy | <ref>{{cite web | title=Albendazole Monograph for Professionals | work=Drugs.com | accessdate=24 July 2017 | url=https://www.drugs.com/monograph/albendazole.html}}</ref> |
- [5-(Propylthio)-1H-benzimidazol-2-yl]-carbamic acid methyl ester
- Uses
- Neurocysticercosis
- From Cysticercus cellulosae, larval form of pork tapeworm (Taenia solium)
- Hydatid disease
- Of liver, lung, and peritoneum by larval form of dog tapeworm Echinococcus granulosus
- Of alveoli by Echinococcus multilocularis in cases where can't remove surgically
- Ascariasis
- By Ascaris lumbricoides
- Baylisascariasis
- By Baylisascaris procyonis
- Tx within 1–3 days of infection
- Helpful to use corticosteroids as well in cases of ocular and CNS infections
- Enterobiasis
- Caused by pinworm Enterobius vermicularis
- Filariasis
- By Mansonella perstans
- Can include antihistamines or coticosteroids to decrease allergic reactions from disintegration of microfilariae from tx
- By Wuchereria bancrofti or Brugia malayi
- As possible adjunct to ivermectin
- Suppresion of microfilaremia caused by these orgs
- Reduce microfilarmia in treating loiasis by Loa loa
- As possible adjunct or replacement to Diethylcarbamazine when that isn't working or can't be used
- Hookworm (cutaneous larva migrans – creeping eruption by larva)
- By dog and cat hookworms
- For eosinophilic entercolitis by dog hookworm Ancylostoma caninum
- By intestinal hookworms Ancylostoma duodenale or Necator americanus
- By dog and cat hookworms
- Toxocariasis (visceral larva migrans)
- By 'dog or cat roundworms (Toxocara canis or Toxocara catis)
- Can add corticosteroids in severe cases of cardiac, ocular, or CNS involvement or inflammation; might need Sx for secondary damage
- Strongyloidiaseis
- By threadworm Strongyloides stercoralis
- As alternative to ivermectin
- Trichostrongyliasis
- By Trichostrongylus
- As alternative to pyrantel pamoate
- Trichuriasis
- By whipworm Trichuris trichiura
- As alternative to mebendazole
- Capillariasis
- By Capillaria philippinensis
- As alternative to mebendazole
- Gnathostomiasis
- By Gnathostoma spinigerum
- With or without Sx removal
- Gongylonemiasis
- By Gongylonema
- Oesophagostomiaeis
- By Oesophagostomum bifurcum
- Trematode (fluke) infections
- By Chinese liver fluke Clonorchis sinensis
- Giardiasis
- Alternative or adjunct to metronidazole
- Can be especially useful in children
- Microsporidiosis
- By Encephalitozoon intestinalis
- Ocular microsporidiosis by E. hellem, E. cuniculi, Vittaforma cornae
- Conjuction with topical fumagillin for fist 2
- Disseminated microsporidiosis by E. hellem, E. cuniculi, E. intestinalis, Pleistophora, Trachipleistophora, Branchiola vesicularum
- Neurocysticercosis
- Cautions
- Teratogenic effects in rats and rabbits
- In treating neurocysticercosis
- Can cause CNS effects such as seizures or hydrocephalus due to inflammatory rxns due to intracerebral cysts caused by tx
- Destruction of cysticercal lesions can cause retinal damage
- Distributed in animal milk; unknown if distributed in human milk
- Interactions
- Cimetidine: increase concentration of albendazole in bile and cystic fluid if treating hydatid cysts
- Dexamethasone: increase albendazole trough concentrations
- Praziquantel: incrases plasma and AUC concentrations of albendazole
- With extrahepatic obstruction: increased serum concentration and half-life of albendazole sulfoxide
- Pharmakokinetics
- Low aqueous solubililty, so poor absorption from GI tract
- Converted to active metabolite albendazole sulfoxide (which actually does antihelminthic activity) before reaching systemic circulation
- Further metabolized to albendazole sulfone and other primary oxidative metabolites
- Wide distribution and detected in urine, bile, liver, cyst wall, cyst fluid, and CSF
- Detect <1% of albendazole sulfoxide in urine (also excreted in bile). Albendazole not detectable in urine
- Chemistry/mechanism
- Benzimidazole derivative
- Binds to beta-tubulin of parasites much better than beta-tubulin of mammals
- Doesn't inhibit glucose uptake in mammals
"Albendazole oxide". Pubchem. Retrieved 24 July 2017.
| copy | <ref>{{cite web | work=Pubchem | title=Albendazole oxide | accessdate=24 July 2017 | url=https://pubchem.ncbi.nlm.nih.gov/compound/83969}}</ref> |
- Alb sulfoxide (aka alb. oxide) also known as ricobendazole
"albendazole (Rx)". Medscape. Retrieved 24 July 2017.
| copy | <ref>{{cite web | title=albendazole (Rx) | work=Medscape | accessdate=24 July 2017 | url=http://reference.medscape.com/drug/albenza-albendazole-342648#4}}</ref> |
- Side effects
- More than 10%
- Headache
- Abnormal liver function
- 1–10%
- Abdominal pain
- Nausea/vomiting
- Dizziness/vertigo
- Increased intracranial pressure
- Meningeal signs
- Alopecia (reversible)
- Fever
- Less than 1% can include:
- Rash/hives
- Agranulocytosis
- Aplastic anemia
- Bone marrow suppression
- Granulocytopenia
- Pancytopenia
- Thrombocytopenia
- Hepatitis
- Acute liver failure
- Acute renal failure
- More than 10%
- Pregnancy category C
- Lactation: unknown
- Mechanism
- Degenerates microtubules in cytoplasm of intestinal and tegmental cells of helminths
- Pharmacokinetics
- Absorption: less than 5%, can increase up to 4–5 times w/fatty meal
- Distribution: Well inside hydatic cysts & CSG
- Protein bound: 70%
- Metabolism: hepatic (rapid sulfoxidation [major], hydrolysis, oxidation]
- Half-life: 8–12 hours
- Peak plasma time: 2–5 hrs
- Excretion urine (less than 1% as active metabolite), feces
- Forms
- 200mg tablet (brand name Albenza)
- Contraindications
- Grapefruit (can increase chance of side effects)
- Limit alcohol (since can cause liver problems)
- Store
- Keep away from light and moisture
"Albenza New FDA Drug Approval". CenterWatch. Retrieved 8 August 2017.
| copy | <ref>{{cite web | title=Albenza New FDA Drug Approval | work=CenterWatch | accessdate=8 August 2017 | url=http://www.centerwatch.com/drug-information/fda-approved-drugs/drug/126/albenza-albendazole}}</ref> |
- FDA approved for hydatid due to Echinococcus granulosis (larva form of dog tapeworm) and neurocysticercosis due to larval form of pork tapeworm, Taenia solium
"Albendazole". Meyler's Side Effects of Drugs (16th\ ed.). Oxford: Elsevier. 2016. pp. 102–110. ISBN 978-0-444-53716-4. {{cite book}}: |access-date= requires |url= (help); Unknown parameter |editors= ignored (|editor= suggested) (help)
| copy | <ref>{{cite book | editors=Aronson, J. K. | title=Meyler's Side Effects of Drugs |edition=16th\ | chapter=Albendazole | location=Oxford | accessdate=2 August 2017 | date=2016 | publisher=Elsevier | isbn=978-0-444-53716-4 | pages=102-110}}</ref> |
- Side effects: abdominal pain, diarrhea, nausea, dizziness, headache
- Has been used for cryptosporidiosis, isosporiasis, microsporidiosis
- Interactions
- Antiepileptics phenytoin, carbamazepine, and phenobarbital all made alb be oxidized, so that reduce concentration of albendazole sulfoxide in plsamsa
Bennett, John E.; Dolin, Raphael; Blaser, Martin J. (28 August 2014). Principles and Practice of Infectious Diseases. Elsevier Health Sciences. p. 520. ISBN 978-1-4557-4801-3.
| copy | <ref>{{cite book | last1=Bennett | first1=John E. | last2=Dolin | first2=Raphael | last3=Blaser | first3=Martin J. | title=Principles and Practice of Infectious Diseases | date=28 August 2014 | page=520 | url=https://books.google.com/books?id=BseNCgAAQBAJ&pg=PA520 | publisher=Elsevier Health Sciences | isbn=978-1-4557-4801-3}}</ref> |
- CYP3A4 converts to inactive metabolite albendazole sulfone
- Diff species produce diff enantiomers; humans mostly produce R(+) enantiomer
R(+) by microsomal flavin monooxidase
- S(-) by cytochrome P450 CYP3A and in the gut epithelium
- Enzymes (mainly CYP3A4) convert alb sulfoxide to alb sulfone
- In pts with neurocyst., albendazole R(+) sulfoxide accumulates more in CSF than S(-)
- R(+) more active agasint Taenia solium than S(-)
- Pharmakokinetics differ a bit btw men and woman
- Oral clearance and volume of distribution lower in women
- Serum peak concentration lower in men
- Food enhances oral bioavailability
- (Presumably) stimulates gastric acid secretion, and alb, absorption is pH-dependent
- Alb. sulf crosses BBB and is in CSF at 43% of plasma levels (though differs btw indivs)
- Can penetrate CNS, so can treat neurocyst.
- Side effects
- Most common: transient liver fxn abnormalities (less than 20%) and alopecia (5%)
- Bone marrow toxicity is rare but irreversible
- Cimetidine: inhibits absorption bc reduces gastric acicidity
- But also inhibits metabolism of alb. sulfoxide by interfering with CYP3A4 enz, so prolongs elmination half-life from 7.4 hours to 19 hours
- Grapefruit: inhibits metabolism of albendazole in intestinal mucosa
- Long-term admin of ritonavir (CYP3A4 inhibitor) decreased AUC and Cmax of alb.
Briggs, Gerald G.; Freeman, Roger K.; Yaffe, Sumner J. (2011). Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Lippincott Williams & Wilkins. p. 31. ISBN 978-1-60831-708-0.
| copy | <ref>{{cite book | last1=Briggs | first1=Gerald G. | last2=Freeman | first2=Roger K. | last3=Yaffe | first3=Sumner J. | title=Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk | date=2011 | page=31 | url=https://books.google.com/books?id=OIgTE4aynrMC&pg=PA31 | publisher=Lippincott Williams & Wilkins | isbn=978-1-60831-708-0}}</ref> |
- If need albendazole during pregnancy, avoid 1st trimester
Boullata, Joseph I.; Armenti, Vincent T. (17 March 2010). Handbook of Drug-Nutrient Interactions. Springer Science & Business Media. p. 306. ISBN 978-1-60327-362-6.
| copy | <ref>{{cite book | last1=Boullata | first1=Joseph I. | last2=Armenti | first2=Vincent T. | title=Handbook of Drug-Nutrient Interactions | date=17 March 2010 | page=306 | url=https://books.google.com/books?id=6MSRviXlDtAC&pg=PA306 | publisher=Springer Science & Business Media | isbn=978-1-60327-362-6}}</ref> |
- Broad specturm, vs. larva and adults of trematodes and cestodes
- If want intestinal parasites, should be given on empty stomach so have intraluminal effects
Bowman, Dwight D. (12 March 2014). Georgis' Parasitology for Veterinarians - E-Book. Elsevier Health Sciences. p. 282. ISBN 978-1-4557-3988-2.
| copy | <ref>{{cite book | last=Bowman | first=Dwight D. | title=Georgis' Parasitology for Veterinarians - E-Book | date=12 March 2014 | page=282 | url=https://books.google.com/books?id=7CFLBAAAQBAJ&pg=PA282 | publisher=Elsevier Health Sciences | isbn=978-1-4557-3988-2}}</ref> |
- Treats giardia in humans, mice, dogs, cattle
- Aplastic anemia/toxic in dogs and cats
Capece, Bettencourt P. S.; Virkel, Guillermo L.; Lanusse, Carlos E. (1 September 2009). "Enantiomeric behaviour of albendazole and fenbendazole sulfoxides in domestic animals: Pharmacological implications". The Veterinary Journal. 181 (3): 241–250. doi:10.1016/j.tvjl.2008.11.010. ISSN 1090-0233.
| copy | <ref>{{cite journal | last1=Capece | first1=Bettencourt P. S. | last2=Virkel | first2=Guillermo L. | last3=Lanusse | first3=Carlos E. | title=Enantiomeric behaviour of albendazole and fenbendazole sulfoxides in domestic animals: Pharmacological implications | journal=The Veterinary Journal | date=1 September 2009 | doi=10.1016/j.tvjl.2008.11.010 | issn=1090-0233 | volume=181 | issue=3 | pages=241-250}}</ref> |
- Most species have more (+) alb sulfoide than (-)
- (-) is depleted at faster rate
- Alb sulfoxide has an oxidized sulfur that makes the chemical more water-soluble
- Alb sulfoxide crosses BBB and placenta in humans
- alb sulfoxide is more water soluble due to oxidized sulfur atom
- alb → alb sulfoxide
- Cytochrome P450 and flavin-monooxygenase
- FMO mainly produce +, while cytochrome P450 isoenzymes 2C6 and 2A1 mainly produce - (rat liver)
- Ruminants: metabolism on GI tract due to gut microflora
- Liver; oxidative metabolism
- GI: reduction of foreign compounds, especially those w/nitro and sulfoxide groups (so alb sulfoxide → alb)
- (+) version was used up more
- (-) alb sulfoxide has lower pharmacological activity, leaves blood faster
Dayan, A. D (1 May 2003). "Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics". Acta Tropica. Preparing to control Schistosomiasis and Soil-transmitted Helminthiasis in the Twenty-First Century. 86 (2): 141–159. doi:10.1016/S0001-706X(03)00031-7. ISSN 0001-706X.
| copy | <ref>{{cite journal | last=Dayan | first=A. D | title=Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics | journal=Acta Tropica | series=Preparing to control Schistosomiasis and Soil-transmitted Helminthiasis in the Twenty-First Century | date=1 May 2003| doi=10.1016/S0001-706X(03)00031-7 | issn=0001-706X | volume=86 | issue=2 | pages=141-159}}</ref> |
- Britain approved for cattle and sheep
- Oral absorption: 20–30% in rats, 1–5% in humans, 50% in cattle
- Very rapid 1st pass metabolism in all species, so that can't reliably detect unchanged drug in plasma
- Eat with fatty food: alb dissolved better in lipids
- Metabolism of albendazole by cytochrome P450 oxidases and other flavin-containing oxidases
- P450 1A1 and 3A4
- P450 enzymes make (-), while flavin enzymes (flavine-adenine-dinucleodtide monooxygenase) make (+)
- P450 isozymes then make alb sulfone
- First approved for human use in 1982
- Not recommended in kids under 6
- Approved in Britain for cattle and sheep, inc. pregnant animals and their young
- Oral absorption
- Rats: 20–30%
- Cattle: ~50%
- Humans: 1–5%
- Very fast 1st pass metabolism in all species, so can't reliably detect unchanged drug in plasma
- Plasma levels of sulfoxide and sulfone are much higher
- Peak levels of albendazole and of alb sulfoxide is 2–3 hours (in humans, rats, and sheep)
- Half life of alb sulfoxide
- 8–12 hours in humans
- Only the metabolites are excreted (since drug is very extensively metabolized); largely in bile
- Alb sulfoxide has a chiral center
- Cytochrome P450 oxidases makes (-), flavin-containing oxidases (+)
- (+) is the main one in human plasma and dogs
- Humans: 80:20 ratio of +:-
- Dogs: 70:30
- Rats is around the same: 59:41
- The + is make by oxidation by a flavine-adenine-dinucleotide monooxygenase
- The - is makde by P450 enzyme
- P450 isoenzymes convert alb sulfoxide to alb sulfone
- P450 1A1 also involved in alb → alb sulfoxide
"EC 1.14.13.8". Retrieved 5 August 2017.
| copy | <ref>{{cite web | title=EC 1.14.13.8 | accessdate=5 August 2017 | url=http://www.chem.qmul.ac.uk/iubmb/enzyme/EC1/14/13/8.html}}</ref> |
- Flavin-containing monooxygenase, aka flavin monooxygenase, aka FAD-containing monooxygenase
Fargetton, X.; Galtier, P.; Delatour, P. (1 December 1986). "Sulfoxidation of albendazole by a cytochrome P450-independent monooxygenase from rat liver microsomes". Veterinary Research Communications. 10 (1): 317–324. doi:10.1007/BF02213995. ISSN 0165-7380.
| copy | <ref>{{cite journal | last1=Fargetton | first1=X. | last2=Galtier | first2=P. | last3=Delatour | first3=P. | title=Sulfoxidation of albendazole by a cytochrome P450-independent monooxygenase from rat liver microsomes | journal=Veterinary Research Communications | date=1 December 1986 | doi=10.1007/BF02213995 | issn=0165-7380 | volume=10 | issue=1 | pages=317-324}}</ref> |
- Previously just thought that cytochrome P450 monooxygenase system was only responsible for oxidation of alb, but later found that also due to flavin-containing monooxygenase (EC 1.14.13.8)
Farrar, Jeremy; Hotez, Peter J.; Junghanss, Thomas; Kang, Gagandeep; Lalloo, David; White, Nicholas J. (26 October 2013). Manson's Tropical Diseases E-Book. Elsevier Health Sciences. p. 807. ISBN 978-0-7020-5306-1.
| copy | <ref>{{cite book | last1=Farrar | first1=Jeremy | last2=Hotez | first2=Peter J. | last3=Junghanss | first3=Thomas | last4=Kang | first4=Gagandeep | last5=Lalloo | first5=David | last6=White | first6=Nicholas J. | title=Manson's Tropical Diseases E-Book | date=26 October 2013 | page=807 | url=https://books.google.com/books?id=GTjRAQAAQBAJ&pg=PA807 | publisher=Elsevier Health Sciences | isbn=978-0-7020-5306-1}}</ref> |
- Increase in liver enzymes: in most cases, was mild to moderate (2 to 4 times normal level)
- Stopping tx recommended when goes above 4x normal levels
- Bone marrow suppression is extremely rare
- Reversible leucopaenia in less than 1% of patients
Finch, Roger G.; Greenwood, David; Whitley, Richard J.; Norrby, S. Ragnar (30 November 2010). Antibiotic and Chemotherapy E-Book. Elsevier Health Sciences. pp. 101, 685, 844. ISBN 978-0-7020-4765-7.
| copy | <ref>{{cite book | last1=Finch | first1=Roger G. | last2=Greenwood | first2=David | last3=Whitley | first3=Richard J. | last4=Norrby | first4=S. Ragnar | title=Antibiotic and Chemotherapy E-Book | date=30 November 2010 | pages=101, 685, 844 | url=https://books.google.com/books?id=DE4Mxc3aesEC&pg=PA101 | publisher=Elsevier Health Sciences | isbn=978-0-7020-4765-7}}</ref> |
- Drug interactions
- Carbamazepine: decrease (+)-alb. sulf AUC by 49% and Cmax by 50–63%
- Phenobarbitol: decrease (+)-alb sulf AUC by 61% and Cmax by 50–63%
- Phenytoin: decrease (+)-alb sulf AUC by 66% and Cmax by 50–63%
- Cimetidine: increase plasma concentration of alb sulf, and t_(1/2 beta) from 7.4 h to 19 h
- Dexamethasone: increase alb suf plasma concentration by 50%
- Levamisole: decrease alb sulf AUC by 75%
- Pharmakokin
- Better oral absorption than other benzimidazole carbamates
- Used for
- Alternative therapy to Ocular larvea migrans p685
- Single dose to eliminate most Ascaris p844
- Highly effective vs. T. trichiura when given with ivermectin
Georgiev, Vassil St (29 December 1997). Infectious Diseases in Immunocompromised Hosts. CRC Press. p. 695. ISBN 978-0-8493-8553-7.
| copy | <ref>{{cite book | last=Georgiev | first=Vassil St | title=Infectious Diseases in Immunocompromised Hosts | date=29 December 1997 | page=695 | url=https://books.google.com/books?id=73QOP6Xqh6EC&pg=PA695 | publisher=CRC Press | isbn=978-0-8493-8553-7}}</ref> |
- Bind to microtubules: interfere w/nutrient uptake and cell division (microtubules needed to form spindles for nuclear division in parasites)
- Microsporidia
- Only place where microtubules are made is in intranuclear spindles. No spindles → no chromosome segregation → clumped chromatin
- Alb changed sporogeny; also resulted in spores w/o developed inner concent, polar tubules extruding from parasitoporous vacuoles
Gouma, D. J. (2004). Update Gastroenterology 2004: New Developments in the Management of Benign Gastrointestinal Disorders. John Libbey Eurotext. p. 144. ISBN 978-2-7420-0538-3.
| copy | <ref>{{cite book | last=Gouma | first=D. J. | title=Update Gastroenterology 2004: New Developments in the Management of Benign Gastrointestinal Disorders | date=2004 | page=144 | url=https://books.google.com/books?id=FfyJeSjyo-IC&pg=PA144 | publisher=John Libbey Eurotext | isbn=978-2-7420-0538-3}}</ref> |
- Pharmacokin
- Main factors for absorption: gastric pH, intestinal degradation
- Gastric pH
- On empty stomach, absorption varies a lot from person to person (diff gastric pHs)
- Intestinal degradation
- Degraded in small intestine lumen by cytochrome P-450 enzymes in the vili
- As one one of the first treatments
- A. lumbricoides (roundworm)
- E. vernicularis (pinworm/threadworm)
- A. duodenale
- Cysticercosis (pork tapeworm larval stage)
- E. muiltilocularis (hydatid disease)
- As alternative
- Trichuris trichiura (whipworm) alt to mebendazole
- Strongyloides stercoralis (alt to thiabendazole)
- A. braziliense: alt to thiabendazole)
- Beef & pork tapeworms: alt to niclosamide or praziquantel
Jung, Helgi; Gonzáles-Esquivel, Dinora F. (2002). "Pharmacology of Anticysticeral Therapy". Taenia Solium Cysticercosis: From Basic to Clinical Science. CABI. pp. 368–371. ISBN 978-0-85199-839-8. {{cite book}}: Unknown parameter |editors= ignored (|editor= suggested) (help)
| copy | <ref>{{cite book | editors=Gagandeep Singh, Sudesh Prabhakar | last1=Jung | first1=Helgi | last2=Gonzáles-Esquivel | first2=Dinora F. | title=Taenia Solium Cysticercosis: From Basic to Clinical Science | chapter=Pharmacology of Anticysticeral Therapy | date=2002 | url=https://books.google.com/books?id=lCAd10-uTtQC&pg=PA368 | publisher=CABI | isbn=978-0-85199-839-8 | pages=368–371}}</ref> |
- Structures of alb → alb sulfoxide → alb sulfone
- Microtubule destruction: vesicles can't transport, intestinal cells can't take up glucose (parasite starves)
- Pharmacokinetics
- alb → alb sulfoxide → alb sulfone and 6 other inactive metabolites
- 2 pathways of alb → alb sulfoxide (sulfoxidation)
- Flavin-containing mono-oxygenase system (oxidized alb via NADPH-dependent reaction)
- Cytocrome P450 oxidizes alb sulfoxide to alb sulfone
- given albendazole: AUC ratio of (+) to (-) alb sulfoixide is 80:20
- Higher levels of (+) in plasma
- alb is 89–91% protein bound; alb sulfoxide is 63–65%
- High protein binding of alb doesn't mean much, since converted to alb sulfoxide so quickly
- Find alb sulfoxide in CSF after oral alb]
- Interactions
- Dexamethasone: presumably impaired elimination of albso, so albso levels in plasma increased by 50%
- Praziquantel: AUC of albso incraseased 4.5-fold
- High therapeutic index
- Possibly bc low solubility, so can't absorb enough to be toxic
- 6–11% patients get headache, nausea, vomiting (most common SEs), due to acute inflammation to to sudden destruction of cysticerci
- High doses of over longer periods of time (1 mo): elevated liver enzymes, headache, hair loss, neutropenia, fever, rash, acute renal failure
- Possibly hepatoxicity, independent of albso levels
- Forms
- 1996 OK'd by FDA against parenchymal NC
- Oral suspension or 200mg or 400mg tablets
- Common brand names: Zentel, Eskazole, Albenza
Junquera, P. "Albendazole Toxicity, Poisoning, Intoxication, Overdose, Antidote: Safety Summary for Veterinary Use on Dogs, Cats, Cattle, Sheep, Goats, Swine and Poultry" (Parasitipedia). Retrieved 24 July 2017.
| copy | <ref>{{cite web | last=Junquera | first=P. | title=Albendazole Toxicity, Poisoning, Intoxication, Overdose, Antidote: Safety Summary for Veterinary Use on Dogs, Cats, Cattle, Sheep, Goats, Swine and Poultry | format=Parasitipedia | accessdate=24 July 2017 | url=http://parasitipedia.net/index.php?option=com_content&view=article&id=2697&Itemid=2960}}</ref> |
- In worms, blocking microtubules disrupts uptake of glucose
- So energy blocked, and worms are paralyzed and die or are expelled
- Also disturb cell division, so worm egg production and development also blocked (i.e. have ovicidal effect)
- Blocks fumarate reductase, enz in helminths that works in energy management
- Overdose signs/symptoms
- Most effects on liver, testicles, and GI tract
- Lethargy, loss of appetite, intestinal cramps, nausea, diarrhea, vomiting
- Also dizziness, convulsions, sleepiness
- No specific antidote
- Warnings
- Pregnant dogs: reduce weight of puppies and cause cleft palate
- Birds: reduce egg-laying and hatching
- Pharmacokinetics
- Metabolized into sulfoxide derivative, which is also sold as ricobendazole
- Ruminants: part of sulfoxide produced released back into rumen, where microbial flora reduces it to albendazole; increasese bioavailability
- Ruminants: 60–70% excreted as metabolites in urine
- Sheep: 14% excreted as bile as active metabolites, so helps work in bile ducts as well
- Cats, dogs, birds: no rumen reservoir, so greatly shortens residual effect; might need higher dose or more frequent treatment
- Dogs: alb. sulfoxide detectable in plasma for less than 12 hours
- Sheep and goat: alb. sulfoxide detectable in plasma for ~3 days
Junquera, P. "Ricobendazole = Albendazole Sulfoxide for Veterinary Use on Cattle, Sheep, Goats, Pig Poultry, Dogs and Cats against roundworms, tapeworms and liver flukes". Retrieved 24 July 2017.
| copy | <ref>{{cite web | last=Junquera | first=P. | title=Ricobendazole = Albendazole Sulfoxide for Veterinary Use on Cattle, Sheep, Goats, Pig Poultry, Dogs and Cats against roundworms, tapeworms and liver flukes | accessdate=24 July 2017 | url=http://parasitipedia.net/index.php?option=com_content&view=article&id=2518&Itemid=2791}}</ref> |
- Completely ineffective vs. external parasites
- The only benzimidazole than can be injected and also is available for drenching
- Used a lot in ruminants in some countries (those in Latin America) but not elsewhere
- All benzimidazoles have no residual effect (unless: kill within a few hours, but don't protect much against reinfestation
- Dogs, cats, cattle, sheep, goats
- Oral LD50: 2400 mg/kg (rats)
- Dermal LD50: not found
- Can be teratogenic
Junquera, P. (12 December 2016). "Trichuris Spp, Parasitic Whipworms of Dogs, Cats and Livestock - Cattle, Sheep, Goats and Pigs; Biology, prevention and control". Parasitopedia. Retrieved 3 August 2017.
| copy | <ref>{{cite web | last=Junquera | first=P. | title=Trichuris Spp, Parasitic Whipworms of Dogs, Cats and Livestock - Cattle, Sheep, Goats and Pigs; Biology, prevention and control | work=Parasitopedia | accessdate=3 August 2017 | date=12 December 2016 | url=http://parasitipedia.net/index.php?option=com_content&view=article&id=2601&Itemid=2883}}</ref> |
- Dogs: Trichuris vulpis, Trichuris campanula
- Cats: Trichuris serrata, Trichuris campanula
- Cattle, sheep, goats and other ruminants: Trichuris discolor, Trichuris globulosa, Trichuris ovis
- Pigs: Trichuris suis
Karkhanis, Aneesh; Hong, Yanjun; Chan, Eric Chun Yong (1 July 2017). "Inhibition and inactivation of human CYP2J2: Implications in cardiac pathophysiology and opportunities in cancer therapy". Biochemical Pharmacology. 135: 12–21. doi:10.1016/j.bcp.2017.02.017. ISSN 0006-2952.
| copy | <ref>{{cite journal | last1=Karkhanis | first1=Aneesh | last2=Hong | first2=Yanjun | last3=Chan | first3=Eric Chun Yong | title=Inhibition and inactivation of human CYP2J2: Implications in cardiac pathophysiology and opportunities in cancer therapy | journal=Biochemical Pharmacology | date=1 July 2017 | doi=10.1016/j.bcp.2017.02.017 | issn=0006-2952 | volume=135 | pages=12-21}}</ref> |
- Albendazole → omega-hydroxyalbendazole by CYP2J2
"KEGG ENZYME: 1.14.13.32". Retrieved 5 August 2017.
| copy | <ref>{{cite web | title=KEGG ENZYME: 1.14.13.32 | accessdate=5 August 2017 | url=http://www.genome.jp/dbget-bin/www_bget?enzyme+1.14.13.32}}</ref> |
- Albendazole monooxygenase, aka cytochrome P450 3A4
Maddison, Jill E.; Page, Stephen W.; Church, David (2008). Small Animal Clinical Pharmacology. Elsevier Health Sciences. pp. 208, 250–280. ISBN 978-0-7020-2858-8.
| copy | <ref>{{cite book | last1=Maddison | first1=Jill E. | last2=Page | first2=Stephen W. | last3=Church | first3=David | title=Small Animal Clinical Pharmacology | date=2008 | pages=208, 250–280 | url=https://books.google.com/books?id=RpsROVqemk8C&pg=PA208 | publisher=Elsevier Health Sciences | isbn=978-0-7020-2858-8}}</ref> |
- Developed in 1973
- Not actually approved for use in cats and dogs
- Broadest spectrum of the benzimidazoles
- Dogs and cats
- Filaroides hirthi (nematode)
- Paragonimus westermani, P. ohirai, P. kellcotti (trematode)
- Pneumocystis carinii (w/trimethoprim)
- Encephalitozoan cuniculi
- Toxacara canis, catis
- Trichinella apiralis
Papich, Mark G. (2007). "Albendazole". Saunders Handbook of Veterinary Drugs (2nd ed.). St. Louis, Mo: Saunders/Elsevier. pp. 8–9. ISBN 978-1-4160-2888-8.
| copy | <ref>{{cite book | last=Papich | first=Mark G. | title=Saunders Handbook of Veterinary Drugs | chapter=Albendazole | location=St. Louis, Mo | date=2007 | edition=2nd | publisher=Saunders/Elsevier | isbn=978-1-4160-2888-8 | pages=8–9}}</ref> |
- "Valbazen"
- Anti-parasitic
- Benzimidazole
- Inhibits glucose uptake in parasites
- For:
- Intestinal helminths
- Capillaria aerophilia, Paragonimus kellicotti, Aelurostrongylus abstrusus, Filaroides sp., Osterus osteri
- Parasites in respiratory system
- Giardia in small animals
- Horses: Dictyocaulus amfieldi, Strongylus vulgaris
- Cattle and sheep as antiparasitic
- Intestinal helminths
- Associated w/bone marrow suppression/toxicity in dogs and cats at high doses
- Other species have high margin of safety
- Side effects: anorexia, lethargy, bone marrow toxicity
- More likely when longer than 5 days
- 113.6 mg/mL suspension and 300 mg/mL paste
- Don't use in 1st 45 days of pregnancy
- 27 days cattle withdrawal time for meat
Plumb, Donald C. (2011). "Albendazole". Plumb's Veterinary Drug Handbook (7th ed.). Stockholm, Wisconsin; Ames, Iowa: Wiley. pp. 19–21. ISBN 978-0-470-95964-0.
| copy | <ref>{{cite book | last=Plumb | first=Donald C. | title=Plumb's Veterinary Drug Handbook | chapter=Albendazole | location=Stockholm, Wisconsin; Ames, Iowa | date=2011 | edition=7th | publisher=Wiley | isbn=978-0-470-95964-0 | pages=19–21}}</ref> |
- "Albenza", "Valbluzen"
- aka albendazolum
- Non-lactating cattle:
- Osteragia ostertagi
- Haemonchus spp
- Trichostrongylus sp
- Nematodus sp
- Cooperice sp
- Bunostomum phlebotomum
- Oesphagostum
- Dictacaulus vivaparous (adult and stage 4 larva)
- Fasciola hepatica (adult)
- Moniezia
- Sheep
- Ostertagia circumcinta
- Marshallagia marshalli
- Haemonchus contortus
- Trichostrongylus
- Nematodus
- Cooperice
- Oesphagostomum
- Chibertia ovina
- Dictacaulus filaria
- Fasciola hepatica
- Fascioides magra
- Moniezoa expanse
- Thysanosoma actinoides
- Cats
- Paragonimus kellicotti
- Capillariasis
- Platynosum
- opisthorchidoe
- Dogs
- Filaroides
- Capillariasis
- Leishmaniases
- Rabbits
- Encephalitozoon phacoclastic uveitis
- E. cumiculi
- Chinchilla
- Giardia
- Birds (ratites): flagellate parasites and tapeworms
- Extra-label in small mammals, goats, pigs for endoparasites
- Mech
- Bind to tubulin and damage, prevent tubulilne polymerization, inhibit microtubule formation
- Total: disrcupt intracellular microtubule transport systems
- At higher concentrations:
- Disrupt metab paths in helminths
- Inhibit metabolic enzymes (inc. malate dehydrogenase and fumarate reductase)
- Bind to tubulin and damage, prevent tubulilne polymerization, inhibit microtubule formation
- Pharmacokin
- Better oral absorption than other benzimidazole
- Side effects
- Dogs: anorexia
- Cats: lethargy, depression, anorexia
- FDA cat C for pregnancy
- Doses @30x normal → cattle dies
- Doses @20x normal → sheep dies
- Drug interactions
- Cimetidine (increase alb in bile and cystic fluid)
- Dexamthasone (increase alb in serum)
- Praziquantel (increase alb in serum)
- Have alb oral 200mg tablets for humans (Rx)
- Albendazole suspension/paste both OTC
Rawden, Helen C.; Kokwaro, Gilbert O.; Ward, Stephen A.; Edwards, Geoffrey (1 April 2000). "Relative contribution of cytochromes P-450 and flavin-containing monoxygenases to the metabolism of albendazole by human liver microsomes". British Journal of Clinical Pharmacology. 49 (4): 313–322. doi:10.1046/j.1365-2125.2000.00170.x. ISSN 1365-2125.
| copy | <ref>{{cite journal | last1=Rawden | first1=Helen C. | last2=Kokwaro | first2=Gilbert O. | last3=Ward | first3=Stephen A. | last4=Edwards | first4=Geoffrey | title=Relative contribution of cytochromes P-450 and flavin-containing monoxygenases to the metabolism of albendazole by human liver microsomes | journal=British Journal of Clinical Pharmacology | date=1 April 2000 | doi=10.1046/j.1365-2125.2000.00170.x | issn=1365-2125 | volume=49 | issue=4 | pages=313-322}}</ref> |
- (In humans:)
- Alb → alb sulfoxide
- Flavin-containing monoxygenase and CYP3A4
- Alb sulfoxide → alb sulfone
- CYP
- Also have alb sulfone → 2-aminosulfone, gamma-hydroxysulfone, and beta-hydroxysulfone
Riviere, Jim E.; Papich, Mark G. (17 March 2009). Veterinary Pharmacology and Therapeutics. John Wiley & Sons. pp. 1054, 1062. ISBN 978-0-8138-2061-3.
| copy | <ref>{{cite book | last1=Riviere | first1=Jim E. | last2=Papich | first2=Mark G. | title=Veterinary Pharmacology and Therapeutics | date=17 March 2009 | pages=1054, 1062 | url=https://books.google.com/books?id=ievLulSqwBAC&pg=PA1054 | publisher=John Wiley & Sons | isbn=978-0-8138-2061-3}}</ref> |
- Mech
- All microtubule functions are inhibited: cell division, maintaining cell shape, cell motility, nutrient absorption, intracellular transport
- Binds much better to parasite tubulin than mammalian tubulin (so wide safety margin in mammals(
- In ruminants, sulfoxide can be turned back to normal albendazole in GI tract
- Preference for turning (+) back over turning (-) back
- Absorption depends on lipid solubility and degree of ionization at GI pH levels, since mucus surface of GI tracts acts as lipid barrier agasint absorption
- (+) sulfoxide, compared to (-):
- Longer in bloodstream
- Higher concentration in tissues/fluids where parasites are
- Higher concentration within parasites
- Higher nemotidicidal activity
"Showing Protein Cytochrome P450 3A4 (HMDBP01018)". Human Metabolome Database. Retrieved 5 August 2017.
| copy | <ref>{{cite web | title=Showing Protein Cytochrome P450 3A4 (HMDBP01018) | work=Human Metabolome Database | accessdate=5 August 2017 | url=http://www.hmdb.ca/proteins/HMDBP01018}}</ref> |
- Cytochrome P450 3A4 = Albendazole monooxygenase
Stipanuk, Martha H.; Caudill, Marie A. (13 August 2013). Biochemical, Physiological, and Molecular Aspects of Human Nutrition - E-Book. Elsevier Health Sciences. p. 564. ISBN 978-0-323-26695-6.
| copy | <ref>{{cite book | last1=Stipanuk | first1=Martha H. | last2=Caudill | first2=Marie A. | title=Biochemical, Physiological, and Molecular Aspects of Human Nutrition - E-Book | date=13 August 2013 | page=564 | url=https://books.google.com/books?id=XVNPAQAAQBAJ&pg=PA564 | publisher=Elsevier Health Sciences | isbn=978-0-323-26695-6}}</ref> |
- Gene CYP3A4 → albendazole monooxygenase
Sweet, Richard L.; Gibbs, Ronald S. (2009). Infectious Diseases of the Female Genital Tract. Lippincott Williams & Wilkins. pp. 379, 382–383. ISBN 978-0-7817-7815-2.
| copy | <ref>{{cite book | last1=Sweet | first1=Richard L. | last2=Gibbs | first2=Ronald S. | title=Infectious Diseases of the Female Genital Tract | date=2009 | pages=379, 382–383 | url=https://books.google.com/books?id=wuR_ngItU5oC&pg=PA379 | publisher=Lippincott Williams & Wilkins | isbn=978-0-7817-7815-2}}</ref> |
- Drug of choice
- A. lumbricoides (single dose)
- E. vermicularis
- Necator americanus,A. duodenale (single dose)
- S. stercoralis
- Can be given with diethylcarbamine to lower microfilaremia level
- T. trichiura (once)
- Trichinella spiralis
- E. granulosis (hydatid cysts), E. multilocularis, hepatid hydatid disease
- Possible adjunct to sx
- Alternative
- Loa loa
- Slowly reduce microfilarial level by having embryotoxic effect on adult worms
- Loa loa
Tran, Christina. "Albendazole". Retrieved 5 August 2017.
| copy | <ref>{{cite web | last=Tran | first=Christina | title=Albendazole | accessdate=5 August 2017 | url=https://web.stanford.edu/group/parasites/ParaSites2005/Albendazole/}}</ref> |
- FDA labeled indications for hydatid diseae and neurocysticercosis
- But lots of off-label uses
Tripathi, K. D. (30 September 2013). Essentials of Medical Pharmacology. JP Medical Ltd. p. 850. ISBN 978-93-5025-937-5.
| copy | <ref>{{cite book | last=Tripathi | first=K. D. | title=Essentials of Medical Pharmacology | date=30 September 2013 | page=850 | url=https://books.google.com/books?id=FfG8AQAAQBAJ&pg=PA850 | publisher=JP Medical Ltd | isbn=978-93-5025-937-5}}</ref> |
- One of drugs of choice
- A. lumbricoides
- Hookworms:A. duodenale, Necator americanos
- Pinworm (E. vermicularis)
- Trichinella spiralis
- Neurocysticercosis
- Hydatid disease (E. granulosus, E. multiocularis)
- Alternative
- S. stercoralis (alt to ivermectin)
- Whipworm T. trichiura: alt to mebendazole
- Filaria by W. bancrofit and B. malayi
- T. saginata and solium (alts to praziquantel for solium, praziquantel or niclosamide for saginata)
Turner, Arthur; Horton, John (30 December 1987). "Albendazole". Logan Turner's Diseases of the Nose, Throat and Ear (10th ed.). CRC Press. pp. 2228–2239. ISBN 978-0-340-92767-0.
| copy | <ref>{{cite book | last1=Turner | first1=Arthur | last2=Horton | first2=John | title=Logan Turner's Diseases of the Nose, Throat and Ear | chapter=Albendazole | date=30 December 1987 | edition=10th | publisher=CRC Press | isbn=978-0-340-92767-0 | pages=2228–2239}}</ref> |
- Originally made as veterinary antihelmintic
- Registered for humans in 1982
- Insoluble in water, so haven't developed parenteral preparations
- Antimicrobial activity
- Very broad spectrum
- Works against most human nematode and cestodes species; less against trematode species
- Mechanism
- Beta tublin
- Loss of cytoplasmic microtubules prevents eggs from hatching
- Pharmacokin
- Drug absorption not needed for intestinal infections
- Systemic parasites: albendazole acts as the prodrug, and albendazole sulfoxide is the active drug
- A bit of alb sulfoxide (0.09–0.88%) excreted in urine in humans (minor elimination pathway)
- Mostly excreted in bile
- Liver: flavin monooxygenase and cytochromes P450 (mainly CYP3A4) to S(-)
- R(+) by microsomal flavin mixed function oxidases
- Some production of S(-) in gut epithelium
- Alb sulfoxide oxidized to alb sulfone mainly by CYP2C (in rat livers, but thought to be the same as in humans)
- 5 major metabolites excreted by humans;
- methyl [5-(propylsulfonyl-1H-benzimidazol-2-yl)] carbamate
- methyl [6-hydroxy 5-(n-propylsulfonyl)-1H-benzimidazole-2-yl)] carbamate
- methyl [5-(n-propylsulfinyl)-1H-benzimidazole-2-yl)] carbamate
- 5-(n-propylsulfonyl)-1H-benzimidazole-2-yl amine
- 5-(n-propysulfinyl)-1H-benzimidazole-2-yl amine
- And some minor hydroxylated sulfated or glucuronidated derivatives
- Interaction with cimetidine
- Previously thought to increase bioavailability
- Now know that doesn't
- Does inhibit albendazole sulfoxide breakdown
- Uses
- "Generally considered to be the tx of choice for single and mixed infections with the common intestinal nematodes"
- Systemic infections: need longer dose regimen
- Alveolar echinococcosis
- Most cases, is just parasitostatic; some suggest that tx should be lifelong if no toxicity (same for cystic echinococcis)
- Used w/surgery
- Capillariasis
- Gnathostomiasis
- Similar effectiveness to ivermectin, but ivermectin dosing is easier (2 days versus 21 days)
- Trichinosis
- Eliminates intestinsal adults and migrating larva that were responsible for symptoms
- T. spiralis and T. pseudospiralis
- Similar efficacy to thiabendazole, but lower side effect rate
- Toxocariasis
- Better at reducing eosinophilia than thiabendazole
- Loaiasis
- Loa loa (eye worm)
- Monsenellosis
- M. perstans
- Works agasint adult worms but not agasint microfilariae
US National Library of Medicine. "ALBENZA- albendazole tablet, film coated ALBENZA- albendazole tablet, chewable". DailyMed. Retrieved 24 July 2017.
| copy | <ref>{{cite web | last=US National Library of Medicine | title=ALBENZA- albendazole tablet, film coated ALBENZA- albendazole tablet, chewable | work=DailyMed | accessdate=24 July 2017 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8941166-b77d-45aa-a6e8-04f1c0afd845}}</ref> |
- Drug interactions
- Dexamethasone: Trough concentrations of alb. sulfoxide increase by 56%
- Praziquantel: increase max plasma concentration of alb. sulfoxide by 50%
- Cimetidine: in patients being treated for hydatid cysts, increase alb. sulfoxide concentrations in bile and cystic fluids by 2-fold
- Theophylline: Al. induces cyotochrome P450 1A in human hepatoma cells; monitor theophylline plasma concentrations
- Warning/precaution
- Bone marrow supression
- Granulocytopenia or pancyotpenia by alb, can cause bone marrow supression, aplastic anemia, and agranulocytosis
- Can be fatal
- Increased risk in those with liver disease and those w/hepatic echinococcosis
- Granulocytopenia or pancyotpenia by alb, can cause bone marrow supression, aplastic anemia, and agranulocytosis
- Teratogenic
- In treating neurocysticercosis, can cause neuro symptoms
- Should receive steroids and anticonvulsants together w/alb. to prevent things like seizures, increased intracranial pressure, focal signs caused by inflammatory reaction of parasitic death in brain
- In treating retina neurocystocercosis, can cause retinal damage
- Hepatic effects
- Increase hepatic enzyme concentrations in 16% in patients (return to normal when tx is stopped)
- Pts w/elevated liver enzymes at increased risk for hepatotoxicity and bone marrow supression
- Can unmask undiagnosed neurocysticercosis when treating hydatid patients
- Bone marrow supression
- Adverse reactions
- Can differ in those being treated for hydatid diseae vs. neurocysticercosis
- Mechanism
- Binds to colchicine-sensitive site of beta-tubulin, inhibiting polymerization
- Parasite resistance due to changing amino acids that make up beta-tubuling, decreasing bindinf of alb.
US National Library of Medicine. "VALBAZEN- albendazole suspension". DailyMed. Retrieved 2 August 2017.
| copy | <ref>{{cite web | last=US National Library of Medicine | title=VALBAZEN- albendazole suspension | work=DailyMed | accessdate=2 August 2017 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94cf5818-f27d-4374-87ad-54a2d9ce6ef1}}</ref> |
- Adult liver flukes
- Fasciola hepatica (cattle, sheep, goats)
- Fascioloides magna (sheep)
- Tapeworms
- Moniezia benedini (cattle), M. expansa (cattle and sheep), Thysanosoma actinioides (sheep)
- Stomach worms
- Ostertagia ostertagi (cattle), O. circumcincta (sheep)
- Barber pole worm (Haemonchus contortus in both, H. placei in cattle)
- Small stomach worm: Trichostrongylus axei
- Intestinal worms
- Thread-necked Intestinal Worm: Nematodirus spathiger (both), N. helvetianus (cattle), N. filicollis (sheep)
- Small intestinal worm/Cooper's worm: Cooperia punctata, (cattle), C. oncophora (both)
- Bankrupt worm: Trichostrongylus colubriformis (both),
- Nodular worm: Oesophagostomum columbianum (sheep), Oesophagostomum radiatum (cattle)
- Large-mouth bowel worm: Chabertia ovina (sheep)
- Hookworm: Bunostomum phlebotomum (cattle)
- Lungworm
- Dictyocaulus viviparus (cattle), Dictyocaulus filaria (sheep)
Waller, Derek G.; Sampson, Tony (4 June 2017). Medical Pharmacology and Therapeutics E-Book. Elsevier Health Sciences. p. 616. ISBN 978-0-7020-7190-4.
| copy | <ref>{{cite book | last1=Waller | first1=Derek G. | last2=Sampson | first2=Tony | title=Medical Pharmacology and Therapeutics E-Book | date=4 June 2017 | page=616 | url=https://books.google.com/books?id=6b0tDwAAQBAJ&pg=PA616 | publisher=Elsevier Health Sciences | isbn=978-0-7020-7190-4}}</ref> |
- Inhibit fumarase reductase, reducing energy produced by Kreb's cycle and impairing glucose uptake
- Acts against adults, larvae, and eggs
- Oral absorption is poor; acts primarily in the gut
Webster, Cynthia (March 2001). Clinical Pharmacology. Teton NewMedia. p. 142. ISBN 978-1-893441-37-8.
| copy | <ref>{{cite book | last=Webster | first=Cynthia | title=Clinical Pharmacology | date=March 2001 | page=142 | url=https://books.google.com/books?id=NmR00leAkt8C&pg=PA142 | publisher=Teton NewMedia | isbn=978-1-893441-37-8}}</ref> |
- Metronidazole and fenbendazole are the most commonly prescribed in dogs; use albendazole (more toxic) when inf is resistant to previous 2
Wiebe, Valerie J. (11 May 2015). Drug Therapy for Infectious Diseases of the Dog and Cat. John Wiley & Sons. p. 247. ISBN 978-1-118-55747-1.
| copy | <ref>{{cite book | last=Wiebe | first=Valerie J. | title=Drug Therapy for Infectious Diseases of the Dog and Cat | date=11 May 2015 | page=247 | url=https://books.google.com/books?id=jLM_CQAAQBAJ&pg=PA247 | publisher=John Wiley & Sons | isbn=978-1-118-55747-1}}</ref> |
- Humans: tablets (220mg)
- Vet: oral paste, oral suspension
- Can penetrate CNS and cystic fluid, so choice for infections of these areas
- Dogs
- Capillaria plica
- P. kellicotti
- F. hirth/Oslerus olseri
- Giardia
- Cats
- P. kellicotti
- Platynosum/Opisthorchiidae
- SE
- More than 10%: anorexia/depression in cats and dogs
- 1-10%: elevated liver enz, nausea, vomiting, diarrhea in cats and dogs
- less than 1%" neutropenia and aplastic anemia w/use longer than 5 days in cats and dogs
- Alb sulfoxide is excreted into milk (1.5% of maternal dose). Poor oral absorption, so inlukely to have effect on nursing animals
Wu, Jashin J. (18 October 2012). Comprehensive Dermatologic Drug Therapy E-Book. Elsevier Health Sciences. p. 137. ISBN 978-1-4557-3801-4.
| copy | <ref>{{cite book | last=Wu | first=Jashin J. | title=Comprehensive Dermatologic Drug Therapy E-Book | date=18 October 2012 | page=137 | url=https://books.google.com/books?id=Tqpsm5WKKlcC&pg=PA137 | publisher=Elsevier Health Sciences | isbn=978-1-4557-3801-4}}</ref> |
- Approved for neurocystocercosis and hydatid disease
- Off-label uses galore
- Inf by A. lumbricoids,Trichuris trichiura, Enterobius vernicualris, Ancylostoma duodenale, Necator americanus, Taenia sp., Strongyloides stercoralis, Giardia
- Crusted scabies (when combined w/topical crotamiton and salicylic acid)
- In inf of Pediculus humanus capitis, but ivermectin is much better
- Balamuthia mandrillaris (cutaneous diseae and granulomatous amebic encephalitis): combo of miltefosine, fluconazole, albendazole
- Bancroftian filariasis: in combo with ivermectin
- Taenia crassiceps
- Induces CYP1A2, so monitor theophylline levels
Wu, Zhexue; Lee, Doohyun; Joo, Jeongmin; Shin, Jung-Hoon; Kang, Wonku; Oh, Sangtaek; Lee, Do Yup; Lee, Su-Jun; Yea, Sung Su; Lee, Hye Suk; Lee, Taeho; Liu, Kwang-Hyeon. "CYP2J2 and CYP2C19 Are the Major Enzymes Responsible for Metabolism of Albendazole and Fenbendazole in Human Liver Microsomes and Recombinant P450 Assay Systems". Retrieved 5 August 2017.
| copy | <ref>{{cite web | last1=Wu | first1=Zhexue | last2=Lee | first2=Doohyun | last3=Joo | first3=Jeongmin | last4=Shin | first4=Jung-Hoon | last5=Kang | first5=Wonku | last6=Oh | first6=Sangtaek | last7=Lee | first7=Do Yup | last8=Lee | first8=Su-Jun | last9=Yea | first9=Sung Su | last10=Lee | first10=Hye Suk | last11=Lee | first11=Taeho | last12=Liu | first12=Kwang-Hyeon | title=CYP2J2 and CYP2C19 Are the Major Enzymes Responsible for Metabolism of Albendazole and Fenbendazole in Human Liver Microsomes and Recombinant P450 Assay Systems | accessdate=5 August 2017 | url=http://aac.asm.org/content/57/11/5448.full}}</ref> |
- Alb → albendazole sulfoxide
- Established as CYP3A4 and flavin-containing monooxygenase (FMO)
- 2010 study study said recombinant CYP2J2 played a bigger role (yes, sulfoxidation) (???)
- Alb → hydroxyalbendazole
- Mainly CYP2J2
- Possibly causes infantile eczema when given during pregnancy
Yaffe, Sumner J.; Aranda, Jacob V. (2010). Neonatal and Pediatric Pharmacology: Therapeutic Principles in Practice. Lippincott Williams & Wilkins. pp. 470–472. ISBN 978-0-7817-9538-8.
| copy | <ref>{{cite book | last1=Yaffe | first1=Sumner J. | last2=Aranda | first2=Jacob V. | title=Neonatal and Pediatric Pharmacology: Therapeutic Principles in Practice | date=2010 | pages=470–472 | url=https://books.google.com/books?id=1e2-yggGeUIC&pg=PA472 | publisher=Lippincott Williams & Wilkins | isbn=978-0-7817-9538-8}}</ref> |
- Originally introduced in 1977 in Australia for sheep
- Licensed for humans in early 1980s
- Usually only needs 1 administration for intestinal nematode infections
- Not licensed in US to treat intestinal nematode infection
- Uses
- Nematodes
- Ascaris lumbricoides (roundworm) (single dose)
- Trichuris trichiura
- Hookworm
- N. americanus and A. duodenale (single dose)
- Cutaneous larva migrans
- Taenis solium, T. saginata (beef tapeworm): praziquantel is better, but albendazole used more in endemic countries bc cheaper and broader spectrum
- Enterobius vericularis
- Capillaria philippensis
- Toxocara canis
- Trichinella spiralis
- Works best when given early; acts on adult worms in intestinal mucosa before they make larva that penetrate the muscle
- Give corticosteroids as well to inhibit infl caused by dying larvae
- Trichostrongylus (single dose)
- Gnathostoma spinigerum
- Filarial nematodes (in combo with DEC or ivermectin)
- Lymphatic filariasis (W. bancrofti, B. malayi, B. timori)
- Loa Loa
- Mansonella perstans
- Nematodes
- In neurocysticercosis
- Works best in pts w/viable cysts in cerebral paenchyma OR when cysticercosis is rapidly progressing
- Old cysts not affected
- Check for ocular cysticeri, since then albendazole can cause changes to existing lesions that can cause permanent blindness
- Pharmakocin.
- Quickly changed to albendazole sulfoxide in liver, which is metabolized more slowly
- Albendazole sulfoxide metabolized to albendazole sulfone (and other oxidative metabolites0
- Pediatric
- Teratogenic in rats and rabbit, but found that OK in people in 2nd and 3rd timester
- Drug interactions
- Cimetidine: reduces gastric acid production or inhibits cytochrome P450-mediated metabolism of albendazole to active metabolite, resuling in lower oral bioavailability
- Cortcosteroids: increase steady-state plasma concentration of albendazole sulfoxide
- Praziquantel
- Theophylline: theophylline induces activity of CYP 1A in hepatoma cells, since also a substrate
- Side effects
- Most common: abdominal pain, nausea, vomiting headache
- Much less common: hypersensitiviy (rash, hives), reversible alopecia, leukopenia
- Rare: agranulocytosis
- If using for a long time (ex. to treat hydatid disease), can increase hepatic enzymes (stops when med stops)
Bridges, J. W.; Kibby, M. R.; Walker, S. R.; Williams, R. T. (October 1968). "Species differences in the metabolism of sulphadimethoxine". Biochemical Journal. 109 (5): 851–856. ISSN 0264-6021. PMC 1187037. PMID 4972257. Retrieved 2017-06-17.{{cite journal}}: CS1 maint: PMC format (link)
| copy | {{cite journal | last1=Bridges | first1=J. W. | last2=Kibby | first2=M. R. | last3=Walker | first3=S. R. | last4=Williams | first4=R. T. | title=Species differences in the metabolism of sulphadimethoxine | journal=Biochemical Journal | accessdate=2017-06-17 | date=October 1968 | url=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1187037/ | pmid=4972257 | pmc=PMC1187037 | issn=0264-6021 | volume=109 | issue=5 | pages=851-856}} |
- Excreted mostly unchanged by dogs
- By human: sulfphadimethoxine N1-glucuronide
Papich, Mark G. (2007). Saunders handbook of veterinary drugs (2nd ed.). St. Louis, Mo: Saunders/Elsevier. pp. 617–618. ISBN 9781416028888.
| copy | {{cite book | last=Papich | first=Mark G. | title=Saunders handbook of veterinary drugs | location=St. Louis, Mo | date=2007 | edition=2nd | publisher=Saunders/Elsevier | isbn=9781416028888 | pages=617–618 }} |
- Wide range
- But resistance is common unless combined with ormetoprim (Primor)
- Dogs are more susceptible to negative effects, since can't acetylate sulfonamides to their metabolites. Doberman pinschers can be especially sensitive.
Plumb, Donald C. (2011). Plumb's veterinary drug handbook (7th ed.). Stockholm, Wisconsin; Ames, Iowa: Wiley. pp. 951, 954. ISBN 9780470959640.
| copy | {{cite book | last=Plumb | first=Donald C. | title=Plumb's veterinary drug handbook | location=Stockholm, Wisconsin; Ames, Iowa | date=2011 | edition=7th | publisher=Wiley | isbn=9780470959640 pages=951, 954}} |
In liver, is acetylated to acetyl.sulfadimethoxine, and excreted like that in bile
- Dogs don't metabolize it in liver: filtered out by kidneys
- Has good reabsorption in the renal tubules → longer half-lives
- Dobermans susceptible to sulfonamide-induced poly-systemic immune complex disease (contraindicated)
- Sulfadimethoxine/ormetoprin
- FDA-approved for skin and soft tissue infections in dogs caused by S. aureus or E. coli
- Sulfadimethoxine alone would be bacteriostatic; together with ormetoprin is bacteriocidal
Riviere, Jim E.; Papich, Mark G. (2013-05-13). Veterinary Pharmacology and Therapeutics. John Wiley & Sons. ISBN 9781118685907.
| copy | {{cite book | last1=Riviere | first1=Jim E. | last2=Papich | first2=Mark G. | title=Veterinary Pharmacology and Therapeutics | date=2013-05-13 | url=https://books.google.com/books?id=xAPa4WDzAnQC&pg=PA835 | publisher=John Wiley & Sons | isbn=9781118685907}} |
p836
- Also spelled sulphadimethoxine
p845
- Long-acting sulfonamide, alone or w/ormetroprim (as ormetoprim-sulfadimethoxine)
- In cattle, pigs, horses, poultry, fish, dogs, and other vert/inverts
- 1/2 life of 13.1 hours in dogs
p857
- Combined with ormetoprim for better antimicrobial activity
- "Rofenaid", to give to chickens and turkeys for food – prevent coccidioisis by Eimeria and fowl cholera
- "Romet" for furunculosis in salmon and trout (food animals)
- "Primor" for dogs for skin/soft tissue inf, urinary tract inf, and intestinal coccidia inf
- Nothing commercially available for cattle, though still used to treat pneumonia
1169
- Only FDA-approved drug for intesinal coccidioisis in dogs and cats
"SulfaMed (sulfadimethoxine) Injection 40% for Animal Use". Drugs.com. Retrieved 2017-06-18.
| copy | {{cite web | title=SulfaMed (sulfadimethoxine) Injection 40% for Animal Use | work=Drugs.com | accessdate=2017-06-18 | url=https://www.drugs.com/vet/sulfamed-sulfadimethoxine-injection-40.html}} |
- IV use in cattle
- Treat "shipping fever complex" (bovine respiratory disease complex), pneumonia by Pasteurella, foot rot (nectrotic pododermatitis), calf diphtheria by Fusobacterium necrophorum
"Sulfonamides and Sulfonamide Combinations". Merck Veterinary Manual. Retrieved 2017-06-18.
| copy | {{cite web | title=Sulfonamides and Sulfonamide Combinations | work=Merck Veterinary Manual | accessdate=2017-06-18 | url=http://www.merckvetmanual.com/pharmacology/antibacterial-agents/sulfonamides-and-sulfonamide-combinations}} |
- Sulfadimethoxine is one of the sulfonamides that last longer (elimintated more slowly), so can be given fewer times a day
- Ormetroprim is diaminopyrimidine: inhibit dihydrofolate reductase in bact quite well (further in in pathway to make folic acid)
- "Potentiated" sulfonamide
- Optimal ratio is usually 1:20 (20 being sulf.), but is sold pharmaceutically as 5:1
- Like all sulfonamides, is most effective at early stages when lots of multiplying, since has more of a bacteriostatic than bacteriocidal effect
- Can sometimes be given IM (sodium sulfadimethoxine)
- Relies on the patient still being able to produce an immune response
- Like all sulfanimides, diffuses easily and reaches a lot of places
- Crystallization in urine can be prevented by adding diaminopyrimidine
- Not actually common in vet med
- Is one of the three sulfonamides actually allowed in lactating dairy cattle (others are sulfabromethazine and sulfathoxypyridazine)
"Albuterol". Drugs.com. American Society of Health-System Pharmacists. Retrieved 2017-06-23.
| copy | {{Cite web | publisher=American Society of Health-System Pharmacists | title=Albuterol | work=Drugs.com | accessdate=2017-06-23 | url=https://www.drugs.com/monograph/albuterol.html}} |
- Available as: inhaler (oral inhalation aerosol), oral nebulization solution, tablets, extended-release tablets, oral solution
- Contraindications
- Known hypersensitivity to albuterol (dugh)
- Hypersensitivity to...
- soya lectin or related foods (soybeans, peanutes)
- Atropine and derivatives
- Caution if have cardio disorder or hypertension
- Caution with seizures or sensitivity to sympathomimetic
- Caution w/diabetes mellitus or hyperthyroidism
- Renal impairment (higher risk of toxicity)
- Adverse effects
- Acute/worsening asthma
- Fatality (excessive dose)
- Acure bronchospasm
- Cardiovascular effects (atrial fib,., supraventricular tachycardia, extrasystoles), BP changes
- Hyperesnsitivity reactions (hives, angioedema, rash, bronchospasm, anaphylaxis, oropharyngeal edema)
- Hypokalemia → cardiovascular effects
- Lactation
- Unknown if distributed in milk, but does cross across placenta
- Geriatric use
- No differences, as long as don't have contraindicated disorders
- Interactions
- B-adrenergic blocking agent → severe bronchospasm in asthmatic patients
- Digoxin → decrease in digoxin levels in serum
- Diuretics (nonpotassiuim-sparing) → decreased serum potassium
- MAOIs → vascular system side effects
- Sympathomimetics → cardiovascular system side effects
- Metabolism
- Metabolized by intestinal wall and liver to inactive metabolites
- But most is excreted by kidneys unchanged (over 70% oral dose within 24 hours)
"Albluterol". National Library of Medicine HSDB Database. Retrieved 2017-06-26.
| copy | {{Cite web | title=Albluterol | work=National Library of Medicine HSDB Database | accessdate=2017-06-26 | url=https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+7206}} |
- Overdose s/s: exaggerated common adverse reactions, esp. angina, hypertention, hypokalemia
- Can get seizures or cardiac arrest
- Mild/moderate overdose: tachycardia, hypertension, tachypnea, tremor, agitation, nausea, vomiting, hypokalemia, hyperglycemia
- Severe overdose: hypotension, dusrhythmias, seizures, acidoses
- Most frequently reported side effect: tremor
- Still, poisoning is uncommon and "rarely results in serious morbitity or death"
- Pharmacokinetics
- Volume of distribution: 2L/kg
"Albuterol Sulfate". RxList. Retrieved 2017-06-22.
| copy | {{Cite web | title=Albuterol Sulfate | work=RxList | accessdate=2017-06-22 | url=http://www.rxlist.com/albuterol-sulfate-drug.htm}} |
- Albuterol prefers Beta2-adrenergic receptors, which are predominant receptors on bronchial smooth muscles
- Activation of these receptors → activation of adenylcyclase → increase in intracellular cAMP → protein kinase A activation → inhibit phosphorylation of myosin and lowers intracellular Ca+ concentration
- Increase in cAMP also → inhibit release of mediators by mast cells in the airway
- Relaces all muscles of airway, from trachea down to terminal bronchioles
- Unlike other betaadrenergic agonists, can have significant cardiovascular effect
- Albuterol crosses BBB
Briggs, Gerald G.; Freeman, Roger K.; Yaffe, Sumner J. (2011). Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Lippincott Williams & Wilkins. pp. 33–34. ISBN 9781608317080.
| copy | {{Cite book | last1=Briggs | first1=Gerald G. | last2=Freeman | first2=Roger K. | last3=Yaffe | first3=Sumner J. | title=Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk | year=2011 | publisher=Lippincott Williams & Wilkins | isbn=9781608317080 | url=https://books.google.ca/books?id=OIgTE4aynrMC&pg=PA33 | pages=33–34}} |
- Can cause maternal and fecal tachycardia
- Major decreases in maternal BP (dropping by 30)
- Maternal adverse effects inc. acute congestive heart failure, pulmonary edema, death
- Can cause temporary hyperglycemia, then increase in serum insulin in both mother and fetus (like all B-mimetics)
- Insulin in cord blood are 2x if get albuterol
- More pronounced in diabetes pts
- Again, like all B-mimetics, increases chance of neonatal respiratory distress syndrome
- Long term in utero exposure assoc. w increased chance of: autism, psychiatric disorders, poor cognitive function, poor motor function, poor performance in school, elevated HR, hypertension
- "Genetic predisposition for toxicity"
Clarke, Kathy W.; Trim, Cynthia M. (2013-06-28). Veterinary Anaesthesia E-Book. Elsevier Health Sciences. p. 612. ISBN 9780702054235.
| copy | {{Cite book | last1=Clarke | first1=Kathy W. | last2=Trim | first2=Cynthia M. | title=Veterinary Anaesthesia E-Book | date=2013-06-28 | publisher=Elsevier Health Sciences | isbn=9780702054235 | url=https://books.google.com/books?id=hZh5AAAAQBAJ&pg=PA612 | page=612}} |
- B2-adrenergic agonistic effect on bronchial smooth muscle as rescue medication for bronchoconstriction in ppls
- Treat horses w/recurrent airway obstruction
- Possibly treat hypoxemia in anesthetized horses
- Can treat emergency situation in asthmatic cats
Cote, Etienne (2014-12-09). "Albuterol Toxicosis". Clinical Veterinary Advisor - E-Book: Dogs and Cats. Elsevier Health Sciences. pp. 45–46. ISBN 9780323240741.
| copy | {{Cite book | last=Cote | first=Etienne | title=Clinical Veterinary Advisor - E-Book: Dogs and Cats | chapter=Albuterol Toxicosis | date=2014-12-09 | publisher=Elsevier Health Sciences | isbn=9780323240741 | pages=45–46 | url=https://books.google.com/books?id=NmziBQAAQBAJ&pg=PR120}} |
- Toxic via inappropriate dosing or pets biting into inhalers or vials for nebulizers
- Brand names: Proventil, Ventolin, Combivent (when combined with ipratropium)
- Dogs more common in overdosing (again, inhaler chewing)
- Greyhounds possibly more susceptible to severe cardia arrhytmias
- Acute onset of panting, vomiting, anxiety, tremor, weakness, leghargy
- At overdose levels, not very selective for beta-2, so has excessive beta-1 and beta-2 actividy
- Beta-2 toxic effects: "hypotension, reflex sinus tachycardia, arrhythmias; tremors from stimulation of receptors in skeletal muscles; vomiting; intracellular shifting of Ka and P secondary to increased ATP enzymes, and respiratory alkalosis from panting
- Beta-1 toxic effects: "positive inotropic effects on the heart, tachychardia, hypertension, restlessness, anxiety"
- Secondary myocardial damage and hypokalemia can also → arrhythmia
- Aerosilized inhalers often have hydrocarbons as propellant → sensitive myocardium and increase risk for arrhythmias
- Weakness due to hypokalemia and prolonged tachycardia
- Treatment
- Beta blockers for tachycardia
- Possibly K, but can have rebound hyperkalemia if give too much
- Benzos for tremors/stimulation
- Can't have induced emesis or activated charcoal if in liquid or syrup form (or inhaled), bc absorbed too fast (can still do for tablets)
- Muscle weakness → collapse in dogs after a few hours, due to severe hypokalemia
- Excellent prognosis for recovery
Hsu, Walter H. (2013-04-25). Handbook of Veterinary Pharmacology. John Wiley & Sons. p. 48. ISBN 9781118714164.
| copy | {{Cite book | last=Hsu | first=Walter H. | title=Handbook of Veterinary Pharmacology | date=2013-04-25 | publisher=John Wiley & Sons | isbn=9781118714164 | url=https://books.google.com/books?id=MGhScg9GZGAC&pg=PT48 | page=48}} |
- "Torpex"
- Aeorsol or oral tablets in dogs, cats, and horses as bronchodilator and to alleviate bronchospasm or cough
- Pharmacokinetics
- pKa of 9.3; so mostly in ionized form at physiological pH
- Absorption from oral form is limited; is faster and absorbs completely from inhaled form
- Inhalation lasts 1–7 hours; oral lasts up to 12 hours (half life of oral is 3–5 hours)
- Metabolized in liver to 4'-O-sulfate, which is excreted in urine
Eghianruwa, Kingsley (2014-01-29). Essential Drug Data for Rational Therapy in Veterinary Practice. AuthorHouse. pp. 13–14. ISBN 9781491800102.
| copy | {{Cite book | last=Eghianruwa | first=Kingsley | title=Essential Drug Data for Rational Therapy in Veterinary Practice | date=2014-01-29 | publisher=AuthorHouse | isbn=9781491800102 | url=https://books.google.com/books?id=CtfIAgAAQBAJ&pg=PA13|pages=13–14}} |
- "Ventolin"
- Relaxes uterine and vascular smooth muscles
- Potassium effect by stimulating Na-K-ATPase
- For cats and dogs: bronchospasm relief; for horses: bronchodilation
- Crosses placenta
- Can enter CNS, with 5% concentration in brain as of that in plasma
- Metabolized in liver to inactive 4'-O-sulfate
- Contraindicated by hypersensitivity to albuterol.
- Use caution with inhalatant anesthetics, during pregnancy, and in ps w/diabetes, hypertheyroidism, and heart disorders
- Drug interactions
- Can develop tolerance, so bronchodilation effects can be increased by giving methylxanthine such as aminophylline
- Antagonizes dinoprost and oxytocin
- Use with other sympathomimetic drugs → more likely to have cardiovascular side effects
- Betra-adrenergic blockers inhibit action of albuterol
- MAOIs and tricyclic antideprresants can incraese pressor effects
- Use w/digitalis can cause cardiac arrthymia
- Use with inhaled anesthesia (that's halogenated hydrocarbon) can increase cardiac arrhythmia
"Inhalation Therapy of Airway Disease". Merck Veterinary Manual. Retrieved 2017-06-22.
| copy | {{Cite web | title=Inhalation Therapy of Airway Disease | work=Merck Veterinary Manual | accessdate=2017-06-22 | url=http://www.merckvetmanual.com/pharmacology/systemic-pharmacotherapeutics-of-the-respiratory-system/inhalation-therapy-of-airway-disease}} |
- Short-acting B2 agonists are main med used for acute bronchoconstriction (work quickly)
- Control symptoms, but not inflammation
- Safe for animals - low toxicity
- "Medication of choice in all species for inhalation therapy of acute airway obstruction"
- Minutes to take effect, last 3-6 hours
- S-albuterol has slower metabolism than R-albutero
- (applies to ppl as well)
- So accumulates in lung
- So assoc. w/increased airway hyperreactivity and pro-inflammatory effects
Lemke, Thomas L.; Williams, David A. (2012-01-24). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. ISBN 9781609133450.
| copy | {Cite book | last1=Lemke | first1=Thomas L. | last2=Williams | first2=David A. | title=Foye's Principles of Medicinal Chemistry | date=2012-01-24 | publisher=Lippincott Williams & Wilkins | isbn=9781609133450}} |
- Slowly metabolized by MAO
Peacock, Rachel (2014-08-26). "Salbutamol Toxicosis in Dogs". AEC: Animal Emergency Centre. Retrieved 2017-06-23.
| copy | {{Cite web | last=Peacock | first=Rachel | title=Salbutamol Toxicosis in Dogs | work=AEC: Animal Emergency Centre | accessdate=2017-06-23 | date=2014-08-26 | url=http://www.aecvets.com.au/News/?id=68}} |
- B1 effects at high doses can → tachyarrhytmia
- Hypokalemia
- B2-adrenergic stimulation of Na-K-ATPase pumps in RBCs, liver cells, and muscle cells → intracellular translocation of K ions
- Hypokalemia → delayed ventricular reporlarization, prolonged action potential duragion, increased automaticity → can contribute to cardiac arrhythmia
Plumb, Donald C. (2011). ""Albuterol Sulfate"". Plumb's Veterinary Drug Handbook (7th ed.). Stockholm, Wisconsin; Ames, Iowa: Wiley. pp. 24–25. ISBN 9780470959640.
| copy | {{Cite book | last=Plumb | first=Donald C. | chapter="Albuterol Sulfate" | pages=24–25 | title=Plumb's Veterinary Drug Handbook | location=Stockholm, Wisconsin; Ames, Iowa | date=2011 | edition=7th | publisher= Wiley | isbn=9780470959640}} |
- Main uses: bronchospasm/cough in cats and dogs; bronchodilator in horses
- Doesn't cross BBB but crosses placenta
- Late stage pregnancy: can inhibit utering contractions
- S form can increase airway inflammation in cats, so even racemic mixture not good as chronic med
- Overdose/toxicity: hypokalemia & hypophosphatemia
Riviere, Jim E.; Papich, Mark G. (2009-03-17). Veterinary Pharmacology and Therapeutics. John Wiley & Sons. p. 1299. ISBN 9780813820613.
| copy | {{Cite book | last1=Riviere | first1=Jim E. | last2=Papich | first2=Mark G. | title=Veterinary Pharmacology and Therapeutics | date=2009-03-17 | publisher=John Wiley & Sons | isbn=9780813820613 | url=https://books.google.com/books?id=ievLulSqwBAC&pg=1299 | page=1299–1300}} |
- Dose in small animals is much smaller than in humans - 20–50 micrograms per kg up to QID vs. 100–200 micrograms per kg up to QID
- Cardiac affects include tachycardia, palpitations, and tremors - more w/B1 agonists, but can be caused by B2 agonists at higher doses
Starkey, E. S.; Mulla, H.; Sammons, H. M.; Pandya, H. C. (September 2014). "Intravenous salbutamol for childhood asthma: evidence-based medicine?". Archives of Disease in Childhood. 99 (9): 873–877. doi:10.1136/archdischild-2013-304467. ISSN 1468-2044. PMID 24938536.
| copy | {{Cite journal | last1=Starkey | first1=E. S. | last2=Mulla | first2=H. | last3=Sammons | first3=H. M. | last4=Pandya | first4=H. C. | title=Intravenous salbutamol for childhood asthma: evidence-based medicine? | journal=Archives of Disease in Childhood | date=September 2014 | pmid=24938536 | doi=10.1136/archdischild-2013-304467 | issn=1468-2044 | volume=99 | issue=9 | pages=873-877}} |
- Alveolar epithelium → absorbed and enters pulmonary circulation
- Toxicity due to B1 and B2 adrenoreceptors outside lungs
- Either
- Filtered out by kidneys
- Metabolized into 4'-O-sulphate → urine
- Half-life: 4-6 hours
US Department of Health and Human Services (2017-04-28). "Albuterol". CHEMM. Retrieved 2017-06-23.
| copy | {{Cite web | last=US Department of Health and Human Services | title=Albuterol | work=CHEMM | accessdate=2017-06-23 | date=2017-04-28 | url=https://chemm.nlm.nih.gov/countermeasure_albuterol.htm}} |
- Albuterol and other B2-adrenergic receptor agonists increase conductance of Ca2+ sensitive and K+ sensitive channels in airway smooth muscle → hyperpolarization → relaxation (independent of cAMP and shit)
- Stimulating B2-adrenergic receptors inhibits function of mast cells, basophils, eosinophils, neutrophils, and lymphocytes
- Increase intracellular cAMP → signalling cascade to inhibit release of inflammatory mediators & cytokines
- Possible in use of chemical defense as "anditode" (mitigate damage) from chlorine gas, mustard gas, phosgene, sarin, soman
Wiley, J. F.; Spiller, H. A.; Krenzelok, E. P.; Borys, D. J. (August 1948). "Unintentional albuterol ingestion in children". Pediatric Emergency Care. 10 (4): 193–196. ISSN 0749-5161. PMID 7937293.
| copy | {{Cite journal | last1=Wiley | first1=J. F. | last2=Spiller | first2=H. A. | last3=Krenzelok | first3=E. P. | last4=Borys | first4=D. J. | title=Unintentional albuterol ingestion in children | journal=Pediatric Emergency Care | date=August 1994 | pmid=7937293 | issn=0749-5161 | volume=10 | issue=4 | pages=193-196}} |
- Most common toxicology signs: tachycardia, widened pulse pressure, hyperglycemia, agistation, low serum CO2, vomiting, hypokelemia
- Threshold dose was 1 mg/kg (three to ten times normal daily dose
Absalom, Anthony R.; Mason, Keira P. (March 1, 2017). Total Intravenous Anesthesia and Target Controlled Infusions: A Comprehensive Global Anthology. Springer. pp. 31, 306. ISBN 9783319476094.
| copy | <ref>{{cite book | last1=Absalom | first1=Anthony R. | last2=Mason | first2=Keira P. | title=Total Intravenous Anesthesia and Target Controlled Infusions: A Comprehensive Global Anthology | date=March 1, 2017 | publisher=Springer | isbn=9783319476094 | pages=31, 306 | url=https://books.google.com/books?id=PLI-DgAAQBAJ&pg=PA608}}</ref> |
- Cremophor EL: 20% solution of polyoxyethylated castor oil surfactant; alfadolone increased alfaxalone solubility
- 2-hydroxylproplyl-beta-cyclodextrin is toxic to ppl
- Phaxan, w/alfaxalone dissolved in 7-sulfo-butyl-ether-beta-cyclodextrin - low toxicty in ppl
Clarke, K. W.; Trim, C. M.; Hall, L. W., eds. (2014). "Chapter 6: General pharmacology of the injectable agents used in anaesthesia". Veterinary Anaesthesia (11th ed.). Oxford: W.B. Saunders. pp. 135–153. doi:10.1016/B978-0-7020-2793-2.00006-2. ISBN 9780702027932.
| copy | <ref>{{cite book | editor-last1=Clarke | editor-first1=K. W. | editor-last2=Trim | editor-first2=C. M. | editor-last3=Hall | editor-first3=L. W. | title=Veterinary Anaesthesia | chapter=Chapter 6: General pharmacology of the injectable agents used in anaesthesia | location=Oxford | date=2014 | edition=11th | publisher=W.B. Saunders | isbn=9780702027932 | pages=135-153 | doi=10.1016/B978-0-7020-2793-2.00006-2}}</ref> |
- Althesin (alfaxalone + alfadone, human version) removed from market in 1984; Saffan (for cats) stayed until alfaxalone
- Saffan
- Vasodilation → lower BP
- Kept "cardiac index"
- histamine release lead to the death of some cats, but Saffan was still less mortal than other anesth, most likely bc less cardiac depression
- Was used in cats and other domestics and exotics (just not dogs)
- Alfaxalone
- Smooth and rapid
- Recovery better when premedicated
- Pre-med certain med + alfaxalone, then anesthesia via CRI alfaxalone:
- Buprenorphine + Acepromazine
- Buprenorphine + Dexmedetomidine
- 2nd required much less alfaxan as CRI
- Alf can use IM: was done routinely w/cats
- Used in exotics: red-eared turtles, axolotl, green iguana, marmosets
- Larger animals: horses, sheep
Clarke, K. W.; Trim, C. M.; Hall, L. W., eds. (2014). "Chapter 15: Anaesthesia of the dog". Veterinary Anaesthesia (11th ed.). Oxford: W.B. Saunders. pp. 135–153. doi:10.1016/B978-0-7020-2793-2.00015-3. ISBN 9780702027932.
| copy | <ref>{{cite book | editor-last1=Clarke | editor-first1=K. W. | editor-last2=Trim | editor-first2=C. M. | editor-last3=Hall | editor-first3=L. W. | title=Veterinary Anaesthesia | chapter=Chapter 15: Anaesthesia of the dog | location=Oxford | date=2014 | edition=11th | publisher=W.B. Saunders | isbn=9780702027932 | pages=135-153 | doi=10.1016/B978-0-7020-2793-2.00015-3}}</ref> |
- Useful as anasth agent if have ventricular arrhythmia (this was for dog)
Clarke, K. W.; Trim, C. M.; Hall, L. W., eds. (2014). "Chapter 16: Anaesthesia of the cat". Veterinary Anaesthesia (11th ed.). Oxford: W.B. Saunders. pp. 499–534. doi:10.1016/B978-0-7020-2793-2.00016-5. ISBN 9780702027932.
| copy | <ref>{{cite book | editor-last1=Clarke | editor-first1=K. W. | editor-last2=Trim | editor-first2=C. M. | editor-last3=Hall | editor-first3=L. W. | title=Veterinary Anaesthesia | chapter=Chapter 16: Anaesthesia of the cat | location=Oxford | date=2014 | edition=11th | publisher=W.B. Saunders | isbn=9780702027932 | pages=499–534| doi=10.1016/B978-0-7020-2793-2.00016-5}}</ref> |
- Alfaxalone doesn't provide analgesia, so required additional stuff to be on board (usually opioids, NSAIDs, nerve blocks, and/or NMDAR-antagonist)
- Sx less than 30 min can use only injectable anesth
- Common anesth combos for general anesth in cats:
- Premed: acepromazine + opioid, induce: alfaxalone + diazepam, maintain: iso or sevo
- Premed: medetomidine or dexmedetomidine + opioid, induce: alfaxalone, maintain: iso or sevo
- Premed: ace + opioid, induce: alfaxalone, maintain: alfaxalone
- Saffan caused histamine release, but was still 3 times less likely to kil cat than any other anesth method at the time
- Need less alfaxalone for induction if dilute with sterile water, possibly by being able to administer more slowly
Clarke, K. W.; Trim, C. M.; Hall, L. W., eds. (2014). "Chapter 19: Anaesthesia for obstetrics". Veterinary Anaesthesia (11th ed.). Oxford: W.B. Saunders. pp. 587–598. doi:10.1016/B978-0-7020-2793-2.00019-0. ISBN 9780702027932.
| copy | <ref>{{cite book | editor-last1=Clarke | editor-first1=K. W. | editor-last2=Trim | editor-first2=C. M. | editor-last3=Hall | editor-first3=L. W. | title=Veterinary Anaesthesia | chapter=Chapter 19: Anaesthesia for obstetrics | location=Oxford | date=2014 | edition=11th | publisher=W.B. Saunders | isbn=9780702027932 | pages=587–598 | doi=10.1016/B978-0-7020-2793-2.00019-0}}</ref> |
- Cesareans: crossed placental barrier and affects the kittens, but doesn't cause decrease in RR (Saffan)
Ferré, Pierre J.; Pasloske, Kirby; Whittem, Ted; Ranasinghe, Millagahamanda G.; Li, Qiang; Lefebvre, Hervé P. (2006). "Plasma pharmacokinetics of alfaxalone in dogs after an intravenous bolus of Alfaxan-CD RTU". Veterinary Anaesthesia and Analgesia. 33 (4): 229–236. doi:10.1111/j.1467-2995.2005.00264.x. ISSN 1467-2987.
| copy | <ref>{{cite journal | last1=Ferré | first1=Pierre J. | last2=Pasloske | first2=Kirby | last3=Whittem | first3=Ted | last4=Ranasinghe | first4=Millagahamanda G. | last5=Li | first5=Qiang | last6=Lefebvre | first6=Hervé P. | title=Plasma pharmacokinetics of alfaxalone in dogs after an intravenous bolus of Alfaxan-CD RTU | journal=Veterinary Anaesthesia and Analgesia | date=2006 | url=http://www.vaajournal.org/article/S1467-2987(16)30932-1/fulltext | doi=10.1111/j.1467-2995.2005.00264.x | issn=1467-2987 | volume=33 | issue=4 | pages=229–236}}</ref> |
- Advantages of alfaxalone over other induction agents
- Safe (was shown to be safe when given to dogs at 5xdose IV)
- Doesn't accumulate bc metabolized and cleared so fast
- Recovery quickly
- Doesn't have much respiratory depression
- Good muscle relaxation
- Derived from progesterone
- Human females recover faster than human males
Grimm, Kurt A.; Lamont, Leigh A.; Tranquilli, William J.; Greene, Stephen A.; Robertson, Sheilah A. (2015). Veterinary Anesthesia and Analgesia (5th ed.). John Wiley & Sons. pp. 289–290. ISBN 9781118526200.
| copy | <ref>{{cite book | last1=Grimm | first1=Kurt A. | last2=Lamont | first2=Leigh A. | last3=Tranquilli | first3=William J. | last4=Greene | first4=Stephen A. | last5=Robertson | first5=Sheilah A. | title=Veterinary Anesthesia and Analgesia | date=2015 | url=https://books.google.com/books?id=WG9uBwAAQBAJ&pg=PA289 | edition=5th | publisher=John Wiley & Sons | isbn=9781118526200 | pages=289–290}}</ref> |
- Injectable anesth
- By itself is not very soluble in water, so combined with alphadolone initially
- Mech
- Lower concentrations: affects ion currents through GABAR
- High concentration: acts as GABA agonist
- Pharmacokin (at 2mg/kg for dogs and 5mg/kg for cats, 1mg/kg for horses)
- Vol. distriution: 2.4L/kg dogs, 1.8L/kg cats, 1.6 in horses
- 1/2 life: 25 min in dogs, 45 min in cats, 33 min in hores
- Plasma clearance (rate): 60 mL/kg/min in dogs, 25 mL/kg/min in cats, 37 mL/kg/min in horses
- Metabolism
- Hepatic; both cyochrome P450-dpendent and conjucation-dependent (Phases I and II)
- Phase I metabolites: same in cats and dogs
- Phase II metabolites: alfaxalone sulfate and alfaxalone glucuronide in cats, alfaxalone glucuronide only in dogs
- Metabolites leave via hepatic/fecal and renal routes
- Pharmacodyn
- CNS
- Reduce EEG activity
- Decrease cerebral blood flow, intracranial pressure, cerebral O2 demands
- Carduivasc
- At normal levels: quite stable
- Resp
- Respiraty depression; apnea most common side effect
- Cats and dogs: decreased RR, minute volume, spO2
- Hepatic/renal/GI
- In Greyhounds, decreased liver blood flow and O2 supply
- CNS
- Species-specific effects
- Dogs
- Increase intraocular pressure
- CRIs as anesthesia for Sx: worked as anesth, but "significant respiratory depression"
- Longer recovery than propofol; stuff like paddling, rigidity, vocalizing
- OK for puppies
- Cats
- OK for kitties
- Horses
- Induce and maintain anesthesia; CRIs as general anesthesia
- Shorter induction and same anesthesia time as ketamine, but much longer recovery
- Ruminant
- Myosis in sheep
- Swine
- Dogs
- Recovery: leave in quiet, dark area
- Can decrease stuff like paddling/hyperreactivity with sedative agents
Klöppel, Heide; Leece, Elizabeth A (January 2011). "Comparison of ketamine and alfaxalone for induction and maintenance of anaesthesia in ponies undergoing castration". Veterinary Anaesthesia and Analgesia. 38 (1): 37–43. doi:10.1111/j.1467-2995.2010.00584.x. ISSN 1467-2987. Retrieved July 17, 2017.
| copy | <ref>{{cite journal | last1=Klöppel | first1=Heide | last2=Leece | first2=Elizabeth A | title=Comparison of ketamine and alfaxalone for induction and maintenance of anaesthesia in ponies undergoing castration | journal=Veterinary Anaesthesia and Analgesia | accessdate=July 17, 2017 | date=January 2011 | url=http://www.vaajournal.org/article/S1467-2987(16)30511-6/pdf | doi=10.1111/j.1467-2995.2010.00584.x | issn=14672987 | volume=38 | issue=1 | pages=37-43}}</ref> |
- Dissolved in 2-hydroxylpropyl-beta cyclodextrin
- Cyclodextrin
- Derived from starch
- Hydrophobic center
Ko, Jeff (November 16, 2012). Small Animal Anesthesia and Pain Management: A Color Handbook. CRC Press. p. 99. ISBN 9781840766332.
| copy | <ref>{{cite book | last=Ko | first=Jeff | title=Small Animal Anesthesia and Pain Management: A Color Handbook | date=November 16, 2012 | url=https://books.google.com/books?id=ofypWW3_NVQC&pg=PA99 | publisher=CRC Press | isbn=9781840766332 | page=99}}</ref> |
- With standard doses, 1/2 life of 25 min in dogs and 45 min in cats
- Doesn't accumulate
Maddison, Jill E.; Page, Stephen W.; Church, David, eds. (2008). "Alphaxalone (±alphadolone)". Small Animal Clinical Pharmacology. Elsevier Health Sciences. pp. 101–103. ISBN 9780702028588.
| copy | <ref>{{cite book | editor-last1=Maddison | editor-first1=Jill E. | editor-last2=Page | editor-first2=Stephen W. | editor-last3=Church | editor-first3=David | title=Small Animal Clinical Pharmacology | chapter=Alphaxalone (±alphadolone) | date=2008 | publisher=Elsevier Health Sciences | isbn=9780702028588 | pages=101–103 | url=https://books.google.com/books?id=RpsROVqemk8C&pg=PA101}}</ref> |
- Protein binding: 30-50%
- Precaution in pts w/hypovolemia, low BP, or pts w/heart disease
Martinez-Botella, Gabriel; Ackley, Michael A.; Salituro, Francesco G.; Doherty, James J. (January 1, 2014). "Natural and Synthetic Neuroactive Steroid Modulators of GABAA and NMDA Receptors". Annual Reports in Medicinal Chemistry. 49: 27–42. doi:10.1016/B978-0-12-800167-7.00003-1. ISSN 0065-7743.
| copy | <ref>{{cite journal | last1=Martinez-Botella | first1=Gabriel | last2=Ackley | first2=Michael A. | last3=Salituro | first3=Francesco G. | last4=Doherty | first4=James J. | title=Natural and Synthetic Neuroactive Steroid Modulators of GABAA and NMDA Receptors | journal=Annual Reports in Medicinal Chemistry | date=January 1, 2014 | doi=10.1016/B978-0-12-800167-7.00003-1 | issn=0065-7743 | volume=49 | pages=27-42}}{{closed access}}</ref> |
- Neuroactive steroids
- Target different GABA A receptors than benzodiazepenes
- Low concentrations: bind to M3/M4 in alpha subunit - allosteric modification of current
- High concentrations: "direct gating of GabaA currents", binds to alpha/beta interface near GABA binding site
- Possibly affect expression levels of GABAa
- Enhance tonic current but have little effect on phasic currents even after prolonged exposure
- Research suggests that neuroactive steroids increase GABAa receptors (so harder to build a tolerance, unlike w/benzos)
- Every since progesterone and 5beta-pregnance-3,2-dione reported to have depressant effect on CNS in rodents in 1941, multiple groups searched for synthetic to use as anasthetic
- Mainly focused on increasing water solubility
- 1971: Althesin (withdrawn from market in 1984 bc anaphylactic reactions)
- Phaxan being developed for use in ppl (alfaxalone in cyclodextrin)
Minter, Larry J; Bailey, Kate M; Harms, Craig A; Lewbart, Gregory A; Posner, Lysa P (July 1, 2014). "The efficacy of alfaxalone for immersion anesthesia in koi carp (Cyprinus carpio)". Veterinary Anaesthesia and Analgesia. 41 (4): 398–405. doi:10.1111/vaa.12113. ISSN 1467-2987.
| copy | <ref>{{cite journal | last1=Minter | first1=Larry J | last2=Bailey | first2=Kate M | last3=Harms | first3=Craig A | last4=Lewbart | first4=Gregory A | last5=Posner | first5=Lysa P | title=The efficacy of alfaxalone for immersion anesthesia in koi carp (''Cyprinus carpio'') | journal=Veterinary Anaesthesia and Analgesia | date=July 1, 2014 | url=http://www.vaajournal.org/article/S1467-2987(16)30300-2/fulltext | doi=10.1111/vaa.12113 | issn=1467-2987 | volume=41 | issue=4 | pages=398-405}}</ref> |
- Added to water, can induce and maintain anesth in koi; doesn't change breathing
Nieuwendijk, Hans (2011-03). "Alfaxalone". Veterinary Anesthesia & Analgesia Support Group. Retrieved July 14, 2017. {{cite web}}: Check date values in: |date= (help)
| copy | <ref>{{cite web | last=Nieuwendijk | first=Hans | title=Alfaxalone | work=Veterinary Anesthesia & Analgesia Support Group | accessdate=July 14, 2017 | date=2011-03 | url=http://www.vasg.org/alfaxalone.htm}}</ref> |
- Originally introduced in 70s mixed w/alfadolone (Althesin for ppl, Saffan for animals)
- Withdrawn bc of severe side effects (histamine release → anaphylactic rxns) caused most likely by solubilizing agent Cremophor EL
- Alfaxalone molecule bound to cyclodextrine to make it water soluble
- Quickly metabolized by liver
- Doesn't cause histamine release
- Rapid onset, short duraction, few side effects
- Compare use/properties to propofol: alfaxalone doesn't affect cardiovasc
- OK to combine with common premedications
- Europe: registered IV
- Can be given IM though (Aus is IM for cats)
- IM, unlike propofol
- Controversy: is it an analgesic? Not a signifcant one
- Side effects
- Give IV slowly, can cause apnea (still less likely than with propofol)
- Agitated when recover if no pre-meds use
- Esp. cats; do best when recovering in quiet, dark room
- Dose
- IV dose "to effect": give enough so you can intubate
- Dose is lower if use dexmedetomidine as premed; lower still if use opioid
- Effects peak in 5 minutes
- Used for cesareans: had little to no effect on babies
- Can replace etomidate as induction agent for high risk pts
- Good anesthesia for sighthounds
- No preservantives
- NZ/AUS labeling says to use contents of vial within 24 hours (or can refridgerate for up to 7 days)
- UK says use discard any extra at once
Rezende, Marlis (June 2015). "Reintroduced Anesthetic Alfaxalone" (PDF). Clinician's Brief. Retrieved July 14, 2017.
| copy | <ref>{{cite web | last=Rezende | first=Marlis | title=Reintroduced Anesthetic Alfaxalone | work=Clinician's Brief | accessdate=July 14, 2017 | date=June 2015 | url=https://www.cliniciansbrief.com/sites/default/files/attachments/MEDS_Reintroduced%20Anesthetic%20Alfaxalone.pdf}}</ref> |
- Steroid, but no glucocorticoid or mineralocorticoid action
- Make GABA A receptors in CNS more sensitive to GABA, enhance transport of Cl-, hyperpolarize neuron cell memb
- Rapid metabolism, so few cumulative effects
- And can use in anesthesia without making recovery longer
- Cardio vasc effects less than that of propofol
- Increased HR, decreased vascular resistance, decresased myocardial contractility
- Most common use: IV induction of anesthesia before maintaining anesthesia where gas is used
- Or can use as maintenance agent if want IV anesthesia for entire procedure (ex. bronchoscopy, tracheal laceration, intracranial disease)
- 60s onset
- Normal dose in dogs give about 10 min anesthesia
- In cats, normal dise gives around 25
- Cats take longer than dogs to recover
- Not licensed for IM or SQ use in US
- Both cause longer recoveries, w/agitation and hypesensitive to stimuli
- Excitement in esp. cats when recovering
- Agitation, paddling, "muscle fasciculations", exag reactions to external stimuli
- Drug interactions
- OK to use with all normal sedatives used
- More expensive than other induction agents
Suarez, Martin A; Dzikiti, Brighton T; Stegmann, Frik G; Hartman, Marthinus (May 2012). "Comparison of alfaxalone and propofol administered as total intravenous anaesthesia for ovariohysterectomy in dogs". Veterinary Anaesthesia and Analgesia. 39 (3): 236–244. doi:10.1111/j.1467-2995.2011.00700.x. ISSN 1467-2987. Retrieved 2017-07-19.
| copy | <ref>{{cite journal | last1=Suarez | first1=Martin A | last2=Dzikiti | first2=Brighton T | last3=Stegmann | first3=Frik G | last4=Hartman | first4=Marthinus | title=Comparison of alfaxalone and propofol administered as total intravenous anaesthesia for ovariohysterectomy in dogs | journal=Veterinary Anaesthesia and Analgesia | accessdate=2017-07-19 | date=May 2012 | url=http://linkinghub.elsevier.com/retrieve/pii/S1467298716304822 | doi=10.1111/j.1467-2995.2011.00700.x | issn=14672987 | volume=39 | issue=3 | pages=236-244}}</ref> |
- Both Althesin and Saffan 1971
- Started with alfaxalone + alfadolone acetate
- Nonlinear pharmacokinetics in cats
- Mainly hepatic metabolism, also a bit of kidney and pulmonary
US National Library of Medicine. "ALFAXAN- alfaxalone injection, solution". DailyMed. Retrieved July 15, 2017.
| copy | <ref>{{cite web | last=US National Library of Medicine | title=ALFAXAN- alfaxalone injection, solution | work=DailyMed | accessdate=July 15, 2017 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5d57f72-71e4-46af-b262-673ceabeff04}}</ref> |
- Animal use only (in US)
- Administer over 60 seconds or until showing that they're anesthetized – give too fast and increase risk of apnea
- Can give less if also gave premed
- Drug interactions:
- OK to use with benzos, opioids, alpha2-agonists, phenothiazines, antibiotics, anticholinergics, vaccines, steroids, dewormers
- Contraindicated if sensitive to alfax or anesthesia/sedation
- Anesthetic overdose or if give bolus
- Can get low BP, apnea, hypoxia, or death
- Arrhythmia due to apnea and hypoxia
- Treat cardiovasc depression with plasma expanders, pressor agents, anti-arrhythmic agents, etc.
- Abuse potential similar to other Schedule 4 drugs
- Physical dependence: no data, but mechanism similar to benzos, so assume that dependence and withdrawal same as benzos
- Precautions
- If use benzo as only premed and then give alfaxan, higher chance of excitation in recovery
- Decrease body temp
- Pharmakocinetic (5 mg/kg for cats, 2 mg/kg for dogs), in 8 animals each
- Steady state volume of distribution:: 1.3 L/kg (cats), 2 L/kg (dogs)
- Half-life: 43 min (cats), 34 min (dogs)
- Clearance rate: 24 mL/min/kg (cat), 59.4 mL/min/kg
- Dogs and cats that got only midazolam as premed needed MORE alfax than normal for induction
Varga, Molly (2014). "Chapter 4: Anaesthesia and Analgesia". Textbook of Rabbit Medicine (2nd ed.). Butterworth-Heinemann. pp. 178–202. ISBN 9780702049798.
| copy | <ref>{{cite book | last=Varga | first=Molly | title=Textbook of Rabbit Medicine | chapter=Chapter 4: Anaesthesia and Analgesia | date=2014 | edition=2nd | publisher=Butterworth-Heinemann | isbn=9780702049798 | pages=178-202}}</ref> |
- In rabbits: can give IV or IM
Visser, S. a. G.; Smulders, C. J. G. M.; Reijers, B. P. R.; Graaf, P. H. van der; Peletier, L. A.; Danhof, M. (September 1, 2002). "Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of Concentration-Dependent Hysteresis and Biphasic Electroencephalogram Effects of Alphaxalone in Rats" (PDF). Journal of Pharmacology and Experimental Therapeutics. 302 (3): 1158–1167. doi:10.1124/jpet.302.3.1158. ISSN 0022-3565. PMID 12183676. Retrieved July 15, 2017.
| copy | <ref>{{cite journal | last1=Visser | first1=S. a. G. | last2=Smulders | first2=C. J. G. M. | last3=Reijers | first3=B. P. R. | last4=Graaf | first4=P. H. van der | last5=Peletier | first5=L. A. | last6=Danhof | first6=M. | title=Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of Concentration-Dependent Hysteresis and Biphasic Electroencephalogram Effects of Alphaxalone in Rats | journal=Journal of Pharmacology and Experimental Therapeutics | accessdate=July 15, 2017 | date=September 1, 2002 | url=http://jpet.aspetjournals.org/content/jpet/302/3/1158.full.pdf | pmid=12183676 | doi=10.1124/jpet.302.3.1158 | issn=0022-3565 | volume=302 | issue=3 | pages=1158-1167}}</ref> |
- Alfaxan at higher concentrations acts on GABA R as agonist, "higher concentrations' being at least 1 microM
Welsh, Liz (May 8, 2013). Anaesthesia for Veterinary Nurses. John Wiley & Sons. p. 153. ISBN 9781118693148.
| copy | <ref>{{cite book | last=Welsh | first=Liz | title=Anaesthesia for Veterinary Nurses | date=May 8, 2013 | url=https://books.google.com/books?id=1F0_tIVik8gC&pg=PT153| publisher=John Wiley & Sons | isbn=9781118693148 | page=153}}</ref> |
- Saffan (alfaxalone + alfadolone)
- Cremphor EL as carrier agent
- Cats: histamine release → edema and hyperemia in ears and paws; sometimes laryngeal or pulmonary edema'
- Dogs: absolutely contraindicated (HUGE histamine release)
- "Alfaxan", 'Vetoquinol"
- Allfadolone not included, since much weaker hypnotic effect than alfaxalone
- Use: induce/maintain general anesthesia, CRI for longer sedation
- Side effects: mild cariovasc and resp depression, muscle twitching
- Contraindications: "inability to secure airway"
Zeltzman, Phil (November 17, 2014). "Why Administering Alfaxalone Requires A Bit of Education". Veterinary Practice News. Retrieved July 14, 2017.
| copy | <ref>{{cite web | last=Zeltzman | first=Phil | title=Why Administering Alfaxalone Requires A Bit of Education | work=Veterinary Practice News | accessdate=July 14, 2017 | date=November 17, 2014 | url=http://www.veterinarypracticenews.com/Why-Administering-Alfaxalone-Requires-A-Bit-of-Education/}}</ref> |
- Released for cats and dogs in AUS in 2000, UK in 2007, Central Europe in 2008, Canada in 2011
- Synthetic neuroactive steroid
- IM sedation, IV induction, IV anesth maintenace
- Doesn't inhibit pain, but does muscle relaxation
- Safe; lowered RR and BP when given too much, but not as much as with propofol, iso, or sevo
- Can use in pediatric (under 3 months)
- US says can keep for 6 hours after opening
Ahmad, Suhail; Mokaddas, Eiman (1 March 2014). "Current status and future trends in the diagnosis and treatment of drug-susceptible and multidrug-resistant tuberculosis". Journal of Infection and Public Health. 7 (2): 75–91. doi:10.1016/j.jiph.2013.09.001. ISSN 1876-0341. {{cite journal}}: Invalid |ref=harv (help)
| copy | <ref>{{cite journal | last1=Ahmad | first1=Suhail | last2=Mokaddas | first2=Eiman | title=Current status and future trends in the diagnosis and treatment of drug-susceptible and multidrug-resistant tuberculosis | journal=Journal of Infection and Public Health | date=1 March 2014 | pages=75-91 | doi=10.1016/j.jiph.2013.09.001 | issn=1876-0341 | volume=7 | issue=2 | ref=harv }}</ref> |
- Resistance to amikacin and kanamycin in TB due to mutation in rrs gene, which codes for a 16S rRNA that is different at the 3' end
- In 80–85% of strains resistant to kanamycin/amikacin
"Amikin (Amikacin): Side Effects, Interactions, Warning, Dosage & Uses". RxList. 10 January 2017. Retrieved 9 August 2017.
| copy | <ref>{{cite web | title=Amikin (Amikacin): Side Effects, Interactions, Warning, Dosage & Uses | work=RxList | accessdate=9 August 2017 | date=10 January 2017 | url=http://www.rxlist.com/amikin-drug.htm }}</ref> |
- "Amikin" brand no longer available in US
"Amikacin Sulfate". Drugs.com. Retrieved 8 August 2017.
| copy | <ref>{{cite web | title=Amikacin Sulfate | work=Drugs.com | accessdate=8 August 2017 | url=https://www.drugs.com/monograph/amikacin-sulfate.html }}</ref> |
- Warnings
- Don't know if safe to use for more than 14 days - potential ototoxicity and nephrotoxicity
- Neurotoxicity (vestibular and permanebt bilateral auditory ototoxicity) if p had renal damage or if p received higher/longer dose than recommended
- Renal damage increased risk of aminoglycoside-induced ototoxicity
- High frequency deafness possible at first
- Vertigo possible
- Numbness, skin tingling, muscle twitching, seizures
- Risk of hearing loss (increases w/increasing peak concentration)
- No symptom of cochlear damage (due to 8th nerve toxicity) during treatment
- So can be partially or fully deaf after finish drug
- Neuromuscular blockade and respiratory paralysis (inc. acute muscular paralysis and apnea) from topical or oral use of aminoglycosides
- Ca salts can reverse neuromusc blockade
- Increased risk for pts getting anesthetics or neuromuscular blocking agents (ex. tubocurarine, succinylcholine) or getting large transfusions of citrated-anticoagulated blood
- Don't use with or sequentally with other neurotoxic/nephrotoxic drugs
- Dehydration and being old increase risk of tox
- Avoid using w/potent diuretics bc diuretics can cause ototox, and can change aminoglycoside concentrations, which would also enhance tox
- Aminoglycoside derived from kanamycin
- Uses:
- Bone and joint infections (serious inf by susceptible gram -)
- Intra-abdominal infections (serious inf by susceptible gram -)
- Inc. peritonitis
- Use as adjunct to clindamycin, metronidazole, piperacillin + tazobactam, ampicillin + sulbactam
- Meningitis (by gram - bact) as adjunct in initial treatment
- With ampicillin for neonatal S. agalactiae or Listeria monocytogenes
- With 3rd generation cephalosporin for neonatal gram- bact meningitis, inc. by E. coli
- With imipenem in adults for menin by E. coli
- With meropenem in menin by Pseudomonas
- With impimenem or colistin for menin by Acinetobacter
- Resp tract inf (serious, by gram -)
- As adjunct ot Beta-lactam or carbapenem for treating nosocomial pneumonia
- Septicemia (by gram -)
- As adjunct to betalactam or carbapenem
- Skin and skin suture infections (serious inf, by susc. gram -)
- UTIs (serious, complicated by susc. gram-)
- Inc. by Enterobacteriaceae or Pseudomonas aeruginosa
- Possibly as adjunct to another tx
- Only use if causing organism is resistant to less toxic drugs
- Mycobacterial
- 2nd line agent in multiple-drug regiments for treating active TB (if have relapse or tx failure) or TB resistant to isoniazid and/or rifampin or when 1st-line drugs can't be tolerated
- Use as alernative in multiple-drug regiments for treating M. avium
- Use for nonpulmonary M. abscessus, M. chelonae, M. fortiuitum
- Infections by Nocardia
- (Usually) As adjunct to sulfonamide if inf is severe or disseminated
- If can't use sufonamide, use amikacin + carbapenem or 3rd gen cephalosporin or tetraxycline or amoxiclav or clarithromycin or cycloserine or linezolid
- Inf by Rhodococcus equi
- Inf in febrile neutropenic patients
- (Empiric therapy)
- Use w/anti-psuedomonal cephalosporin or extended-spectrum penicillin or carbapenem
- Administration
- IV or IM
- Can be given intrathecally or intraventricularly for meningitit or other CNS infection
- If giving IV with a beta-lactam, don't admix them; administer separately
- IV and IM dosage is the same
- Special populations
- Old people: age-related decrease in kidney fxn
- PPl w/muscular disorder like myasthenia gravis or parkinsons since amikacin has strong curare-like effect on neuromusc junctions and can make muscle weakness worse
- Pregnancy category D
- Possible harm to fetus
- W/comcurrent aminoglycoside, can cause bilateral congentical deafness
- Low concentration in lactated milk
- Pediatric: immature renal system (→ prolonged serum half-lif)
- Contraindications
- Sensitivity to aminoglycosides (cross-allergenic)
- Sensitivity to sulfite, since amikacin has sodium metabisulfite and can cause allergic-type reactions
- Possibility of additive toxicity, so avoid concurrent or sequential use of other neurotoxic/nephrotoxic drugs, esp. bacitration ,cisplatin, ampotericin B, cephaloridine, paromomycin, viomycin, polymyxin B, colistin, vancomycin, or other aminoglyc.
- Potent diuretic
- Neuromuscular blocking agents (tubocurarine, succinylcholine, decamethonium)
- Topical use (small or large fields) → irriversible deafness, renal failure, death
- Drug interactions (specific)
- Acyclovir, amphotericin B, bacitracin, capreomycin, cisplatin, colistimethate/colistin, polymyxin B, vancomycin → can increase neurotox, ototox, or nephrotox effects
- Penicillins: additive antibact effect against Enterobacteriaceae or P. aeruginosa
- Cephalosporin: possible increase in nephrotox; randomly elevate creatnine levels
- Amikacion can be inactivated beta-lactams, though not as much as other aminoglyocosides
- Carbapenem: additive/synergistic effect agasint some gram + bact
- Chloramphenicol, clindamycin, tetracycline: possibly antagonism w/aminoglycos.
- Diuretics: increased risk of ototox (since diuretics can cause them); increase SE of aminoglycosides, since can change their concentration in serum or tissue
- Nuromuscular blocking agents (see above)
- Indomethacin: possibly increase serum aminoglycosides in premature babies
- Pharmacokin
- Not absorbed orally
- Peak serum concentration within 0.5–2 hours after IM
- Distributed into:
- Bone, heart, gallbladder, lung tissue, bile, sputum, bronchial secretions, interstitial fluids, pleural fluids, synovial fluids
- Low concentration in CSF from IM or IV; high concentration in CSF from intraventricular
- Crosses placenta
- Less than or equal to 11% plasma protein binding
- 94-96% of a single IM or IV dose secreted unchanged by glomerular filtration within 24 hours
- 2-3h hour half-life
- Preparations
- 50mg/mL inj
- 250mg/mL inj
Aronson, J., ed. (2016). "Amikacin". Meyler's Side Effects of Drugs (16th ed.). Oxford: Elsevier. pp. 207–209. doi:10.1016/B978. ISBN 978-0-444-53716-4. {{cite book}}: External link in (help); Invalid |chapterurl=|ref=harv (help); Unknown parameter |chapterurl= ignored (|chapter-url= suggested) (help)
| copy | <ref>{{cite book | editor-last=Aronson | editor-first=J. | title=Meyler's Side Effects of Drugs | chapter=Amikacin | location=Oxford | year=2016 | chapterurl=http://www.sciencedirect.com/science/article/pii/B9780444537171002663 | pages=207-209 | doi=10.1016/B978 | edition=16th | publisher=Elsevier | isbn=978-0-444-53716-4 | ref=harv }}</ref> |
- Effective against many G- aerobes that are resistant to gentamicin and tobramycin
- Some strains of S. aureus can inactivate amikacin via phosphorylation and adenylation
- Amikacin + Ticarcillin or azlocillin is one of best abx combos for febrile granulocytopenia in those w/cancer
- Less active than gentamicin on per-gram basis
Aronson, J., ed. (2016). "Aminoglycoside antibiotics". Meyler's Side Effects of Drugs (Sixteenth Edition). Oxford: Elsevier. pp. 216–236. doi:10.1016/B978. ISBN 978-0-444-53716-4. {{cite book}}: External link in (help); Invalid |chapterurl=|ref=harv (help); Unknown parameter |chapterurl= ignored (|chapter-url= suggested) (help)
| copy | <ref>{{cite book | editor-last=Aronson | editor-first=J. | title=Meyler's Side Effects of Drugs (Sixteenth Edition) | chapter=Aminoglycoside antibiotics | location=Oxford | year=2016 | chapterurl=http://www.sciencedirect.com/science/article/pii/B9780444537171002705 | pages=216-236 | doi=10.1016/B978 | publisher=Elsevier | isbn=978-0-444-53716-4 | ref=harv }}</ref> |
- Ototox w/amikacin: 14% of patients
- Needs long duration of tdx and repeated courses or high cumulative dose
- Cause high-frequency hearing loss (beyond range of normal speech)
- Hearing loss of 15 decible at 2 or more frequencies, or 20 decibels at at least 1 freuency: 18%
- Nephrotox w/amikacin: 8.5%
Bauman, Robert W. (2015). Microbiology: With Diseases by Body System (4th ed.). Boston: Pearson. p. 294. ISBN 978-0-321-91855-0. {{cite book}}: Invalid |ref=harv (help)
| copy | <ref>{{cite book | last=Bauman | first=Robert W. | title=Microbiology: With Diseases by Body System | location=Boston | year=2015 | page=294 | edition=4th | publisher=Pearson | isbn=978-0-321-91855-0 | ref=harv }}</ref> |
- Type of aminoglycoside that binds to 30S of ribosome and changes its shape so that can't read mRNA codons correctly
Boothe, Dawn. "Aminoglycosides - Pharmacology". Merck Veterinary Manual. Retrieved 9 August 2017.
| copy | <ref>{{cite web | last=Boothe | first=Dawn | title=Aminoglycosides - Pharmacology | work=Merck Veterinary Manual | accessdate=9 August 2017 | url=http://www.merckvetmanual.com/pharmacology/antibacterial-agents/aminoglycosides }}</ref> |
- Expanded-spectrum aminoglyc
- Resistance by bact enzymes
- Amikacin is more resistant to enzymatic hydrolysis than kanamycin
- Half-life: 60 min (dogs), 45 min (horses), 115 min (sheep)
- Volume of distribution (mL/kg): 300 (dogs), 207 (horses), 200 (sheep)
- Clearance (mL/kg/min): 3.5 (dogs), 0.75 (horses), 0.7 (sheep)
- Half-life
- Dogs: 60 min
- Horses: 45 min
- Sheep: 115 min
Caminero, José A; Sotgiu, Giovanni; Zumla, Alimuddin; Migliori, Giovanni Battista (1 September 2010). "Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis". The Lancet Infectious Diseases. 10 (9): 621–629. doi:10.1016/S1473-3099(10)70139-0. ISSN 1473-3099. {{cite journal}}: Invalid |ref=harv (help)
| copy | <ref>{{cite journal | last1=Caminero | first1=José A | last2=Sotgiu | first2=Giovanni | last3=Zumla | first3=Alimuddin | last4=Migliori | first4=Giovanni Battista | title=Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis | journal=The Lancet Infectious Diseases | date=1 September 2010 | pages=621-629 | doi=10.1016/S1473-3099(10)70139-0 | issn=1473-3099 | volume=10 | issue=9 | ref=harv }}</ref> |
- Treating MDR tuberculosis, use several different drugs
- Regimen includes capreomycin; if that doesn't work, trade out for kanamycin; if that doesn't work, trade out for amikacin
- Although capreomycin is often skipped out on - not available everywhere, and more expensive than kanamycin
- Regimen includes capreomycin; if that doesn't work, trade out for kanamycin; if that doesn't work, trade out for amikacin
- Cross-resistance
- Resistance to streptomycin usually still susc to amikacin
- Resistance to capreomycin usually still susc to amikacin
- Resistance to amikacin also resistant to kanamcin and capreomycin
- Resistant to kanamycin: diff levels of resistance to amikacin
- Never use amikacin 1st, bc will confer cross-resistance to other drugs
Corti, Natascia; Taegtmeyer, Anne; Imhof, Alexander (1 January 2011). "Miscellaneous antibacterial drugs". Side Effects of Drugs Annual. A worldwide yearly survey of new data in adverse drug reactions. 33: 509–540. doi:10.1016/B978-0-444-53741-6.00026-X. ISSN 0378-6080. {{cite journal}}: Invalid |ref=harv (help)
| copy | <ref>{{cite journal | last1=Corti | first1=Natascia | last2=Taegtmeyer | first2=Anne | last3=Imhof | first3=Alexander | title=Miscellaneous antibacterial drugs | journal=Side Effects of Drugs Annual | series=A worldwide yearly survey of new data in adverse drug reactions | date=1 January 2011 | pages=509-540 | doi=10.1016/B978-0-444-53741-6.00026-X | issn=0378-6080 | volume=33 | ref=harv }}</ref> |
- Causes vestibular toxicity at 7.4%
- (Most likely) By creating excessive oxidative free radicals (time-dependent, but not dose-dependent)
- Reduce risk by minimizing duration of exposure
- Electrolyte imbalance (aminoglyc in general)
- Change renal tubular function → changes in fluid/electrolyte/acid-base → hypokalemia and acidosis or alkalosis
- UTI (aminoglyc in general): nephrotox more common in those w/glomerular filtration rate under 60mL/min/1,73 m3, diabetes mellitus, treatment with other nephrotox drugs or iodinated contrast agents, hypotension
- Amikacin damages vestibular organ in infants more often than damages the cochlea
- Amikacin attributed to Type 5 Barter-like syndrome w/severe hypocalcemia
- Susceptibility factors
- Correlation btw lower gestational age and/or birth weight percentile and lower amikacin clearance
Cote, Etienne (2010). Clinical Veterinary Advisor - E-Book: Dogs and Cats. Elsevier Health Sciences. p. 27. ISBN 978-0-323-06876-5. {{cite book}}: Invalid |ref=harv (help)
| copy | <ref>{{cite book | last=Cote | first=Etienne | title=Clinical Veterinary Advisor - E-Book: Dogs and Cats | year=2010 | page=27 | publisher=Elsevier Health Sciences | isbn=978-0-323-06876-5 | ref=harv }}</ref> |
- Nocardiosis: sulfonamides are drugs of choice; might end up needeing amikacin or imipenem
Cunha, Burke A. (1 November 2006). "New Uses for Older Antibiotics: Nitrofurantoin, Amikacin, Colistin, Polymyxin B, Doxycycline, and Minocycline Revisited". Medical Clinics of North America. Antimicrobial Therapy. 90 (6): 1089–1107. doi:10.1016/j.mcna.2006.07.006. ISSN 0025-7125. {{cite journal}}: Invalid |ref=harv (help)
| copy | <ref>{{cite journal | last=Cunha | first=Burke A. | title=New Uses for Older Antibiotics: Nitrofurantoin, Amikacin, Colistin, Polymyxin B, Doxycycline, and Minocycline Revisited | journal=Medical Clinics of North America | series=Antimicrobial Therapy | date=1 November 2006 | pages=1089-1107 | doi=10.1016/j.mcna.2006.07.006 | issn=0025-7125 | volume=90 | issue=6 | ref=harv }}</ref> |
- Amikacin stx makes it immune to aminogly-inactivating enzymes
- Only one location on stx makes it vulnerable – ginteamicin and tobramycin have 6
- Aminogly w/"greatest degree" of activity against P. aeruginosa and the one least likely to cause resistance
- Mostly against aeribic gram- bacilli
- Rarely used as monotherapy
- Pharmacokin
- Plasma protein binding: less than 5%
- 95% excreted unchanged
- 2 hr serum half life normally; 50 hrs in end-stage renal disease
- volume of distribution 0.25 L/kg
- Single daily dose "virtually eliminates" nephrotox/ototox potential
- CSF penetation: 15% (w/inflamed meninges, is 20%)
- Traditional uses
- Combo therapy for P. aeruginosa and aerobic G- bacilli
- Increased/new uses; combo therapy for:
- MDR P. aeruginosa
- MDR Klebsiella pneumoniae
- MDR Acenitobacter baumannii
- MDR M. tuberculosis
DrugBank (2 August 2017). "Amikacin". DrugBank. Retrieved 10 August 2017.
| copy | <ref>{{cite encyclopedia | editor-last=undefinedDrugBank | editor-first=undefinedDrugBank | title=Amikacin | encyclopedia=DrugBank | accessdate=10 August 2017 | date=2 August 2017 | url=https://www.drugbank.ca/drugs/DB00479 }}</ref> |
- Mech
- Binds to 4 nucleotides of 16S rRNA and 1 amino acid of protein S12 (of 30S ribosome)
- Interferes w/decoding site near nucleotide 1400 in 16S rRNA of 30S subunit (the region that interacts w/the wobble base of tRNA anticodon)
- Interference w/initiation complex, misreading mRNA
- Binds to 4 nucleotides of 16S rRNA and 1 amino acid of protein S12 (of 30S ribosome)
Eghianruwa, Kingsley (2014). Essential Drug Data for Rational Therapy in Veterinary Practice. Author House. pp. 16–17. ISBN 978-1-4918-0000-3. {{cite book}}: Invalid |ref=harv (help)
| copy | <ref>{{cite book | last=Eghianruwa | first=Kingsley | title=Essential Drug Data for Rational Therapy in Veterinary Practice | year=2014 | url=https://books.google.com/books?id=h4zCAgAAQBAJ&pg=PA16 | pages=16–17 | publisher=Author House | isbn=978-1-4918-0000-3 | ref=harv }}</ref> |
- Amikin (human), Amiglyde (vet)
- Aminocyclitol
- Sparingly soluble in water; works best in alkaline environment; heat resistant
- Rapidly bacateriocidal to most G-
- Resistant to aminoglyc-inactivating enzymes
- Binds to 30S and 50S subunits
- Abnormal initiation complexes accumulate
- Misread mRNA and add incorrect amino acid
- Uses
- Treating aerobic G- resistant to gentamicin and tobramycin
- Treating G- eye infections (esp. by P. aeuroginosa)
- Uterine absorption poor
- Ocular absorption has been found (when have conjunctivitis(
- Bioavilability: >90% from IM or SQ injections
- Distribution
- Sequestered in the inner ear and kidneys
- Vd = 0.27 L/kg in humans (lower in obesity, higher in newborns)
- 0.15–0.3 in cats and dogs
- 0.26–0.58 in horses
- Clearance higher in those w/cystic fibrosis
- Interactions; indomethacin, enflurane, and methoxyflurane increase tox potential
Esposito, Susanna; Canevini, Maria Paola; Principi, Nicola (1 July 2017). "Complications associated with antibiotic administration: neurological adverse events and interference with antiepileptic drugs". International Journal of Antimicrobial Agents. 50 (1): 1–8. doi:10.1016/j.ijantimicag.2017.01.027. ISSN 0924-8579. {{cite journal}}: Invalid |ref=harv (help)
| copy | <ref>{{cite journal | last1=Esposito | first1=Susanna | last2=Canevini | first2=Maria Paola | last3=Principi | first3=Nicola | title=Complications associated with antibiotic administration: neurological adverse events and interference with antiepileptic drugs | journal=International Journal of Antimicrobial Agents | date=1 July 2017 | pages=1-8 | doi=10.1016/j.ijantimicag.2017.01.027 | issn=0924-8579 | volume=50 | issue=1 | ref=harv }}</ref> |
- Ototox: more toxic to cochlea (vs. vestibulatory system)
- Neuromusc blockade in a way that mimics myasthenia gravis
- More often assoc w/renal disease, neuromusc diseae, botulism, hypocalcemia, use w/muscle relaxants
Ettinger, Stephen J.; Feldman, Edward C. (2009). Textbook of Veterinary Internal Medicine. Elsevier Health Sciences. ISBN 978-1-4377-0282-8. {{cite book}}: Invalid |ref=harv (help)
| copy | <ref>{{cite book | last1=Ettinger | first1=Stephen J. | last2=Feldman | first2=Edward C. | title=Textbook of Veterinary Internal Medicine | year=2009 | url=https://books.google.com/books?id=4Qzau1jagOYC&pg=PA1976 | publisher=Elsevier Health Sciences | isbn=978-1-4377-0282-8 | ref=harv }}</ref> |
- Choices in animals p594
- Alt choice for respiratory tract infection (1st are clavamox, fluoroquinolones, cephalosporins)
- Alt choice for septicemia (1st are csame as above)
- Active agasint kennel cough p595
- Aminoglyc nephrotox in dogs and cats p1976
- Not metabolizes, low molecular weight, high water solubililty →all factors that make it excreted almost completely via urine
- Easily ionize to cationic complexes and bind to anionic sites on epithelial cells of proximal tubule
- Internalized by pinocytosis
- Renal cortical concentrations 10x of plasma concentration → renal tubular damage
- Factors that increase risk of tox: prolonged use (more than 5 days), high trough levels (>5 microg/mL), pre-existing renal disease, dehydration, hypokalemia, hypocalcemia, hypomagnesemia, metabolic acidosis, age, concurrent nephrotox drug admin, diureitcs, antiprostaglandins
- Tox can be reduced by less frequent dosing
- Efficacy of aminoglycs is assessed by peak concentrations, but toxicity correlated more to trough concentrations (so dosing every 24 hrs instead of every 8 hours)
- Severe, unstable bacterial pneumonia p1103
- As pat of combo therapy w/a beta-lactam
- Avoid in neonates p523
- 2nd line tx for Mycobacteriam avium-intracellular complex and non-TB mycobacteria in dogs and cats p879
- Pus and necrotic debris bind and inactivate vancomycin and aminoglycs → they become ineffective p591
Forney, Barbara. "Amikacin for Veterinary Use". Wedgewood Pharmacy. Retrieved 9 August 2017.
| copy | <ref>{{cite web | last=Forney | first=Barbara | title=Amikacin for Veterinary Use | work=Wedgewood Pharmacy | accessdate=9 August 2017 | url=http://www.wedgewoodpetrx.com/learning-center/professional-monographs/amikacin-for-veterinary-use.html }}</ref> |
- FDA for dog and intra-uterine for horse
- Amikacin and gentamicin most common aminoglycs in vet medicine
- Dogs and cats
- Topical otic for bact infections in ear (dogs and cat) (most common P. aeruginosa)
- Poor activity in presence of pus and cellular debris, so clean ear first
- Corneal ulcer (most common P. aeruginosa)
- Horses
- Freq. w/IV penicillins
- Opthalmic preparations, regional limb perfusion, joint lavage, intraarticular injections
- Side effects
- Ototox: cats are more sensitive to vestibular damage by aminoglycs
- Inj site reactions w/IM injections
- Nephrotox, ototox
- Neuromusc. blockade, facial edema, peripheral neuropathy
- Overdose
- "Hemodialysis, peritoneal dialysis, and complexation using of the penicillins"
Hsu, Walter H. (2013). Handbook of Veterinary Pharmacology. John Wiley & Sons. p. 486. ISBN 978-1-118-71416-4. {{cite book}}: Invalid |ref=harv (help)
| copy | <ref>{{cite book | last=Hsu | first=Walter H. | title=Handbook of Veterinary Pharmacology | year=2013 | url=https://books.google.com/books?id=MGhScg9GZGAC&pg=PT486 | pages=486 | publisher=John Wiley & Sons | isbn=978-1-118-71416-4 | ref=harv }}</ref> |
- Infected corneal ulcers in horses: fortified cephazolin solutions, often used in combo w/fortified amikacin
- All aminoglycs are toxic to intraocular stx
Kondo, Shinichi; Hotta, Kunimoto (1 January 1999). "Semisynthetic aminoglycoside antibiotics: Development and enzymatic modifications". Journal of Infection and Chemotherapy. 5 (1): 1–9. doi:10.1007/s101560050001. ISSN 1341-321X. {{cite journal}}: Invalid |ref=harv (help)
| copy | <ref>{{cite journal | last1=Kondo | first1=Shinichi | last2=Hotta | first2=Kunimoto | title=Semisynthetic aminoglycoside antibiotics: Development and enzymatic modifications | journal=Journal of Infection and Chemotherapy | date=1 January 1999 | url=https://www.jstage.jst.go.jp/article/antibiotics1968/25/12/25_12_695/_pdf | pages=1-9 | doi=10.1007/s101560050001 | issn=1341-321X | volume=5 | issue=1 | ref=harv }}</ref> |
- Amikacin: large side chains attached onto kanamycin; block access of various enzymes that converge resistance
- AAC = aminoglycoside acetyltransferase
- AAD = aminoglycoside adenylyltransferase
- Resistance
- In P. aeruginosa, enzyme = AAC(6')-IV (also confers resistance to kanamycin, gentamicin, aand tobramycin)
- In S. epidermidis, and S. aureus, enzime - AAD(4',4) (also confers resistance to kanamycin, apramycin, and tobramycin)
- Susceptibility in E. coli w./enzyme AAD(2) (but confers RESISTANCE to kanamycin and gentamycin)
Mader, Douglas R.; Divers, Stephen J. (2013). Current Therapy in Reptile Medicine and Surgery - E-Book. Elsevier Health Sciences. pp. 41, 382. ISBN 978-0-323-24293-6. {{cite book}}: Invalid |ref=harv (help)
| copy | <ref>{{cite book | last1=Mader | first1=Douglas R. | last2=Divers | first2=Stephen J. | title=Current Therapy in Reptile Medicine and Surgery - E-Book | year=2013 | url=https://books.google.com/books?id=2phWAgAAQBAJ&pg=PA382| pages=41, 382 | publisher=Elsevier Health Sciences | isbn=978-0-323-24293-6 | ref=harv }}</ref> |
- Pythons, gopher snakes, lizards, sea turtles, gopher tortoises, alligators
- Bullfrogs p41
Maggs, David; Miller, Paul; Ofri, Ron (2013). Slatter's Fundamentals of Veterinary Ophthalmology - E-Book. Elsevier Health Sciences. p. 37. ISBN 978-0-323-24196-0. {{cite book}}: Invalid |ref=harv (help); More than one of |pages= and |page= specified (help)
| copy | <ref>{{cite book | last1=Maggs | first1=David | last2=Miller | first2=Paul | last3=Ofri | first3=Ron | title=Slatter's Fundamentals of Veterinary Ophthalmology - E-Book | year=2013 | url=https://books.google.com/books?id=8QCduRN3zR0C&pg=PA37 | pages=525 | page=37 | publisher=Elsevier Health Sciences | isbn=978-0-323-24196-0 | ref=harv }}</ref> |
- Can inject subconjunctivally
Maire, P.; Bourguignon, L.; Goutelle, S.; Ducher, M.; Jelliffe, R. (2017). "Chapter 20 - Individualizing Drug Therapy in the Elderly". Individualized Drug Therapy for Patients. Boston: Academic Press. pp. 373–382. doi:10.1016/B978. ISBN 978-0-12-803348-7. {{cite book}}: External link in (help); Invalid |chapterurl=|ref=harv (help); Unknown parameter |chapterurl= ignored (|chapter-url= suggested) (help)
| copy | <ref>{{cite book | last1=Maire | first1=P. | last2=Bourguignon | first2=L. | last3=Goutelle | first3=S. | last4=Ducher | first4=M. | last5=Jelliffe | first5=R. | title=Individualized Drug Therapy for Patients | chapter=Chapter 20 - Individualizing Drug Therapy in the Elderly | location=Boston | year=2017 | chapterurl=http://www.sciencedirect.com/science/article/pii/B9780128033487000204 | pages=373-382 | doi=10.1016/B978 | publisher=Academic Press | isbn=978-0-12-803348-7 | ref=harv }}</ref> |
- Average clearance at age 20 is 6 L/hr
- Average clearance at age 80 is 3 L/h (with larger standard deviation)
Monteleone, Peter M.; Muhammad, Naseem; Brown, Robert D.; McGrory, John P.; Hanna, Samir A. (1 January 1983). "Amikacin Sulfate". Analytical Profiles of Drug Substances. 12: 37–71. doi:10.1016/S0099-5428(08)60163-X. ISSN 0099-5428. {{cite journal}}: Invalid |ref=harv (help)
| copy | <ref>{{cite journal | last1=Monteleone | first1=Peter M. | last2=Muhammad | first2=Naseem | last3=Brown | first3=Robert D. | last4=McGrory | first4=John P. | last5=Hanna | first5=Samir A. | title=Amikacin Sulfate | journal=Analytical Profiles of Drug Substances | date=1 January 1983 | pages=37-71 | doi=10.1016/S0099-5428(08)60163-X | issn=0099-5428 | volume=12 | ref=harv }}</ref> |
- Alteration of kanamycin A, bc resistant bacteria were speading\
- Made 1st in 1972 in Tokyo
- FDA-approved in 1976
- Synth diagram
Morris, Daniel O.; Kennis, Robert A. (2012). Clinical Dermatology, an Issue of Veterinary Clinics: Small Animal Practice, E-Book. Elsevier Health Sciences. p. 29. ISBN 978-1-4557-7377-0. {{cite book}}: Invalid |ref=harv (help)
| copy | <ref>{{cite book | last1=Morris | first1=Daniel O. | last2=Kennis | first2=Robert A. | title=Clinical Dermatology, an Issue of Veterinary Clinics: Small Animal Practice, E-Book | year=2012 | url=https://books.google.com/books?id=TsKQVAWxHg4C&pg=PA29 | page=29 | publisher=Elsevier Health Sciences | isbn=978-1-4557-7377-0 | ref=harv }}</ref> |
- Can give SQ at home for pyoderma
- Nephrotox: renal proximal tubular necrosis
- Still might be less nephrotox than other aminoglycs, inc. gentamicin
- Signs: decreased specific gravity, cats, proteinuria, glycoosuria, finally azotemia
- Renal tox is usually reversible with early drug withdrawal
- Ototox
- Causes apoptosis in inner ear hair cells
Orsini, James A. (1 August 2017). "Update on Managing Serious Wound Infections in Horses: Wounds Involving Joints and Other Synovial Structures". Journal of Equine Veterinary Science. 55: 115–122. doi:10.1016/j.jevs.2017.01.016. ISSN 0737-0806. {{cite journal}}: Invalid |ref=harv (help)
| copy | <ref>{{cite journal | last=Orsini | first=James A. | title=Update on Managing Serious Wound Infections in Horses: Wounds Involving Joints and Other Synovial Structures | journal=Journal of Equine Veterinary Science | date=1 August 2017 | pages=115-122 | doi=10.1016/j.jevs.2017.01.016 | issn=0737-0806 | volume=55 | ref=harv }}</ref> |
- For subcutis infections in horses (cellulitis, ulcerative lymphangitis), usually caused by Staphylococcus
- In combo with cephalosporin
- Inf of synovial stx (joint, tendon sheath, bursa), either traumatic or surgical
- Cephalosporin + amikacin; add metronidazole for wounds on distal limb or anywhere likely to have fecal contamination
- Staphylococcus infections
- Amikacin more likely than gentamicin to work, but susceptibility to amikacin in equine MRSA is variable
- Less effective agasint Streptococcus than gentamicin
- Enterobacter: better than gentamicin
- E. coli and other enterobacteria: amikacin better than gentamicin
- Pasteurella: gentamicin better than amikacin
- Choice abx against Pseudomonas
Papich, Mark G. (2015). "Amikacin". Saunders Handbook of Veterinary Drugs: Small and Large Animal (4th ed.). Elsevier Health Sciences. pp. 25–27. ISBN 978-0-323-24485-5. {{cite book}}: External link in (help); Invalid |chapterurl=|ref=harv (help); Unknown parameter |chapterurl= ignored (|chapter-url= suggested) (help)
| copy | <ref>{{cite book | last=Papich | first=Mark G. | title=Saunders Handbook of Veterinary Drugs: Small and Large Animal | chapter=Amikacin | year=2015 | chapterurl=https://books.google.com/books?id=ip8_CwAAQBAJ&pg=PA25 | pages=25–27 | edition=4th | publisher=Elsevier Health Sciences | isbn=978-0-323-24485-5 | ref=harv }}</ref> |
- "Amiglyde-V" (vet version)
- More active than gentamicin against many Gram-
- 1/2 life short in most animals (1-2 hours)
- Horses;
- Local administration as an intrauterine lavage to treat metritis
- Regional limb perfusion
- Dogs, cats, horses, cattle
Park, Je Won; Ban, Yeon Hee; Nam, Sang-Jip; Cha, Sun-Shin; Yoon, Yeo Joon (1 December 2017). "Biosynthetic pathways of aminoglycosides and their engineering". Current Opinion in Biotechnology. Chemical biotechnology • Pharmaceutical biotechnology. 48: 33–41. doi:10.1016/j.copbio.2017.03.019. ISSN 0958-1669. {{cite journal}}: Invalid |ref=harv (help)
| copy | <ref>{{cite journal | last1=Park | first1=Je Won | last2=Ban | first2=Yeon Hee | last3=Nam | first3=Sang-Jip | last4=Cha | first4=Sun-Shin | last5=Yoon | first5=Yeo Joon | title=Biosynthetic pathways of aminoglycosides and their engineering | journal=Current Opinion in Biotechnology | series=Chemical biotechnology • Pharmaceutical biotechnology | date=1 December 2017 | pages=33-41 | doi=10.1016/j.copbio.2017.03.019 | issn=0958-1669 | volume=48 | ref=harv }}</ref> |
- Amikacin = has 4-amino-2-hydroxybutyrate group instead of an H that kanamycin A has
Plumb, Donald C. (2011). "Amikacin Sulfate". Plumb's Veterinary Drug Handbook (7th ed.). Stockholm, Wisconsin: Wiley. pp. 39–43. ISBN 978-0-470-95964-0. {{cite book}}: Invalid |ref=harv (help)
| copy | <ref>{{cite book | last=Plumb | first=Donald C. | title=Plumb's Veterinary Drug Handbook | chapter=Amikacin Sulfate | location=Stockholm, Wisconsin | year=2011 | pages=39–43 | edition=7th | publisher=Wiley | isbn=978-0-470-95964-0 | ref=harv }}</ref> |
- IA injection in foals for G- septic arthritis
- Mechanism
- Irriversible binding to 30S
- Concentration-dependent Abx
- Covers
- Many G- and some G+
- Including most species of E. coli, Klebsiella, Proteus, Pseudomonas, Salmonella, Enterobacter, Serratia, Shigella, Mycoplasma, Staphylococus
- Better action in alkaline environment
- Pharmacokin
- Topically absorbed if used in irrigation during sx
- Orally absorbed only if pt has hemorrhagic or necrotic enteritis
- IM dogs and cats: peak level is after 1/2-1 hr
- SQ injections: peak is slightly later, more variable
- IM or SQ has bioavailability greater than 90%
- Distribution
- Mainly in extracellular fluid, inc. ascitic, pleural, pericardial, peritoneal, synovial, and abscess
- High levels in sputusm, bronchial secretions, and bile
- Don't easily cross BBB or penetrate ocular tissue
- CSF levels range from 0–50% (unpredictable)
- AGs tend to accumulate in kidneys and inner ear, possibly explaining their toxicity
- Volume of dist: 0.15–0.3 L/kg in dogs and cats, 0.26–0.58 in horses
- May be a lot larger in newborns and young animals bc more extracellular fluid fraction
- Cross placenta; 15–50% of serum concentration reaches fetus
- Mainly in extracellular fluid, inc. ascitic, pleural, pericardial, peritoneal, synovial, and abscess
- Mostly glomerular filtratoin
- Half-life: 5 hrs in foals, 1.14–2.3 hrs in adult horses, 2.2–2.7 hrs in calves, 1–3 hours in cows, 1.5 hours in sheep, 0.5–2 hours in dogs and cats
- Contraindication
- Hypersensitive to AGs
- No other absolute contraindications, bc these drugs are often the only effective agents in severe G- infections
- Extreme caution in those w/renal disease
- Risk for tox: age (young or old), fever, sepsis, dehydration
- Reduced dosage for sighthounds bc have smaller volumes of distribution
- Generally considered contraindicated in rabbits/hares bc harm GI floral balance
- Adverse effects
- Nephrotox
- Tubular necrosis
- Thought to be interference w/phospholipid metabolism in lysosomes of proximal renal tubular cells → proteolytic enzymes leak into cytoplasm
- Manifested by increases in BUN, creatinine, nonprot nitrogen in serum; decreases in urine specific gravity and creatinine clearance
- Possible proteinuria and cells/casts seen in urine
- Usually reversible when abx discontinued
- Slightly less nephrotox than gentamicin
- Ototox (tox of 8th cranial nerve)
- Manifested as vestibular or auditory signs
- Auditory signs more common w/amikacin
- Cats sensitive to vestibular effects of AGs
- Neuromusc blockade
- Facial edema
- Pain/infl at injection site
- Peripheral neuropath
- Hypersensitivity reactions
- Rare: GI clinical signs, hematologic and hepatic effects
- Nephrotox
- Pregnant/nursing
- Rare, but can cause ototox or nephrotox in fetuses
- Excreted in milk, but unlikely to be of significant concern after baby is at least a few days old
- Overdose
- Hemodialysis: reduce serum concentrations well, but not viable for most vet pts
- Peritoneal dialysis: reduces serum concentrations, but not as well as above
- Complexation of drug w/either carbenicillin or ticarcillin (humans) almost as effective as hemodial
- Drug interactions
- Beta-lactams: synergistic effect vs. bact
- Cephalosporins: use together is controversial; potentially add on to nephrotox
- Loop diuretics (furosemide, torsemide) or osmotic diuretics (mannitol): can increase nephrotox or ototox
- NSAIDs: also can cause nephrotox, so some say avoid
- Other nephrotox drugs: cisplatin, ampohotericin B, polymyxin B, vancomycin
- Beta-lactams: synergistic effect vs. bact
- Dose 1x a day in most mammals
- AGs have a "post-antibiotic effect" where surviving bact don't replicate as well even when abx below MIC concentration
- Dogs and cats: IM, IV, SQ
- Ferrets, rabbits, guinea pigs, chinchillas, hamsters, rats, mice, prairie dogs, cattle, horses, birds, crocodilians, fish (WTF)
- Birds
- Sunken eyes/sinusitis in macaws (by susc bact)
- Snakes: common for resp infections; use lower dose for Python curtus
- Turtles: bacterial shell disease, used often with beta-lactam
- aka amikacin sulfphate, amikacini sulfas
Riviere, Jim E.; Papich, Mark G. (2013). Veterinary Pharmacology and Therapeutics. John Wiley & Sons. p. 931. ISBN 978-1-118-68590-7. {{cite book}}: Invalid |ref=harv (help)
| copy | <ref>{{cite book | last1=Riviere | first1=Jim E. | last2=Papich | first2=Mark G. | title=Veterinary Pharmacology and Therapeutics | year=2013 | url=https://books.google.com/books?id=xAPa4WDzAnQC&pg=PA931 | page=931 | publisher=John Wiley & Sons | isbn=978-1-118-68590-7 | ref=harv }}</ref> |
- 50 mg/mL injectible (Amikin, Amiglyde) and 250 mg/mL intrauterine solution for horses
- Bioavilability: 90% IM and 100% SQ in cats
- Dogs, calves
- Snakes, tortoises
Scholar, Eric M.; Pratt, William B. (2000). The Antimicrobial Drugs (2nd ed.). Oxford University Press, USA. pp. 15–19. ISBN 978-0-19-975971-2. {{cite book}}: Invalid |ref=harv (help)
| copy | <ref>{{cite book | last1=Scholar | first1=Eric M. | last2=Pratt | first2=William B. | title=The Antimicrobial Drugs | year=2000 | url=https://books.google.com/books?id=gACeB8XCnpgC&pg=PA15 | pages=15–19 | edition=2nd | publisher=Oxford University Press, USA | isbn=978-0-19-975971-2 | ref=harv }}</ref> |
- Enterobacter, E. coli, Klebsiella pneumonia, indole-positive Proteus (Providencia rettgeri, Morganella morganii, Proteus vulgaris), Serratia marcescens, Acinetobacter, Pseudomonas a., Mycobacterim tuberculosis, Mycobacterium avium, Mycobacterium fortuitum, Nocardia
US National Library of Medicine. "amikacin". Pubchem. Retrieved 11 August 2017.
| copy | <ref>{{cite web | last=US National Library of Medicine | title=amikacin | work=Pubchem | accessdate=11 August 2017 | url=https://pubchem.ncbi.nlm.nih.gov/compound/37768 }}</ref> |
- Binds to 30S ribosome subunit: locks 16S rRNA and S12 protein within 30S
US National Library of Medicine (17 August 2016). "AMIKACIN SULFATE- amikacin sulfate injection". DailyMed. Retrieved 8 August 2017.
| copy | <ref>{{cite web | last=US National Library of Medicine | title=AMIKACIN SULFATE- amikacin sulfate injection | work=DailyMed | accessdate=8 August 2017 | date=17 August 2016 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0b56f6df-a05d-4520-8bf0-d7cefe20f6ad }}</ref> |
- Pharmacokin
- Volume of distribution: 24 liters
- Excreted via glomerular filtration
- Spinal fluids in infants: 10-20% (can reach 50% in meningitis)
- Crosses placenta at 16% peak maternal serum concentration
- 1/2 life in mom is 2 hours, 1/3 life in fetus is 3.7 hours
- Mechanism
- Binds to prokaryotic ribosome and inhibits protein synth
- Vs. gram+ and gram-
- Resistance
- Salmonella, Shigella
- Some aminoglycoside inactivating enzymes that work against gentamicin, tobramycin, or kanamycin don't work agasint amikacin
- Activity
- Lower activity against Gram+ other than Straphylococcus
- Gram-
- Pseudominas
- E. coli
- Proteus
- Klebsiella
- Enterobacter
- Serratia
- Acinetobacter
- Citrobacter freundii (in vitro)
- Uses
- Short-term of serious infections by susceptible gram-, inc. Pseudomonas, E. coli, Proteus, Klebsiella, Enterobacter, Serratia, Acinetobacter
- Effective against: Bacterial septicemia (inc. neonatal), serious inf of repiratory tract, bones and joints, CNS, skin and soft tissue, intra-abdominal, burns, post-op infections, complicated UTIs
- Some severe inf (ex. neonatal sepsis), use w/penicillin-type to cover any Gram+ bact
- Pregnancy
- Aminoglyc.: deafness to fetuses (no serious effect by other aminogl.)
- No harm to fetuses in rat/mice studies
- Sulfite sensitivity (seen more in people w/asthma)
- Can lead to C. difficile-associated diarrhea
- Adverse effects
- Neurotox-ototox
- Toxic effect on 8th cranial nerve → hearing loss, loss or balance
- Cochlear damage (inc. losing high frequency hearing) happens before clinical hearing loss can be detected
- Neurotox-neuromuscular blockade
- Nephrotox
- Increases serum creatinine, albuminuria, RBCs, WBCs, azotemia, oliguria
- Renal function changes are reversible when end drug
- Rare side effects: skin rash, drug fever, headache, paresthesia, tremor, nausea/vomiting, eosinophilia, arthralgia, anemia, hypotension, hypomagnesemia
- Macular infarction tat can lead to permenent vision loss after inj into the eye (intravitreous)
- Neurotox-ototox
- Overdose
- Peritoneal dialysis or hemodyalisis to remove amikacin from blood
- Can use exchange transfusion for newborns
- Usually treat for 7–10 days
- At normal dose, uncomplicated inf by amikacin-sensitive bact should respond within 24-4 8 hours
- Supplied as amikacin sulfate injection (colorles solution, sometimes can become very pale yellow)
- Inactive ingredients: sodium metabisulfite, sulfuric acid, water, sodium citrate
US National Library of Medicine (9 March 2017). "AMIGLYDE-V- amikacin sulfate injection". DailyMed. Retrieved 8 August 2017.
| copy | <ref>{{cite web | last=US National Library of Medicine | title=AMIGLYDE-V- amikacin sulfate injection | work=DailyMed | accessdate=8 August 2017 | date=9 March 2017 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e2abecaf-9532-45a0-a284-5697b2aa38f1 }}</ref> |
- "AMIGLYDE-V": by vet Rx only
- For intrauterine use in horse
- Uterine infections (endometritis, metritis, poyometra) by susc. bacteria (inc. E. voli, Pseudomonas, Klebsiella)
Vardanyan, Ruben; Hruby, Victor (2016). "Chapter 32 - Antimicobacterial Drugs". Synthesis of Best-Seller Drugs. Boston: Academic Press. pp. 669–675. doi:10.1016/B978. ISBN 978-0-12-411492-0. {{cite book}}: External link in (help); Invalid |chapterurl=|ref=harv (help); Unknown parameter |chapterurl= ignored (|chapter-url= suggested) (help)
| copy | <ref>{{cite book | last1=Vardanyan | first1=Ruben | last2=Hruby | first2=Victor | title=Synthesis of Best-Seller Drugs | chapter=Chapter 32 - Antimicobacterial Drugs | location=Boston | year=2016 | chapterurl=http://www.sciencedirect.com/science/article/pii/B9780124114920000328 | pages=669-675 | doi=10.1016/B978 | publisher=Academic Press | isbn=978-0-12-411492-0 | ref=harv }}</ref> |
- 2nd-line anti-TB drug
WebMD. "amikacin (Rx)". Medscape. Retrieved 9 August 2017.
| copy | <ref>{{cite web | last=WebMD | title=amikacin (Rx) | work=Medscape | accessdate=9 August 2017 | url=http://reference.medscape.com/drug/amikin-amikacin-342516#0 }}</ref> |
- Uses
- Hospital-acquired pneumonia w/beta-lactam or carbapenem
- Mycobacterium infections
- Inhaled liposomal amikacin
- Can use for non-TB mycobacteria
- P. aerugionosa lung infections or bronchopulmonary P. aeruginosa in pts w/cystic fibrosis
- Inhaled liposomal amikacin
- Bronchiectasis in pts w/P. aeruginosa infections or non-TB mycobacteria or other susc bacteria
- Interactions/contraindications
- SEVERE
- Amphotericin B: both increase nephrotox and/or ototox
- Cidofovir: same
- Neomycin PO: same
- Serious (use alternative)
- abobotulinumtoxina (and other shit from botox bact) effect increased, risk of apnea
- atracurium: effect increased, risk of apnea
- BCG vaccine live: amikacin decreases effect by pharmacodynamic antagonism. Wait until done w/amikacin tx
- Cholera vaccine: pharm. antagonism. Systemic abx can work against cholera vax
- Ioversol (contrast medium): both increase nephrotox and/or ototox
- Quinidine: increases level of amikacin by P-glycoprotein (MDR1) efflux transporter
- Typhoid vax live: effect decreased by pharm. antagonism.
- Use caution/monitor
- amiodarone: increase level or effect of amikacin by P-glycoprotein efflux transporter
- conjugated estrogens (oral forms): effect decreased bc intestinal flora altered. Low risk of contraceptive failure
- Clarithromycin: MDR1 efflux transporter
- Clotrimazole: same
- Cyclosporine: same
- deferasirox: reports of acute renal failure
- dienogest/estradiol valerate (oral): decreased bc amikacin changes intestinal flora
- a lot more, I'm not doing this
- SEVERE
- Side effects
- 1-10%: neurotox, nephrotox, ototox
- Less than 1%: hypotension, headache, drug fever, rash, nausea/vomiting, eosiniphilia, paresthesia, tremor, arthralgia, weakness, allergic rxn
Bowen, Jon; Heath, Sarah (2005). Behaviour Problems in Small Animals: Practical Advice for the Veterinary Team. Elsevier Health Sciences. p. 52. ISBN 978-0-7020-2767-3.
| copy | <ref>{{cite book | last1=Bowen | first1=Jon | last2=Heath | first2=Sarah | title=Behaviour Problems in Small Animals: Practical Advice for the Veterinary Team | date=2005 | page=52 | publisher=Elsevier Health Sciences | isbn=978-0-7020-2767-3 | url=https://books.google.com/books?id=aRpgViLvf1oC&pg=PA52}}</ref> |
- 2 most common benzos in vet med are diazepam and alprazolam
- Benzos: limit depth perception, so don't allow cats outside
- Alprazolam: more rapid onset; preferable for cats
- Dose dogs and cats at two to three times a day
Wanamaker, Boyce P.; Massey, Kathy (25 March 2014). Applied Pharmacology for Veterinary Technicians - E-Book. Elsevier Health Sciences. p. 93. ISBN 978-0-323-29170-5.
| copy | <ref>{{cite book | last1=Wanamaker | first1=Boyce P. | last2=Massey | first2=Kathy | title=Applied Pharmacology for Veterinary Technicians - E-Book | date=25 March 2014 | page=93 | url=https://books.google.com/books?id=7s3sAwAAQBAJ&pg=PA93 | publisher=Elsevier Health Sciences | isbn=978-0-323-29170-5}}</ref> |
- One of most common benzos in vet med (along w/diazepam and lorazepam)
Bill, Robert L. (2016-09-01). Clinical Pharmacology and Therapeutics for Veterinary Technicians - E-Book. Elsevier Health Sciences. p. 105. ISBN 9780323444026.
| copy | {{cite book | last=Bill | first=Robert L. | title=Clinical Pharmacology and Therapeutics for Veterinary Technicians - E-Book | date=2016-09-01 | publisher=Elsevier Health Sciences | isbn=9780323444026 | page=105 | url=https://books.google.com/books?id=0Hf2DAAAQBAJ&pg=PA105}} |
- Nonsystemic antacid: given orally, but not absorbed - chemically neutralize
- Not really absorbed →few side effects
- Largest groups of OTC nonsystemic antacids are blends of magnegium oxide and al. oxide
- Pure al. oxide is Amphojel
Lambert Vet Supply. "Use of Aluminum Hydroxide Helps Stabilize Pet Renal Failure Issues". General Pet Health Articles. Retrieved 2017-06-30.
| copy | {{cite web | last=Lambert Vet Supply | title=Use of Aluminum Hydroxide Helps Stabilize Pet Renal Failure Issues | work=General Pet Health Articles | accessdate=2017-06-30 | url=http://www.lambertvetsupply.com/Aluminum-Hydroxide-and-Renal-Failure}} |
- As adjuvant in human and pet vaccines
- Powder is most popular form
- Cheap, OTC
- Doesn't accumulate in body, so no toxicity
- No serious side effects (some constipation in small animals)
- OTHER USES
- Horses with chronic renal failure
- Adjuvant for vax for livestock
Lifelearn Inc (2010-11-01). [vcahospitals.com/know-your-pet/aluminum-hydroxide "Aluminum Hydroxide"]. Know Your Pet. Retrieved 2017-06-30. {{cite web}}: Check |url= value (help)
| copy | {{cite web | last=Lifelearn Inc | title=Aluminum Hydroxide | work=Know Your Pet | accessdate=2017-06-30 | date=2010-11-01 | url=vcahospitals.com/know-your-pet/aluminum-hydroxide}} |
- Reduce hyper-P in pts w/renal failure
- Binding to dietary P, reducing amount that's absorbed from intestines
- Kidneys normally filter excess P out, but P accumulates if kidneys failing
- High P → lethargy, poor appetite
- Al. hydroxide used when dietary restriction/renal diet not enough
- Powder that you mix into food, or capsules or liquid
- Most likely side effect in small animals is constipation
Papich, Mark G. (2007). "Aluminum Hydroxide and Aluminum Carbonate". Saunders Handbook of Veterinary Drugs (2nd ed.). St. Louis, Mo: Saunders/Elsevier. pp. 15–16. ISBN 9781416028888.
| copy | {{cite book | last=Papich | first=Mark G. | title=Saunders Handbook of Veterinary Drugs | chapter=Aluminum Hydroxide and Aluminum Carbonate | location=St. Louis, Mo | date=2007 | edition=2nd | publisher=Saunders/Elsevier | isbn=9781416028888 | pages=15–16}} |
- Cats, dogs, and horses
- As a gel: Amphogel
- In combo with diets that reduce phosphorous
- Antacid action (neutralizes stomach acid) is short
- Often substituted with Ca carbonate or Ca citrate, since not available everywhere/from many sources (bc has Al)
Plumb, Donald C. (2011). "Aluminum Hydroxide". Plumb's Veterinary Drug Handbook (7th ed.). Stockholm, Wisconsin; Ames, Iowa: Wiley. pp. 36–37. ISBN 9780470959640.
| copy | {{cite book | last=Plumb | first=Donald C. | title=Plumb's Veterinary Drug Handbook | chapter=Aluminum Hydroxide | location=Stockholm, Wisconsin; Ames, Iowa | date=2011 | edition=7th | publisher=Wiley | isbn=9780470959640 | pages=36–37}} |
- "Amphogel"
- Oral antacid/phosphate binder
- Decreases hyperphosphatemia in patients w/renal failure if diet changes don't work
- Al salts bind to dietary P, reducing amount of P absorbed from intestine
- Small animals; can cause constipation
- Class A for pregnancy
- Hard to OD orally
- Dogs & foals: also used as adj. therapy for gastric ulcers
"Amlodipine 5mg Tablets". emc. 2017-05-30. Retrieved 2017-07-03.
| copy | "Amlodipine 5mg Tablets". emc. 2017-05-30. Retrieved 2017-07-03. |
- Can combined with other drugs when treating hypertension
- Contraindication:
- Pt sensitive to dihydropyridines
- Don't use in cardiogenic shock, severe aortic stenosis, unstable angina (excluding variant angina) or severe hypotension
- Warning
- Amlodipine can cause pulmonary edema in pts with heart failure
- If pt has impaired liver function, drug will have longer half-life
- Pregnancy: haven't established safety; reproductive toxicity at high does
- Unknown if excreted in breast milk
"Amlodipine Besylate Monograph for Professionals". Drugs.com. Retrieved 2017-06-29.
| copy | "Amlodipine Besylate Monograph for Professionals". Drugs.com. Retrieved 2017-06-29. |
- Ca-channel blockers preferred for high BP in patients with certain preexisting conditions (ex. ischemic heart disease) and old people, and black people (respond better)
- Don't use for acute crises
- Amlodopine-associated edema risk can go down if add ACE inhibitor or angiotensin II
- Combo therapy (NOT in order of strength)
- Amlodopine/atorvastatin for hypertension (former) and dyslipidemias and preventing cardiovascular events (latter)
- Or for CAD (former) and same for latter
- Amlodopine/aliskiren if need more than one agent for BP control (can give individually or as combo)
- Amlodopine/aliskiren/hydrochlorothiazide combo tablet if BP still not decreasing
- Amlodopine/benazepril combo if either has failed indivi
- Or if amlodopine alone gave edema
- Amlodopine/olmesartan for ppl who need more for BP
- Amlodopine/olmesartan/hydrohclorothiazide
- Amlodipine/Perindopril
- Or if amlodipine alone gave edema
- Amlodipine/telmisartan
- Amdlodipine/valsartan
- Amlodipine/valsartan/hydrochlorothiazide
- Use for Prinzmetal variant angina and chronic stable angina pectoris
- Can be taken orally
- Side effects: edema, dizziness, flushing, palpitations, fatigue, nausea, abd pain (flushing, palpitations, and sleepiness more common in women)
- Interactions
- Increased amlodipine levels
- CYP3A inhibitor
- Antifungals (maybe)
- Diltiazem
- Clarithromycin
- Statins (HMG-CoA reductase inhibitors): increases simvastatin levels (not all statins though)
- Increases cyclosporine levels and tracrolimus levels
- Increased amlodipine levels
- Bioavailability
- Highest level 6-12 hours after oral
- 64-90%
- Works for at least 24 hours
- around 93% plasma protein binding
- Mostly (90%) metabolized to inactive metabolites by liver
- Excreted either as metabolite or unchanged in urine
- Half-life is 30-50 hours
- Mechanism
- Prevents passing of Ca ions into myocardial and vasc. smooth muscle cells
- Peripheral arterial vasodilator
- Acts on vascular smooth muscle to reduce peripheral vascular resistance and BP
- Reduces total peripheral resistance
- Blocks constriction in coronary arteries
- oral tablets or capsules
"Norvasc (amlodipine besylate) tablets label - 019787s047lbl.pdf" (PDF). Retrieved 2017-06-29.
| copy | "Norvasc (amlodipine besylate) tablets label - 019787s047lbl.pdf" (PDF). Retrieved 2017-06-29. |
- Use:
- High BP
- Coronary artery disease
- Chronic stable angina
- Vasospastic angina
- Sometimes Coronary artery disease
- Warnings/side effects
- Unlikely to have acute high BP bc has slow onset
- Most common: headache edema
- Has chart of % side effects vs. placebo
- At 10 mg, most common were (increased with dose):
- Edema 10.8% (vs. 0.6% placebo); more in women (3x)
- Dizziness 3.4% (vs. 1.5%)
- Flushing 2.6% (vs. 0); more in women
- Palpitaions 4.5% (vs. 0.6%); more in women
- Not dose related
- Fatigue 4.5% vs. 2.8%
- Nausea 2.9% vs. 1.9%
- Abdominal pain 1.6% vs. 0.3%
- Sleepiness 1.4% vs. 0.6%
- At 10 mg, most common were (increased with dose):
- Interactions
- Increased amlodipine levels with CYP3A4 inhibitors
- Mechanism
- Exp data suggests that it binds to both dihydropyridine and nondihydropyridine binding sites on Ca channels
- Inhibits more on vascular smooth muscle than cardiac muscle
- pKa = 8.6; gradual association/dissociation with binding site
- Pharmacodynamics
- Decreases BP, but not change HR or catecholamine levels
- Pharmacakinetics not affected by renal impairment
- Metabolism: 90% to inactive metabolite in liver, rest excreted in urine
- ~93% of circulating drug bound to plasma proteins in patients with high BP
- Steady plasma levels occur after 7-8 days of taking med
Diamondback Drugs. "Amlodipine in Veterinary Medicine". Retrieved 2017-06-29.
| copy | Diamondback Drugs. "Amlodipine in Veterinary Medicine". Retrieved 2017-06-29. |
- Hypertension in cats and dogs
- Oral liquid
- Most commonly given to cats that also have kidney disease
- Side effects rare in vet med
Forney, Barbara. "Amlodipine for Veterinary Use". Wedgewood Pharmacy. Retrieved 2017-06-29.
| copy | Forney, Barbara. "Amlodipine for Veterinary Use". Wedgewood Pharmacy. Retrieved 2017-06-29. |
- Systemic high BP in cats; lesser extent: heart failure and high BP in dogs
- Cats
- Considered successful 1st line of treatment
- Renal disease cats sometimes also get ACE inhibitors to prevent potential glomerular damage
- Decreases proteinuria in most cats with chronic renal disease
- Dogs
- Congestive heart failure, mitral valve regurgitation, systemic hypertension due to renal disease
- ACE inhibitors are usually 1st line for high BP; amlodipine is add-on
- Congestive heart failure, mitral valve regurgitation, systemic hypertension due to renal disease
Hitchings, Andrew; Lonsdale, Dagan; Burrage, Daniel; Baker, Emma (2014-03-30). The Top 100 Drugs e-book: Clinical Pharmacology and Practical Prescribing. Elsevier Health Sciences. p. 90. ISBN 9780702055157.
| copy | Hitchings, Andrew; Lonsdale, Dagan; Burrage, Daniel; Baker, Emma (2014-03-30). The Top 100 Drugs e-book: Clinical Pharmacology and Practical Prescribing. Elsevier Health Sciences. p. 90. ISBN 9780702055157. |
- Vasodilation and compensatory tachycardia of amlodipine can cause → ankle swelling, flushing, headache, palpitations
- Unstable angina: amlodipine causes "reflex increase in contractility and tachicardia, which increases myocardial oxygen demand"
- Can provoke collapse in severe aortic stenosis
Li, Jie Jack (2015). "Amlodipine (Novasc)". Top Drugs: History, Pharmacology, Syntheses. Oxford University Press. pp. 37–48. ISBN 9780199362585.
| copy | Li, Jie Jack (2015). "Amlodipine (Novasc)". Top Drugs: History, Pharmacology, Syntheses. Oxford University Press. pp. 37–48. ISBN 9780199362585. |
- Class: 1,4-dihydropyridine calcium channel blocker
- FDA approved in 1990
- 3rd gen calcium channel blocker - higher bioavailability and longer half life
- Most prescribed antihypertensive drug in world in 2003
- Stuck on calcium channel, so don't affect concentrations of Na or K
- Specficially L-type voltage-gated calcium channels
- Dihydropyridines can aldo inhibit cyclic PDE
- Structure
- Basic amine group (pKa 8.6) → longer half-life and high bioavailability
- So molecule is >90% ionized at physiological pH
- Basic amine group (pKa 8.6) → longer half-life and high bioavailability
- Like with most other dihydropyrimidines, S isomer (-) is more active
- Oxidized by CYP450 to become inactive pyridyl metabolite (NH → N, and ring becomes phenyl group)
- Vasodilation from amlodipine can cause reduced cardiac output in ppl w/severe aortic stenosis
Maddison, Jill E.; Church, David, eds. (2008). Small Animal Clinical Pharmacology. Elsevier Health Sciences. p. 571. ISBN 9780702028588.
| copy | Maddison, Jill E.; Church, David, eds. (2008). Small Animal Clinical Pharmacology. Elsevier Health Sciences. p. 571. ISBN 9780702028588. |
- Can help with glaucoma in animals
- Treatment for glaucoma reduces intraocular pressure → blood flow to optic nerve increases → sudden release of Ca from mitochondria, which can damage optic nerve
- Ca channel blockers like amlodipine can prevent this/protect optic nerve from damage
Papich, Mark G. (2007). "Amlodipine Besylate". Saunders Handbook of Veterinary Drugs (2nd ed.). St. Louis, Mo: Saunders/Elsevier. pp. 26–27. ISBN 9781416028888.
| copy | Papich, Mark G. (2007). "Amlodipine Besylate". Saunders Handbook of Veterinary Drugs (2nd ed.). St. Louis, Mo: Saunders/Elsevier. pp. 26–27. ISBN 9781416028888. |
- ACE inhibitors less effective in cats
- 2.5, 5, 10mg tablets
- [Cats and dogs only]
Plumb, Donald C. (2011). "Amlodipine Besylate". Plumb's Veterinary Drug Handbook (7th ed.). Stockholm, Wisconsin; Ames, Iowa: Wiley. pp. 53–54. ISBN 9780470959640.
| copy | Plumb, Donald C. (2011). "Amlodipine Besylate". Plumb's Veterinary Drug Handbook (7th ed.). Stockholm, Wisconsin; Ames, Iowa: Wiley. pp. 53–54. ISBN 9780470959640. |
- "Norvasc"
- High BP in cats (often 1st choice)
- Decrease BP in dogs w/chronic renal failure, but otherwise meh
- Activates renin-angiotensin aldosterone system (RAAS) in healthy dogs at higher doses except with ACE inhibitor
- Cat: high BP often sign of other disease (renal failure, thryotoxic cardiomyopathy, etc.)
- Mech: decrease impulse formation and conduction velocity in cardiac cells
- Diuretic in dogs
- Concerns
- Renal disease in cats with high BP
- Local increase in RAAS activity higher pressure bc of efferent arteriolar constriction
- Renal disease in cats with high BP
- Infrequent, bug in cats; azotemia, lethargy, hypokalemia, reflex tachychardia, weight loss
- Dogs: possible gingival hyperplasia with chronic use
"Amoxicillin / clarithromycin / lansoprazole and ampicillin Drug Interactions". Drugs.com. Retrieved 22 February 2018.
| copy | <ref>{{cite web | title=Amoxicillin / clarithromycin / lansoprazole and ampicillin Drug Interactions | work=Drugs.com | accessdate=22 February 2018 | url=https://www.drugs.com/drug-interactions/amoxicillin-clarithromycin-lansoprazole-with-ampicillin-188-0-196-0.html }}</ref> |
- [theoretic] Lanzoprazole increases gastric pH so can decrease absorption of ampicillin; ampicillin needs acidic environment to be asorbed
"Ampicillin". DrugBank. 2 August 2017. Retrieved 23 August 2017.
| copy | <ref>{{cite encyclopedia | title=Ampicillin | encyclopedia=DrugBank | accessdate=23 August 2017 | date=2 August 2017 | url=https://www.drugbank.ca/drugs/DB00415 }}</ref> |
- Inhibit cell wall synthesis: ampicillin binds to penicillin binding proteins (PBPs)
- Inhibitor of
- Stable against hydrolysis by variety of beta-lactamases, inc. penicillinases, cephalosporinases
- Take on empty stomach
"Ampicillin Monograph for Professionals". Drugs.com. Retrieved 18 August 2017.
| copy | <ref>{{cite web | title=Ampicillin Monograph for Professionals | work=Drugs.com | accessdate=18 August 2017 | url=https://www.drugs.com/monograph/ampicillin.html }}</ref> |
- Uses
- Endocarditis
- Enterococcal endocarditis, w/aminoglycoside
- Endo by slow-growing fastidious gram-negative bacilli (HACEK group: Haemophilus parainfluenzae, H. aphrphilus, Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, Kingella kingae)
- W/gentamicin
- By susceptible staphylococci, streptococci, E. coli, P. mirabilis, or Salmonella
- Prevention of endocarditis in those w/cardiac conditions undergoing dental, oral, respiratory tract, or esophageal procedures, or GU and GI procedures
- Meningitis/other CNS
- By Neisseria mengingitisis, S. agalactiae, Listeria monocytogenes, E. coli, H. influenzae, S. pneumoniae
- Drug of choice for neonatal S. agalactiae meningitis and L. monocytogenes; use w/aminoglycoside
- For Haemophilus influenzae, used w/chloramphenicol
- Respiratory tract infections
- By S. aureus (inc strains resistant to penicillin), Streptococcus, S. pyogenes, H. influenzae (non-penicillinase strains only)
- Don't use for strept or staph rep infections if penicillin works
- Septicemia
- Susc. staph, strept, enterococci, E. coli, P. mirabilis, Salmonella
- UTIs
- Susc. enterococci (drug of choice), E. coli, P. mirabilis
- Infections by Eikenella corrodens (drug of choice)
- Used to be used for gonorrhea and associated infections, but too many penicillin-resistant strains now
- Listeria monocytogenes, alone or w/aminoglycoside
- Drug of choice for tx during pregnancy, granulomatosis infantiseptica, sepsis, endocarditis, meningitis, foodborne infections
- Whooping cough (prevent and treat 2ndary infections)
- Salmonella infections, inc. typhoid fever, and inc. chronic carriers of T. typhi
- Shigella infections
- Previously a drug of choice before resistance strains of S. flexneri and S. sonnei started popping up more
- Prevent early-onset neonatal group B streptococcal disease
- Amp given to pregnant women identified as GBS carriers in prenatal screenings
- Perioperative prophylaxis for vaginal hysterectomy or C-sections
- Endocarditis
- Administration
- Orally
- But not as initial treatment for severe infections; can be follow-up to IV or IM ampicillin
- Slow IV injection/infusion
- IM injection
- Orally
- Contraindications: hypersensitivity to any penicillin
- Warning
- Can cause C. diff-associated colitis
- Hypersensitivity reactions
- Higher risk of rash in patients w/mono
- Pregnancy category B
- Distributed into maternal milk
- Renal clearance delayed in young infants bc renal function not fully matured
- Common side effects: diarrhea, nausea, rash
- Interactions
- Allopurinol: increase risk of rash, though unclear if bc allopurinol or bc of hyperuricemia in those patients
- Aminoglycosied: synergistic effects
- Chloramphenicol: evidence of antagonism
- Hormonal contraceptives: possible decrease of efficacy of oral contraceptives w/estrogen and increased probability of breakthrough bleeding
- Methotrexate: possible decrease in renal clearance of both drugs
- Probenecid: decreased renal tubular secretoin
- Sulbactam: synergistic bactericidal effect against bact that make beta-lactamase
- Sulfonamides: antagonism
- Glucose test: possible false-positives in urine glucose tests that use Clinitest, Benedict's solution, or Fehling's solution. Use glucose tests that are based on enzymatic glucose oxidase reactions instead
- Uric acid test: possible false increased serum concentration of uric acid if use copper-chelate method; use phosphotungstate or uricase method
- Pharmacokinetics
- Bioavailability
- 30–55% oral dose absorbed in GI tract of fasting adults
- Peak concentration in serum in 1–2 hours
- IM: peak concentrations faster and higher
- IV: peak concentrations immediately after infusion
- Food decreased rate and extent of absorption
- Distribution
- Ascitic, synovial, pleural fluids, and liver, bile, lungs, gallbladder, prostate, muscle, middle ear effusions, bronchial secretions, sputum, maxillary sinus secretions, tonsils, saliva, sweat, tears
- Into CSF at 11–65% serum concentrations
- Crosses placenta
- Into milk at low concentrations
- 15–25% protein binding
- Lower in neonates (8–12%)
- Metabolism
- Hydrolysis of beta-lactam ring to penicilloic acid ("microbiologically inactive")
- Eliminated in urine: mostly renal tubular secretion, also glomerular filtration
- A bit in bile and feces
- 20–64% of an oral dose excreted unchanged in urine in 6–8 hours; and 60–70% IM dose, 73–90% IV dose
- Half-life: 0.7–1.5 hours
- Bioavailability
- Take w/full glass of water 1 hour before or 2 hours after meal
"Ampicillin - Warnings and Precautions". DrugLib. 16 September 2013. Retrieved 23 February 2018.
| copy | Unstrip size limit exceeded (5,000,000) |
- Anaphylactic reaction more common with parenteral therapy
- Rash in mono - remains a few days to a week after drug is done; so not recommended in ppl with mono
"Drug interactions between amikacin and ampicillin". Drugs.com. Retrieved 22 February 2018.
| copy | Unstrip size limit exceeded (5,000,000) |
- Can inactivate aminglycosides by forming a complex with them. can be avoided by administering them separately instead of in combined IV container or line
"Drug interactions between ampicillin and anisindione". Drugs.com. Retrieved 22 February 2018.
| copy | Unstrip size limit exceeded (5,000,000) |
- Can inactivate aminglycosides by forming a complex with them. can be avoided by administering them separately instead of in combined IV container or line
"Drug interactions between ampicillin and bismuth subcitrate potassium / metronidazole / tetracycline". Drugs.com. Retrieved 22 February 2018.
| copy | Unstrip size limit exceeded (5,000,000) |
- Tetracycline reduces effect of penicillins: inhibits protein synthesis, which is needed to make the cell walls (which penicillins impede)
"Drug interactions between ampicillin and cholera vaccine, live". Drugs.com. Retrieved 22 February 2018.
| copy | Unstrip size limit exceeded (5,000,000) |
- Can lower immunological response to live cholera vaccine enough to prevent if from being effective
"Drug interactions between ampicillin and Folex PFS". Drugs.com. Retrieved 22 February 2018.
| copy | Unstrip size limit exceeded (5,000,000) |
- Large doses of penicillins can elevate serum concentrations of methotrexate (inhibit renal tubular secretion)0
"Drug interactions between ampicillin and typhoid vaccine, live". Drugs.com. Retrieved 22 February 2018.
| copy | Unstrip size limit exceeded (5,000,000) |
- Typhoid vaccine (same interaction as cholera vaccine)
- Esp. bc amp is used to treat Salmonella, and typhoid vax is vs, Salmonella typhi (so can't mount an immune response)
Boothe, Dawn. "Penicillins". Merck Veterinary Manual. Retrieved 22 August 2017.
| copy | Unstrip size limit exceeded (5,000,000) |
- Broad-spectrum, semisynth
- Destroyed by beta-lactamase
- Aminopenicillin (amoxicillin is also)
- Susceptible genera include Staph, Strept, Trueperella, Clostridium, Eschericia, Klebsiella, Shigella, Salmonella, Proteus, Pasteurella
- Sulbactam given w/ampicilin to protext agasint beta-lactamase
- Food impairs absorption of ampicillin
Eghianruwa, Kingsley (2014). Essential Drug Data for Rational Therapy in Veterinary Practice. AuthorHouse. pp. 26–27. ISBN 978-1-4918-0010-2. {{cite book}}: Invalid |ref=harv (help)
| copy | Unstrip size limit exceeded (5,000,000) |
- aka aminobenzylpenicillin
- Inhibits transpeptidase enzyme, blocking synth of peptidoglycan
- Can go intra mammary in animals
- Well-absorbed from GI tract
- Bioavailability: 62% (plus-minus 17%) in humans
- Distribution: through most tissues, concentrated in liver and kidneys
- In CSF only when meninges are inflamed, and then at 5–10%
- 15–20% plasma protein binding (lower in neonates)
- Small portion is metabolized by hydrolysis to inactive penicilloic acid
- Half-life
- 1.3 +/- 0.2 hours in humans
- Higher w/uremia or hepatic cirrhosis, or in neonates
- 12 hours in animals
- Side effects
- 10%: skin rash, diarrhea, vomiting
- rare: Severe abdominal cramp, encephalopathy, seizure, lymphocytic leukemia
- Can cause superinfection after oral admin
- Overdose → neuromuscular hypersensitivity, electrolyte imbalance, renal failure
Erskine, Ronald. "Mastitis in Sows". Merck Veterinary Manual. Retrieved 22 August 2017.
| copy | Unstrip size limit exceeded (5,000,000) |
- Ampicillin given systemically for mastitis in sows
Giguère, S.; Prescott, John F.; Dowling, Patricia M. (2013). Antimicrobial Therapy in Veterinary Medicine. John Wiley & Sons. pp. 167–170. ISBN 978-1-118-67507-6. {{cite book}}: Invalid |ref=harv (help)
| copy | Unstrip size limit exceeded (5,000,000) |
- 1/2 systemic availability of amoxicillin (20–40% vs. 60–70%)
- Hetacillin and pivampicillin are ampicillin esters developed to increase systemic availability
- Forms
- Sodium salt
- Trihydrate salts (less soluble and thus absorbed less intestinally, but ok in aq preparations for inj)
- Aq forms reconstituted are unstable after several hours
- Inj forms should be given within 6 hour intervals (bc short half-life) to maintain
- Toxicities/adverse effects
- Don't give to small rodents or rabbis bc can produce clostridial colitis (C. dif; in rabbits, C. spiroforme)
- Uses
- Cattle, sheep, and goats, oral ampicillin has been used to treat E. coli and Salmonella (but resistance more common so now not as effective)
- Bovine respiratory disease (but no advantage over penicillin G)
- Don't use much in horses bc don't have much advantage over benzyl penicilins, largely due to acquired resistance in G- bact
- For mixed aerobic-anaerobic infections, such as from cat bites
- Canine urinary tract infections (over 90% of S. aureus, streptococci, and P. mirabilis, almost 90% of E. coli, and 65% of Klebsiella are susceptible to ampicillin at concentrations used to treat UTIs)
- Oral in poultry to prevent or treat salmonellosis, E. coli sepsis, S. aureus sepsis
Gruenberg, Walter. "Overview of Salmonellosis". Merck Veterinary Manual. Retrieved 22 August 2017.
| copy | Unstrip size limit exceeded (5,000,000) |
- Resistance to ampicillin is plasma-mediated; can transfer btw different bacteria
Hauser, Alan R. (2012). Antibiotic Basics for Clinicians: The ABCs of Choosing the Right Antibacterial Agent. Lippincott Williams & Wilkins. p. 25. ISBN 978-1-4511-1221-4. {{cite book}}: Invalid |ref=harv (help)
| copy | Unstrip size limit exceeded (5,000,000) |
- Additional amino group in side chains of ampicillin and amoxicillin make them more hydrophilic and lets them enter porins of outer membranes of some G– rods (ex. E. coli, P. mirabilis. S. enterica, Shigella)
Magdesian, K. Gary (2017). Equine Pharmacology, an Issue of Veterinary Clinics of North America: Equine Practice, E-Book. Elsevier Health Sciences. p. 59. ISBN 978-0-323-52438-4. {{cite book}}: Invalid |ref=harv (help)
| copy | Unstrip size limit exceeded (5,000,000) |
- Sodium and trihydrate forms
- Ampicillin trihydrate can be given orally to foals (but in adult horses, beta-lactam antibiotics have very low bioavail)
- Used to be that some gram- nonenteric microbes, as well as E. coli, Klebsiella, and Proteus not susc to penicillin but susc to ampicillin
- But decades of use has made ampicillin lose some effectiveness
- Pseudomonas and many Enterobacter are resistant to penicillin and ampicillin
- One of the few abx that work against multidrug resistant Enterococcus faecalis and E. faecium
McAuley, David. "AMPICILLIN - Intravenous (IV) Dilution". GlobalRPh.
| copy | Unstrip size limit exceeded (5,000,000) |
- Rapid IV admin lead to convulsive seizures
- Powder reconstituted with sterile water or bacteriostatic water
- Lasts longest with reconstituted with sterile water, saline, or LRS (8 hours in fridge, 24hrs - 72 hours in fridge depending on choice of reconstitution and concentration, with low concentration lasting longer)
- Sterile water: 48–72 hours
- Saline: 24–48 hours
- LRS: 24 hours
- Can also be reconstituted in 5% dextrose, but stable for only 1 or two hours (in or out of fridge)
Papich, Mark G. (2015). Saunders Handbook of Veterinary Drugs: Small and Large Animal. Elsevier Health Sciences. pp. 43–47. ISBN 978-0-323-24485-5. {{cite book}}: Invalid |ref=harv (help)
| copy | Unstrip size limit exceeded (5,000,000) |
- Narrow spectrum, similar to that of amoxicillin
- Streptococci, non-beta-lactamase producing staphpylococci, other gram +
- Many staphylococci resistant due to beta-lactamase production
- Most enteric gram- bacilli of Enterobacteriaceae are resistant
- Susc. gram-: Proteus, Pasteurella multocida, Histophilus
- Resistance among G- is common
- Half-life is 1–1.5 hours in most animals
- Oral absorption is less than 50% in cats and dogs, less than 4% in horses
- Adverse reaction mostly due to penicillin allergy
- Absorbed around 50% less than amoxicillin when given orally
- Storage
- After reconstituting ampicillin sodium, stability is dependent on concentration
- If w/sterile water at 250 mg/mL, is stable for 1 hr at room temp
- Increase time if dilute in IV fluids (saline, LRS), if put in fridge
- Dogs, cats, horses, cattle
- Cattle withdrawal time: 6 days for meat, 48 hours for milk (at 6 mg/kg)
- Ampicillin + sulbactam
- Sulbactam: beta lactamase inhibitor, similar activity to clavulanate not as active against clavulonate vs. some gram- beta-lactamase enzymes
- For general bacteria infections
- Use when resistance to ampicillin is expected
- Can only be given by injection
- Need more frequent/higher doses for gram- infections
Piscitelli, Stephen C.; Rodvold, Keith A.; Pai, Manjunath P. (2011). Drug Interactions in Infectious Diseases. Springer Science & Business Media. pp. 213–214. ISBN 978-1-61779-213-7. {{cite book}}: Invalid |ref=harv (help)
| copy | Unstrip size limit exceeded (5,000,000) |
- Ampicillin having effect on oral contraceptives has been disputed
Rello, Jordi; Kollef, Martin H.; Díaz, Emilio; Rodríguez, Alejandro (2010). Infectious Diseases in Critical Care. Springer Science & Business Media. p. 172. ISBN 978-3-540-34406-3. {{cite book}}: Invalid |ref=harv (help)
| copy | Unstrip size limit exceeded (5,000,000) |
- Poorly bound penicillins like amp cross placental barrier better
- Get concentration in amniotic fluid that is 0.5–1 times that of in maternal plasma; can lead to high concentration of drug in newborn
- bc increased blood volume and renal clearance, ampicillin concentrations can be reduced by up to 50% in pregnant women, so need higher doses for same abx effect
- No evidence of embryotoxic, fetotoxic, or teratogenic effects
- Cat B by FDA, like all penicillins
US National Library of Medicine. "AMPICILLIN- ampicillin injection, powder, for suspension". DailyMed. Retrieved 21 August 2017.
| copy | Unstrip size limit exceeded (5,000,000) |
- [Vet version]
- Pharmacology
- Peak serum levels in cats and dogs in 30 min. after SQ or IM injections; 1-2 hours in cattle after IM injections
- Uses
- Upper resp infections, tonsilitis, and bronchopneumonia by hemolytic streptococci, S. aureus, E. coli, P. mirabilis, Pasteurella
- UTIs due to P. mirabilis, E. coli, Staph, hemolytic streptococci, Enterococcus
- GI inf due to Enterococc, Staph, E. coli
- Abscesses, pustular dermatitis, cellulitis, anal gland infections due to E. coli, P. mirabilis, hemolytic strept, Staph, Pasteurella
- Cattle resp tract infections: bacterial penumonia (shipping fever, calf pneumonia, bovine pneumonia) by Aerobacter, Klebsiella, Staph, Strept, Pasteurella multocida, E. coli
US National Library of Medicine. "AMPICILLIN- ampicillin sodium injection, powder, for solution". DailyMed. Retrieved 21 August 2017.
| copy | Unstrip size limit exceeded (5,000,000) |
- Pharmacology
- Into CSF and brain only when meninges are inflamed
- Excreted largely unchanged in urine; can be delayed if also getting probenecid at same time
- Active form more in bile than in serum
- Is least serum-bound of all the penicillins (average of 20% vs. 60–90%)
- Well-tolerated by most patients
- Use
- Resp tract infections by: S. pneumoniae, S. aureus, H. influenzae, Group A beta-hemolytic streptococci
- Meningitis by: E. coli, Group B streptococci, other Gram - (ex. Listeria monocytogenes, N. meningitidis)
- Add aminolgycoside for more effectiveness vs. Gram-
- Septicemia and endocarditis by Streptococcus, susc. Staphylococcus, enterococci
- Gram- sepsis by E. coli, Proteus mirabilis, Salmonella
- Endocarditis by enterococcal strains
- Add aminoglycoside for better effectiveness vs. streptococcal endocarditis
- UTIs by: E. coli and P. mirabilis
- GI infections by: Salmonella (inc. typhoid fever)
- Contraindications: hypersensitivity to any penicillin (can → fatal anaphylactoid reactions; more common in parenteral therapy, though also happens w/oral admin)
- Warnings
- C. diff diarrhea (from mild diarrhea to fatal colitis)
- 43–100% of pts w/mononucleosis get skin rash w/apmicillin (7 to 10 days after oral amp is started; goes away a few days to a week after ended)
- Usually maculopapular, pruritic, and generalized
- Interactions:
- Transient elevation of transaminase in serum after ampicillin
- Skin rashes more common if given w/allopurinol
- High concentrations of ampicillin: false positive for glucose reaction tests
- Side effects
- More likely in those w/sensitivity to penicillins and those w/history of allergy, asthma, hay fever, or hives
- GI (most often w/oral form): glossitis, stomatitis, black "hairy" tongue, nausea, vomiting, entercolitis, pseudomembraneous colitis, diarrhea
- Hypersens.
- Frequent: skin rashes and hives
- Some: exfoliative dermatitis and erythema multiforme
- Liver: moderate rise in serum glutamic oxaloacetic transaminase (esp. in infants)
- Hemic/lymphatic: anemia, thrombocytopenia, thrombocytopenic purpura, eosinophilia, leukopenia, agranylocytis (all reversible and thought to be caused by hypersens.)
Wanamaker, Boyce P.; Massey, Kathy (2014). Applied Pharmacology for Veterinary Technicians - E-Book. Elsevier Health Sciences. pp. 243–245. ISBN 978-0-323-29170-5. {{cite book}}: Invalid |ref=harv (help)
| copy | Unstrip size limit exceeded (5,000,000) |
- Broad-spectrum penicillin
- Antagonists include chloramphenicol, erythromycin, tetracyclines, cephalosporidines
- IM injections of ampicillin/sulbactam can be painful; IV injection can cause thrombophlebitis
- "Principen" for humans; "Polyflex" for animals
- Ampicillin/sulbactam: Unasyn (human only)
WebMD. "ampicillin (Rx)". Medscape. Retrieved 22 August 2017.
| copy | Unstrip size limit exceeded (5,000,000) |
- Off-label use as endocarditis prophylaxis
- IV or IM before procedure in pts who can't take oral amoxicillin
- Forms: capsules, oral suspension, powder for injection
- Metabolized in liver
WebMD. "Principen (ampicillin) Drug Side Effects, Interactions, and Medication Information". eMedicineHealth. Retrieved 23 February 2018.
| copy | Unstrip size limit exceeded (5,000,000) |
- Overdose inc. behavioral changes, confusion, black outs, convulsions
Weiner, Carl P.; Rope, Kate (2013). The Complete Guide to Medications During Pregnancy and Breastfeeding: Everything You Need to Know to Make the Best Choices for You and Your Baby. St. Martin's Press. pp. 47–49. ISBN 978-1-250-03720-6. {{cite book}}: Invalid |ref=harv (help)
| copy | Unstrip size limit exceeded (5,000,000) |
- One of most commonly used drugs in pregnancy
- Reduces risk of post-op fever in c-section
- Pregnancy increases clearance
- Ampicillin/sulbactam prolongs period of time btw water breaking to delivery in women where water breaks before 37 weeks
- No evidence of birth defects in humans or rodents
- Some amounts (minimal) secreted in breast milk; considered OK
Haft, Wendy A.; McAffe, Richard (9 March 2015). "Antiemetics". In Sikka, Paul K.; Beaman, Shawn T.; Street, James A. (eds.). Basic Clinical Anesthesia. Springer. doi:10.1007/978-1-4939-1737-2_14. ISBN 978-1-4939-1737-2.
| copy | Unstrip size limit exceeded (5,000,000) |
- PONV = postoperative nausea and vomiting (159)
- 5HT3 receptor antagonists (160)
- ex. ondansetron, dolasetron, ganisetron, palonosetron
- Fewer side effects than other antiemetics
- Dopamine antagonists
- 3 types of dopamine antagonists used:
- Phenothiazines
- ex. perphenazine, promethazine, prochlorperazine
- perphenazine given preop enhances effects of ondansetron and dolasetron
- Butyrophenones
- ex. droperidol (most effective when used with other antiemetics)
- haloperidol (161)
- Benzamides
- ex. metoclopramide inhibits DA receptors in CTZ and increases gastric motiligy
- Phenothiazines
- 3 types of dopamine antagonists used:
- Corticosteroids
- ex. dexamethasone, methylprednisolone
- Not completely understood how they are antiemetics
- Histamine blockers (H1)
- Inhibits H1 receptros in vestibular system
- Most of the drugs in this category are also weak anticholinergics (also inhibit M1 [muscarinic] receptors that are in vestibular system)
- When used with dopamine antagonists, can decrease risk of extrapyramidal side effects
- ex. diphenhydramine, dimenydrinate, hydroxyzine, meclizine
- Anticholinergic
- ex. scopolamine (most common anticholinergic for PONV)
- Neurokinin 1 receptor antagonists
- NK1 receptor antagonists inhibit signals that the nucleus tractus solitarius (NTS) receives from CTZ
- Also inhibits substance P (which binds to area postrema and in GI tract to casue nausea)
- ex. aprepitant; most effective when used with corticosteroids and 5HT3 receptor blockers
Schaefer, Christof; Scialli, Anthony; Rost van Tonningen, Margreet (2001). "Antiemetics and hyperemesis gravidarum". Drugs During Pregnancy and Lactation: Handbook of Prescription Drugs and Comparative Risk Assessment. Gulf Professional Publishing. ISBN 978-0-444-50763-1.
| copy | Unstrip size limit exceeded (5,000,000) |
- Antiemetics don't increase birth defect rate (40)
- Antihistamines (41)
- Generally effective for nausea/vomiting in pregnancy
- Doxylamine – effective, but only marketed for pregnancy in Canada
- Meclozine
- Has anticholinergic activity
- Complete or good relief in 98% patients studied
- Buclizine
- Not really used in pregnancy
- Cyclizine
- Similar to meclizine; longer half-life than meclizine, but effects last 4 hours (vs. 24 hours of meclizine)
- Dimenydrinate (45)
- Partial or complete relief in 46%
- Diphenhydramine
- Sedating properties, today used as hypnotic
- Metoclopramide
- Blocks dopamine receptors also
- Phenothiazine antiemetics [no preview available]
- Serotonin antagonists [no preview available]
Portable Pathophysiology. Lippincott Williams & Wilkins. 28 January 2006. ISBN 978-1-58255-455-6.
| copy | Unstrip size limit exceeded (5,000,000) |
Antiemetics decrease nausea → reduce urge to vomit (262) Antihistamines
- ex. Buclizine, cyclizine, himenhydrinate, diphenhydramine, hydroxyzine, meclizine, trimethobenzamide
- Method of action unclear
- Used for nausea/vomiting caused by inner ear stimulation → motion sickness
- Except trimethobenzamide
Phenothiazines
- ex. chlorpromazine, perphenazine, prochlorperazine, promethazine
- Block dopamine receptors in "chemoreceptor trigger zone of brain"/may "directly depress vomiting center"
- For severe nausea and vomiting
- Used for chemo or radiotherapy
Serotonin-receptor antagonists
- ex. Dolasteron, ganisteron, ondansetron
- Block serotonin receptors in "chemoreceptor trigger zone" and vagal nerve terminals (so work in both CNS and peripheral nervous system)
- Used for chemo or radiotherapy
Diemunsch, Pierre; Grélot, Laurent (2003). "Potential of Substances P Antagonists as Antiemetics". In Donnerer, Josef (ed.). Antiemetic Therapy. Karger Medical and Scientific Publishers. pp. 78–97. ISBN 978-3-8055-7547-8.
| copy | Unstrip size limit exceeded (5,000,000) |
Triggers for vomiting (79)
- "Emetic coordinating circuitry" is in medulla oblongata
- Area postrema though to have chemoreceptor for triggering vomiting
- Motion and space sickness
- Involves M1 (muscarinic) receptor (acetylcholine), 5-HT1A receptor (serotonin), H1 receptor (histamine)
- Chemotherapy, radian, and postoperative
- 5-HT3 receptor
- Blood poisoning
- D2 receptor detects apomorphine, adrenergic receptor 2 detects xylazine
- Also includes ipecac and LPS (??)
- 5-HT3 receptor antagonists fail against emetogens like opioid or dopaminergic agonists, copper sulfate, or motion (80)
(continue)
Gralla, Richard J.; Osoba, David; Kris, Mark G.; Kirkbride, Peter; Hesketh, Paul J.; Chinnery, Lawrence W.; Clark-Snow, Rebecca; Gill, David P.; Groshen, Susan; Grunberg, Steven; Koeller, James M.; Morrow, Gary R.; Perez, Edith A.; Silber, Jeffrey H.; Pfister, David G. (1 August 1999). "Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines". Journal of Clinical Oncology. 17 (9): 2971–2971. ISSN 0732-183X. PMID 10561376. Retrieved 2015-10-08.
| copy | Unstrip size limit exceeded (5,000,000) |
Uses: chemo and radiation patients
Classes of antiemetics
- Serotonin receptor antagonists
- ex. Dolasetron (Anzemet), Granisetron (Kytril), Ondansetron (Zofran), Tropisetron (Navoban)
- These are the 4 agents that are commercially available in many countries
- Antagonis of 5-HT3 receptor, highly selective and high affinity
- Low side effects
- Conflicting efficacy for delayed (after >24 hours) emesis, but definitely useful for acute emesis
- Corticosteroids
- ex. Dexamethasone, methylprednisolone (some also use prednisone)
- Among most frequently-used
- Most useful category for delayed emesis (vomiting more than 24 hours after chemo session)
- Ones with lower therapeutic index/more side effects
- Dopamine receptor antagonists
- DA2 antagonists
- ex. Metoclopramide, prochlorperazine
- Butyrophenones (also anti DA)
- ex. haloperidol and droperidol
- Phenothiaines (also anti DA)
- ex. prochlorperazine and thiethylperazine
- Cannabinoids
- Dronabinol (plant extract), nabilone and levontradol (both synthetic)
- Dronabinol less effective than metoclropamide
- Inhalant marijuana found not to be effective (study with chemotherapy)
- Dopamine receptor antagonists
- Adjuncts (not recommended as single agents)
- Benzodiazepines
- esp. Lorazepam
- Mostly given bc anxiolytic effects is useful for antiemetic
- Antihistamines
- Can be given as antiemetic or to prevent dystonic reactions with dopamine antagonists
- ex. Diphenhydramine, hydroxyzine, benztropine (studies haven't shown antiemetic activity for these drugs)
- Benzodiazepines
- Combining serotonin antagonists with corticosteroids
- Together, work better than when alone for chemotherapy
For radiation therapy, the one recommended for both full-body and hemi-body is serotonin receptor antagonist
Quinlan, Jeffrey D.; Hill, D. Ashley (1 June 2003). "Nausea and Vomiting in Pregnancy - American Family Physician". American Family Physician. 68 (1): 121–128.
| copy | Unstrip size limit exceeded (5,000,000) |
- Pyridoxine and doxylamine are safe for pregnant women
- Ginger is popular treatment for morning sickness; has proven to be effective in treating hyperemesis gravidarum
- No known fetal abnormalities
- No known fetal abnormalities
- Pyridoxine (vitamin B6)
- Alone or with doxylamine
- Doesn't cause birth defects
- Alone or with doxylamine
- Many initial studies that showed birth defects from antiemetics were later debunked
Bornstein, Set (2010). "Important ectoparasites of Alpaca (Vicugna pacos)". Acta Veterinaria Scandinavica. 52 (Suppl 1): S17. doi:10.1186/1751-0147-52-S1-S17. ISSN 1751-0147. Retrieved 28 November 2012.{{cite journal}}: CS1 maint: unflagged free DOI (link)
| copy | Unstrip size limit exceeded (5,000,000) |
- Alpaca and llama often called "New World camels"
- Vicuña and guanaco often called "South American camels"
"llama". Century Dictionary and Cyclopedia. wordnik. Retrieved 28 November 2012.
| copy | Unstrip size limit exceeded (5,000,000) |
- llama is often called the "American camel"
"Bactrian Camel: Camelus bactrianus". National Geographic. Retrieved 28 November 2012.
| copy | Unstrip size limit exceeded (5,000,000) |
- Lifespan in captivity: 50 years
- 7ft tall (inc. hump)
- Weigh 1800 lbs
- When give birth, is usually to 1 calf after 12–14 mo. gestation
- When fat depleted, humps → floppy and flabby
- Live in Central and e. Asia rocky deserts
- Very hot in summer (38º+), very cold in winter (-29º)
- Bactrian camel can survive in both (change coats)
- Only real wild camels still existing are Bactrian
- Gobi Desert, less than 1000 left
"The amazing characteristics of the camels". Camello Safari. Retrieved 26 November 2012.
| copy | Unstrip size limit exceeded (5,000,000) |
- "A fully-grown adult camel stands 1.85m/6 feet at the shoulder and 2.15m/7 feet at the hump."
- Meat
- Delicacy in Arabian diet
- Tastes like beef
- Tough to chew
- Milk
- More nutritious than cow milk
- Lower in fat and lactose, higher in potassium, iron, and Vit. C
- More nutritious than cow milk
Mukasa-Mugerwa, E. (1981). The Camel (Camelus Dromedarius): A Bibliographical Review. International Livestock Centre for Africa Monograph. Vol. 5. Ethiopia: International Livestock Centre for Africa.
| copy | Unstrip size limit exceeded (5,000,000) |
Origins and Distribution p. 1–10
- Genus Camelus has 2 species: dromedary (C. dromedarius) and Bactrian (C. bactrianus)
- Origin traced to Protylopus (1)
- Was in N. America in Eocene (1)
- Camelidae disappeared from N. America (unknown why)
- Camelidae Migrated across Bering Straits to Asia (late Pliocene/early Glacial epochs" (1)
- Camels and llama evolved over 1mya from common N. American ancestor
- Dromadary evolved from 2-humped version
- Domesticated Bactrian earlier than 2500 BC
- Domesticated dromedary around 3000 BC in s. Arabia (3)
- Somalia
- Has largest herd in world
- Sudan
- 2nd largest in world – almost 3 million
Reproductive Performance p. 11–32 [DROMEDARY]
- Anatomy
- Male
- Testes look similar to that of horse (11)
- Right testicle is often a bit smaller than left one (11)
- Diameter of seminiferous tubules smallest in summer and largest in winter (12)
- Breeding season: larger testes, more spermatogenesis (12)
- Has prostate gland, no seminal vesicles (12)
- Point of penile sheath points posteriorly, so when camels pee, urine goes backwards (13)
- Large casing: non-erect penis is hidden inside (like horse) (13)
- Average length of camel penis is 60cm (13)
- Female
- Reproductive tract is like that of a horse (13)
- Size and weights of gonads vary with ovarian activiy (14)
- Gonads = "Fairly flattened with numerous ovisacs, giving them the appearance of a bunch of grapes (14)
- Left ovary's Graffian follicles usually slightly larger than those of the right (14)
- Follicular activity decreases when get farther into pregnancy (14)
- More ovulation from left ovary than right
- Ovulation needs copulation to occur (15) ("induced ovulator")
- Male
- Castration
- Domestic males not reserved for breeding often castrated (18)
- Camels become more maneagable
- Domestic males not reserved for breeding often castrated (18)
- Mating
- From behind (20)
- Single mating session → ejaculate 3 or 4 times (21)
Production and Utilization 59–80
- Camel slaughter for meat: Kenya, Ethiopia, Sudan, Somalia (65)
- Average carcass weight: 300–400 kg for dromedary male, 250–300 kg for dromedary female, 650 kg (estimate) for Bactrian male (67)
- Best time for meat is 2.5 years: as get older, meat → tougher and less tasty (68)
- Some nomads consume camel blood (68)
"How Fast Can Camels Run and How Long Can They Run For?". Big Site of Amazing Facts. Retrieved 29 November 2012.
| copy | Unstrip size limit exceeded (5,000,000) |
- Start of race: 40mph
- Pace slows; average speed of racing camel is 25mph
- Gentle jog: 16mph
- Trotting: 9–10mph
- Walking: 2–3mph
Bronx Zoo. "Camel Adaptations" (Flash). Wildlife Conservation Society. Retrieved 29 November 2012.
| copy | Unstrip size limit exceeded (5,000,000) |
- Thick hair to keep warm at night
- Thick hair around/in ear: protect from sand
- Also coated with thick wax to stave off sand
- Feet are wide; get wider when step with them
- Easier to walk long distances
- Eyes: raised ridge above eye + thick, long lashes to keep sand out
- And protect from sun
- Long legs away from ground, which is hotter
- Pads on knees to protect when kneeling
"Camels - Old World Camels". Science Encyclopedia. Net Industries. Retrieved 29 November 2012.
| copy | Unstrip size limit exceeded (5,000,000) |
- Bactrian named after Baktria region of Persia
- Can carry twice as much in weight as dromedary camels can
- Can carry up to 1000 lbs
- Racing (dromedary) camels can run up to 100mi in a day
- 1- and 2-humped camels can interbreed
- Child has 2 humps, called "tulu"
- Has 3rd eyelid (transparent) that dislodges sand from eye
- Mouth has thick, leathery lining
- Can eat thorny plants
Fahmy, Miral (21 March 2002). "'Cama' camel/llama hybrids born in UAE research centre". Science in the News. The Royal Society of New Zealand. Retrieved 28 November 2012.
| copy | Unstrip size limit exceeded (5,000,000) |
- In UAE
- Rama, male born 1998
- Kamilah, female, born February 2002
- Camels and llamas don't mate in wild, but have same number of chromosomes
- Camelids only ovulate in intercourse, so have to inject female llamas with gonadotorphin to start ovulation
- Then inseminate llama with "fresh camel semen" collected with artifical vagina
- Gestation: 11 mo.
- Have also had male llama and female camel
- Camas like mules: sterile
- Cama project funded by Dubai's crown prince
Campbell, Duncan (15 July 2002). "Bad karma for cross llama without a hump". The Guardian. Retrieved 2 March 2009.
| copy | Unstrip size limit exceeded (5,000,000) |
- Rama the cama: longer legs than llama, no hump
- Wanted cama to be like desert mule
"Joy for world's first camel and llama cross". Metro UK. 6 April 2008. Retrieved 29 November 2012.
| copy | Unstrip size limit exceeded (5,000,000) |
- Camas:
- No hump
- Llama coat
- Ears are 1/2-way in length btw camel's and llamas
- "Strong, desert-ready legs of a camel"
- Partially cloven feet (like mix of camel's foot pad and llama's cloven feet)
- This source says no male llamas and female camels
Potts, Danel. "Bactrian Camels and Bactrian-Dromedary Hybrids". Silkroad. 3 (1).
| copy | Unstrip size limit exceeded (5,000,000) |
- Hybrids of dromedary and Bactrian have one hump, but is asymmetrical and has indentation (4–12cm deep) dividing back from front
- Or can look flat
- Animal is 2.32m tall at hump; 2.15m tall at shoulder
- Legs are long
- Weight average is 650kg
- Can carry ~400–450kg, more than dromedary or Bactrian
- "Indeed Herodotus says that camels carried provisions for the advancing Persians, marvelling that Xerxes' camel train was attacked by lions while marching between Acanthus and Therma, even though the lions had never seen that beast before, nor had any experience of it. We do not know whether these were dromedaries, like those used by Cyrus against Croesus of Lydia."
"Fun facts about the Camel". The Jungle Store. Retrieved 3 December 2012.
| copy | Unstrip size limit exceeded (5,000,000) |
- "A camel's poop is so dry you can use it immediately to start a fire"
- Don't actually spit - vomit (so don't waste water)
- Babies born without hump
- Bactrians
- Hump are ~75lbs each
- Long shaggy coat in winter, shed in spring
- Camels sometimes cluster to keep cool - when body temp is lower than env temp
- 3rd eyelid moves sideways like windshield wiper
- Can still see if that eyelid is closed, so can travel in sandstorms
- Nose traps moisture from exhalations
- Normally herbivore, but becomes omnivore when food is scarce (will eat owners' tents)
- Drink brackish water
- Sharp teeth
- Camel can be fully trained and be able to carry full load by age 5
"Kidneys and Concentrated Urine". Temperature and Water Relations in Dromedary Camels (Camelus dromedarius). Davidson College. {{cite web}}: |access-date= requires |url= (help); Italic or bold markup not allowed in: |work= (help); Missing or empty |url= (help)
| copy | Unstrip size limit exceeded (5,000,000) |
- "A concentrated urine with a syrupy consistency was noted to change to a watery and colorless urine after only a short time of drinking"
Bernstein, William J. (6 May 2009). A Splendid Exchange: How Trade Shaped the World. Grove Press. pp. 54–55. ISBN 9780802144164.
| copy | Unstrip size limit exceeded (5,000,000) |
p. 54
- Protolypus of N. America around size of rabbit
- Beginning of Pleistocene (3mya), Isthmus of Panama formed and Protolypus migrated to S. America
p. 55
- Camel gained water-storing abilities in Arabia
Harington, C. R. (June 1997). "Ice Age Yukon and Alaskan Camels". Yukon Beringia Interpretive Centre. Government of Yukon, Department of Tourism and Culture, Museums Unit. Retrieved 3 December 2012.
| copy | Unstrip size limit exceeded (5,000,000) |
- Protylopus common in open woodlands of what is now S. Dakota (earliest known camelids, 24–25 mya)
- Early Pliocone (~5mya), spread to S. America and Old World (Bering Isthmus)
- S. America line → llamas, etc.
North Dakota Industrial Commission Department of Mineral Resources. "Poebrotherium" (Document). North Dakota State Government. {{cite document}}: Unknown parameter |accessdate= ignored (help); Unknown parameter |url= ignored (help)
| copy | Unstrip size limit exceeded (5,000,000) |
- Poebrotherium was early camel in open-woodland area of N. Dakota, ~30mya
- Goat-sized
- Looked like llama
- Runners
- [Picture]
"Fossil camel skull (Poebrotherium sp.)". Science Buzz. Science Museum of Minnesota. January 2004. Retrieved 3 December 2012.
| copy | Unstrip size limit exceeded (5,000,000) |
- ~35mya fossil
- Similar chars to camels: teeth, limbs
- Prob. look more like llamas than camels (no evidence of humps)
Kindersley, Dorling (2 June 2008). "Camels". Encyclopedia of Dinosaurs and Prehistoric Life. Penguin. pp. 266–7. ISBN 9780756682415.
| copy | Unstrip size limit exceeded (5,000,000) |
- Aepycamelus: 2m tall at shoulder, ate leaves from trees
- Open woodland/grassland with trees
- N. America in Miocene
- "High camel"
- Long leg and neck bones
- Like camels, had (probably): divided upper lip, long and curved neck, two-towed feet
- Stenomylus from Oligocene (~30mya), small early camel with huge teeth
- Pointed hooves and walked on tippytoes
Singh; Tomar. Evolutionary Biology (8th revised ed.). New Delhi: Rastogi Publications. p. 334. ISBN 9788171336395.
| copy | Unstrip size limit exceeded (5,000,000) |
- In upper Miocene/lower Pliocene, Procamelus → main ancestor of modern camel
- Main divergence had begun in Oligocene
Worboys, Graeme L.; Francis, Wendy L.; Lockwood, Michael (30 March 2010). Connectivity Conservation Management: A Global Guide. Earthscan. p. 142. ISBN 9781844076048.
| copy | Unstrip size limit exceeded (5,000,000) |
- End of Pleistocene: evidence that early Native Americans hunted N. American mega fauna: Camelops hesternus, mammoths (Mammuthus imperator), mastodon (Mammut americanum), horses (dinohippus sp.)
- Some also claim N. American overhunting → these species' extinction, but has been disputed
MacPhee, Ross D. E.; Sues, Hans-Dieter (30 June 1999). Extinctions in Near Time: Causes, Contexts, and Consequences. Springer. pp. 18, 20, 26. ISBN 9780306460920.
| copy | Unstrip size limit exceeded (5,000,000) |
p. 18
- FC: "First contact" with humans
p. 20
- N. America extinctions: Camelops hestrnus, mammoth, mastodon, horse, ground sloth, saber-tooth, short-faced bear
- 12,000 to 10,000 years ago
p. 26
- N. America: FC → megafauna extinctions
Fedewa, Jennifer L. (2000). "Camelus bactrianus". Animal Diversity Web. University of Michigan Museum of Zoology. Retrieved 4 December 2012.
| copy | Unstrip size limit exceeded (5,000,000) |
- Almost all camels are now domestic
- Carry packages, transportation
- Can take vocal commands from age 1
- Humans use camel meat and milk
- Fat from humps is melted and served in cooking
- Poop is uses as fuel for heating
- Loose hair → clothes, blankets, carpets, tents
- Tanned hide → shoes, sandals, other leather stuff
- Some countries: camels show wealth
- When hungry, camels can eat people's tents, sandals, or blanks
"Bactrian & Dromedary Camels". Factsheets. San Diego Zoo Global Library. March 2009. Retrieved 4 December 2012.
| copy | Unstrip size limit exceeded (5,000,000) |
- Domestication ~4000–2000 BC
- Wild camels, not domestic, can drink salt water slush if no fresh water available
- Domestic camels maintained in semi-wild state: watered by man, but get food from wild vegetation
- If unguarded, will still return to a familiar well
- Wild camels are super shy and can spot danger from 2–3 miles away
- Integral part of nomad culture
- Females can produce milk several years after birth
- Bactrian: 5L/day
- Dromedary: 20 L/day
- Males used for carrying
- Can carry 200kg
- Can pull more than 1 ton on wheeled cart
- Can carry more than horse bc convex back
- Females can produce milk several years after birth
- Used in combat: horses afraid of their smell
- US Army Camel Corps in California in late 1800s
- Needs 8x salt as cattle and sheep do
- Only ungulates to mate in sitting position
- Also only ungulates not to lick and clean baby
- Milk
- Staple food of desert nomad tribes
- Richer in fat and protein than cow milk
- Can't → butter traditionally with churning
- Must be soured first
- Then churned
- Then have clarifying agent added
- Milk → yogurt readily
- Used as medicinal product in India
- Bedouin tribe believes has curative powers
Walker, Matt (22 July 2009). "Wild camels 'genetically unique'". Earth News. BBC. Retrieved 4 December 2012.
| copy | Unstrip size limit exceeded (5,000,000) |
- Few hundred wild Bactrians remain, and are distinct from domestic ones
- Bactrians are last remaining wild camels
Bulliet, Richard W.; Crossley, Pamela Kyle; Headrick, Daniel R.; Hirsch, Steven W.; Johnson, Lyman L. (1 January 2010). The Earth and Its Peoples: A Global History: To 1550. Cengage Learning. p. 220. ISBN 9781439084748.
| copy | Unstrip size limit exceeded (5,000,000) |
- S. Arabian saddle: good for riding
- Baggage can be tied to wooden arches at front
- Militarily inefficient: rider kneels on cushion behind hump, so hard to hold weapons
- North Arabian saddle
- 1st centuries BC
- Solid wooden frame, can attach loads
- Warriors had solid loads and height advtg.s
- s. Sahara saddles
- Lightest and most efficient
- Sahara trade → camel domestication
Bulliet, Richard W. (1975). The Camel and the Wheel. Columbia University Press. pp. 23, 25, 28, 35–36, 38–40. ISBN 9780231072359.
| copy | Unstrip size limit exceeded (5,000,000) |
p. 23
- Camel > ox + wagon transport because:
- Can carry/draw twice as much
- Faster and can cover more ground
- 20–25 mi in one stretch
- More journeys per year and per lifetime
- Live and work 4x as long
- Can survive for stretches without food/water
- Tenacity/endurance
- Can cover ground a wagon would stick in
- Can cross shallow rivers where would have to unload wagon
- Wagon liable to breaking down
- Wagon adds on a dead weight
p. 25
- Wagon: 1 person per 2 animals
- Camel: 1 person per string of 3–6 camels
- Chariot had been main military transport
- In 700s BC, started to be overtaken by cavalry (on camels) as main force of Assyria
- Increased camel traffic → decreased road maintenance in that area
p. 28
- 1st rabbit-sized ancestor of camel
p. 35–36
- Camel domestication in book of Genesis
- Abraham got bribes from Egypt Pharaoh to have Sarah in haram: sheep, oxen, asses, camels
- W. F. Albright: scholar of Biblical history and Palestinian archaeology
- Mentions of camels in Abraham period: priests tampering with earlier texts
- Wanted to make it fit in more with social conditions
- Semites of Abraham time herded sheep, goats, and donkeys; not camels
p. 38–40
- Somalia has ~4 million camels
- Horn of Africa: "one of the largest and most abundant camel territories in the word"
- Somalis, unlike other camel people, never ride their camels (said it made them easy targets)
- Milk was dietary staple, esp. in wet seasons
- Don't really use camels to carry shit
Gabriel, Richard A. (2007). Soldiers' Lives Through History: The Ancient World. Greenwood Publishing Group. p. xvi. ISBN 9780313333484.
| copy | Unstrip size limit exceeded (5,000,000) |
- 853 BC: Battle of Qarqar, first use of camel cavalry (by Gingibu the Arab)
Bhatia, Vimal (23 July 2012). "BSF to ditch camels to ride sand scooters". The Times of India. Retrieved 4 December 2012.
| copy | Unstrip size limit exceeded (5,000,000) |
...They have camels
Gann, Lewis Henry; Duignan, Peter (1972). Africa and the World: An Introduction to the History of Sub-Saharan Africa from Antiquity to 1840. University Press of America. ISBN 9780761815204.
| copy | Unstrip size limit exceeded (5,000,000) |
- "The camel was acclimatized in Egypt long before the time of Christ and was subsequently adopted by the Berbers of the desert, who used camel cavalry to fight the Romans. The Berbers spread the use of the camel across the Sahara."
Southern, Pat (1 October 2007). The Roman Army: A Social and Institutional History. Oxford University Press. p. 123. ISBN 9780195328783.
| copy | Unstrip size limit exceeded (5,000,000) |
- Camel Riders (Dromedarii) [in TOC, listed under auxiliary units]
- Eastern provinces: Roman army unites often had some camel riders
- Btw. 32 and 36 dromedarii listed in an early roster
- A 1000-camel unit, ala I Ulpia adromedariorum milliaria was raised by Trajan and stationed in Syria
- No consistency in whether organized as infantry or cavalry – depended on province
Fleming, Walter L. (February 1909). "Jefferson Davis's Camel Experiment". The Popular Science Monthly. Vol. 74, no. 8. Bonnier Corporation. p. 150. ISSN 0161-7370.
| copy | Unstrip size limit exceeded (5,000,000) |
- "Other trials of the camel were made in 1859 by Major D. H. Vinton, who used twenty-four of them in carrying burdens for a surveying party...All in all, he concluded, the camel was much superior to the mule."
Mantz, John (20 April 2006). "Camels in the Cariboo". In Basque, Garnet (ed.). Frontier Days in British Columbia. Heritage House Publishing Co. pp. 51–54. ISBN 9781894384018.
| copy | Unstrip size limit exceeded (5,000,000) |
- Camels have been used by US Army
- US Army Camel Corps established early 1856
- 70 camels shipped to Texas from Arabia
- Tested them out – rode 4000 miles without incident
- US Secretary of War recommended in 1858 that funds → 1000 more camels
- Recommendation repeated twice after, but Congress didn't grant it bc worried about upcoming Civil War
- Camels stationed at Camp Verde near San Antonio, Texas
- Western terminal of Camel Corps was Fort Tejon, near present-day Bakersfield, California
- Lt. Beale: one good camel worth 4 army mules
- Could carry more than 5 times normal mule load
- Bought dromedaries and Bactrians
- "The outbreak of the American Civil War doomed the U.S. Army Camel Corps"
- Texas → Confederacy
- Most camels just wandered away into the desert
- Some dude from Cariboo bought 25 → gold rush in Canada
Nicolle, David (26 March 1991). The Desert Frontier. Rome's Enemies. Vol. 5 (illustrated, reprint ed.). Osprey Publishing. p. 4. ISBN 9781855321663.
| copy | Unstrip size limit exceeded (5,000,000) |
"Nevertheless the military prowess of desert peoples impressed the Romans, who recruited large numbers as auxiliary cavalry and archers. In addition to providing the Roman Army with its best archers, the Easterners (largely Arabs but generally known as 'Syrians') served as Rome's most effective dromedarii or camel-mounted troops." (4)
Herodotus (440 BC). The History of Herodotus. Retrieved 4 December 2012. {{cite book}}: Check date values in: |date= (help)
| copy | Unstrip size limit exceeded (5,000,000) |
- "He collected together all the camels that had come in the train of his army to carry the provisions and the baggage, and taking off their loads, he mounted riders upon them accoutred as horsemen. These he commanded to advance in front of his other troops against the Lydian horse; behind them were to follow the foot soldiers, and last of all the cavalry. When his arrangements were complete, he gave his troops orders to slay all the other Lydians who came in their way without mercy, but to spare Croesus and not kill him, even if he should be seized and offer resistance. The reason why Cyrus opposed his camels to the enemy's horse was because the horse has a natural dread of the camel, and cannot abide either the sight or the smell of that animal. By this stratagem he hoped to make Croesus's horse useless to him, the horse being what he chiefly depended on for victory. The two armies then joined battle, and immediately the Lydian war-horses, seeing and smelling the camels, turned round and galloped off; and so it came to pass that all Croesus's hopes withered away."
User:Prof. Squirrel/Notes/Template
User:Prof. Squirrel/Notes/Template
User:Prof. Squirrel/Notes/Template
User:Prof. Squirrel/Notes/Template
User:Prof. Squirrel/Notes/Template
User:Prof. Squirrel/Notes/Template
User:Prof. Squirrel/Notes/Template
User:Prof. Squirrel/Notes/Template
User:Prof. Squirrel/Notes/Template
User:Prof. Squirrel/Notes/Template
User:Prof. Squirrel/Notes/Template
{{/Template |citation={{cite web| last = Jupiter Infomedia Ltd| title = Bikaner Camel Corps, Presidency Armies in British India| work = IndiaNetzone| accessdate = 6 December 2012| date = 28 November 2012
Content Disclaimer
Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.
- The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
- There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
- It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
- Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
- Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.